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OPSOMMING
Hierdie studie ondersoek ŉ Suid-Afrikaanse kleurling-familie wat presenteer het met progressiewe 
dementia en bewegingswanfunksie in ‘n aantal individue binne drie generasies. Aanvanklike 
simptome sluit in persoonlikheidsveranderings en tremors, wat progressief verander het na ernstige 
dementia en totale immobiliteit. Die gemiddelde aanvangsouderdom van persone met die simptome 
was in die dertigjare en mortaliteit het binne 10 -15 jaar ingetree. Die doel van die studie was om die 
genetiese oorsaak van die siektetoestand te bepaal en die patologie te ondersoek.
‘n Mutasie-soektog wat moontlik na die fenotipe kon lei, is in die familie gedoen. Dit het mutasies 
in Huntington-siekte, Parkinson-siekte, Dentatorubral-Pallidoluysian-atrofie, spinoserebrale-ataksie 
(tipe 1, 2, 3, 6, en 7), Huntington Tipe-2-siekte (HDL2) en verskeie mitokondriale siektes ingesluit. 
Enkelstring konformasie-polimorfisme analise en direkte DNA-volgorde-bepaling is gebruik om 
nukleotied-veranderinge te bepaal. Genotipering op ŉ ABI genetiese-analiseerder is gebruik om 
herhalingsvolgorde-verlengings se grootte te bepaal. Deur gebruik te maak van haplogroep- en Kort-
Tandem-Herhalings-analise (STRs) van die Y-chromosoom en mitokondriale DNA van ‘n aangetaste 
individu, is die familie se etniese oorsprong bepaal. Ten einde die geen-uitdrukking te bestudeer is 
Omgekeerde Transkriptasie Polimerase Kettingreaksie (RT-PCR) en komplementêre DNA-analise 
(cDNA) van die Junctophilin-3 (JPH3)-geen gedoen.
Na uitsluiting van verskeie bekende mutasies is ‘n herhalingsvolgorde-verlenging in die HDL2-geen 
in die familie aangetoon. Huntington Tipe-2 siekte is seldsaam en word veroorsaak deur ŉ CAG/
CTG-herhalingsverlenging in ŉ alternatief-uitgedrukte transkripsie van die JPH3-geen. HDL2 kom 
meestal by swartmense van Afrika-oorsprong voor. Die familie in hierdie ondersoek se etniese 
oorsprong-bepaling het aangedui dat hulle van kleurling-afkoms is. Hierdie is die eerste beskryfde 
Suid-Afrikaanse kleurling-familie met ’n herhalingsvolgorde-verlenging in die HDL2-geen. ŉ Loods-
studie het die voorkoms van die herhalingsvolgorde-verlenging onder drie Suid-Afrikaanse sub-
populasies ondersoek, ten einde te bepaal of swart Afrikane meer geneig is om die siekte te ontwikkel. 
ŉ Statisties beduidende verskil (P=0.0014) in die voorkoms van die herhalingsvolgorde-verlenging 
is onder die swart en kaukasiese Afrikane gevind. Geen gevolgtrekking kon egter gemaak word dat 
swart Afrikane ‘n groter herhalingsvolgorde-verlenging het nie.  
Die herhalingsvolgorde-verlenings is geleë in ŉ alternatief-uitgedrukte transkripsie van die JPH3-
boodskapper RNA (mRNA). Ten spyte van die feit dat die JPH3 geen-omgewing hoogs behoue 
gebly het tussen mens-, muis-, en sjimpansee-genome, kom die herhalingsvolgorde nie in die 
muis-homoloog van die geen voor nie. Deur gebruik te maak van fetale brein “cDNA” en PCR met 
voorvoerders wat spesifiek is vir die twee transkripsie-produkte, het hierdie studie onafhanklik bevestig 
dat verskillende JPH3-“mRNA” transkripsie produkte (die vollengte en ‘n korter alternatief) voorkom. 
As gevolg van die afwesigheid van breinweefsel van HDL2-geaffekteerdes, is die transkripsie-
produkte in twee aangetaste individue se limfosiete ondersoek. “Real-time” PCR is gedoen met RNA 
wat uit limfosiete geïsoleer is van twee HDL2-aangetasdes. Hierdie eksperimente was onvoldoende 
en vereis verdere optimisering. “Real-time” PCR eksperimente in verskillende weefsels (brein en 
ander) van HDL2-geaffekteerdes behoort meer inligting te verskaf oor die JPH3-geen. 
In hierdie studie is die eerste kleurling-familie met ‘n CAG/CTG herhalingsvolgorde-verlenging in 
die HDL2-geen identifiseer. Genetiese raadgewing en pre-simptomatiese toetse in onaangetaste 
individue binne die familie is nou moontlik. Hierdie studie het sekere eienskappe van die geen 
onafhanklik bevestig. Verdere navorsing op HDL2 is noodsaaklik om die siekte beter te verstaan. 
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ABSTRACT
A South African family of Mixed Ancestry presented with a rapidly progressive dementia and a 
movement disorder which affected a number of individuals across three generations. The initial 
symptoms included personality changes and tremors that escalated to severe dementia and 
eventually a completely bedridden state. It was determined that the mean age at onset was in the 
third decade of life and affected individuals died within 10-15 years after the onset of symptoms. 
The aim of the present study was to elucidate the genetic cause of the disorder in this family and to 
further investigate the patho-biology of the disease. 
Mutations that could possibly cause the observed phenotype in this family were screened for. These 
included loci implicated in Huntington’s disease, Parkinson’s disease, Dentatorubral-Pallidoluysian 
Atrophy, Spinocerebellar ataxias (types 1, 2, 3, 6, and 7), Huntington’s disease-like 2 (HDL2) and 
several mitochondrial disorders. Single-strand Conformation Polymorphism (SSCP) analysis and 
direct sequencing were used to detect possible mutations while genotyping on an ABI genetic 
analyser was used to detect disorders caused by repeat expansions. Haplogroup and Short Tandem 
Repeats (STRs) analyses of the Y-chromosome and mitochondrial DNA of one affected family 
member was used to determine the family’s genetic ancestry. Reverse transcriptase polymerase 
chain reaction (RT- PCR) and complementary DNA (cDNA) analyses of the Junctophlin-3 (JPH3) 
gene was performed to provide information on the expression profile of this gene.
 
After the exclusion of several genetic loci it was shown that this family had HDL2. This is a rare 
disease caused by a CAG/CTG repeat expansion in an alternatively spliced version of the JPH3 
gene. HDL2 occurs almost exclusively in individuals of Black African ancestry. The genetic ancestry 
data suggested that the family member was most likely of South African Mixed Ancestry making this 
the first reported family of South African Mixed Ancestry with HDL2. A pilot study investigated the 
repeat distribution amongst three South African sub-populations in order to determine whether there 
was a bias in the repeat distribution that possibly predisposes Black Africans to develop the disease. 
The results showed a statistically significant difference (P= 0.0014) in the distribution of the repeats 
between the Black African and Caucasian cohorts. However, no conclusions could be drawn as to 
whether Black Africans harboured larger repeats that predisposes them to developing HDL2.
The expanded repeat is located in an alternatively spliced version of the JPH3 mRNA. Interestingly, 
this repeat is not present in the mouse homologue of the gene although the rest of the genomic 
sequence is highly conserved across the human, mouse and chimpanzee genomes. Using foetal 
brain cDNA and PCR primers designed to be specific for different JPH3 isoforms, independent 
confirmation of the presence of two JPH3 mRNA transcripts (the full length and a shorter alternatively 
spliced version) was provided. In the absence of brain tissue from an HDL2-affected individual, it was 
investigated whether both JPH3 mRNA transcripts could be detected in lymphocytes. Using RNA 
isolated from the transformed lymphocytes of two HDL2-affected family members, real-time PCR 
was attempted. These experiments produced inconclusive results and required further optimisation. 
Further RT-PCR experiments for JHP3 expression in different tissues (brain and other) obtained 
from HDL2-affected individuals would be of interest.
The present study identified the first Mixed Ancestry family with HDL2. This family will now be able 
to request genetic counselling and pre-symptomatic testing for all at-risk family members. Aspects of 
this study provided independent confirmation of characteristics of the mutated gene. More research 
on HDL2 will be crucial in understanding the pathogenesis of this disease.
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CHAPTER ONE: INTRODUCTION 
 
As this thesis deals with a disorder that manifests with dementia and movement 
abnormalities, a brief introduction to the physiology of the brain is provided. This 
introduction will focus on a description of components of the brain that are commonly 
affected in neurodegenerative and movement disorders. In addition, it also focuses on 
disorders that manifest with the specific symptoms present in this family. 
 
1.1  The physiology of the brain 
  
The central nervous system (CNS) is the centre for the integration and reception of all 
nerve impulses generated in the body. It consists of two main components, the brain and 
the spinal cord and contains two types of cells, namely neurons and neuroglia (glial 
cells) [Tortora and Grabowski, 1996]. 
 
Neurons transmit impulses and are in contact with each other at synapses or junctions. It 
is through this network of neurons that a stimulus, occurring in any body part, is relayed 
and processed in the brain.  
 
 Unlike neurons, glial cells can multiply and divide. Essentially, the purpose of glial cells 
is to protect, nurture and repair damaged cells in the CNS. There are four types of glial 
cells (Figure 1.1). Astrocytes are star shaped and their main functions are relaying 
impulses and metabolising neurotransmitters. Microglia has a protective function in that 
they engulf and phagocytosise foreign particles. Ependymal cells provide structural 
support while oligodendrocytes produce a myelin sheath which is a fibrous layer that 
protects parts of the neuron. The myelinated portions of the neurons form the white 
matter of the brain and spinal cord. The grey matter is unmyelinated and contains the 
cell bodies of neurons [Tortora and Grabowski, 1996].   
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Figure 1.1: A diagram of the four types of glial cells that occur in the brain [Taken from McGraw-
Hill online learning centre].  
 
The brain can further be sub-divided into four regional components namely, cerebrum, 
cerebellum, diencephalon and the brainstem (Figure 1.2). 
 
 
 
 
Figure 1.2: A schematic diagram of the four main components of the brain [Adapted from  
McGraw-Hill online learning centre].  
 
1.1.1 The cerebrum  
 
The cerebrum makes up the bulk of the brain and has highly convoluted grey matter on 
the surface which is known as the cerebral cortex. The cerebrum is known as the “seat 
of intelligence” as it regulates and produces almost all processes associated with the 
brain. The cerebrum is separated into the left and right hemispheres by a central groove 
called the longitudinal fissure. Each hemisphere further consists of four lobes namely the 
frontal, occipital, parietal and temporal lobes (Figure 1.3).  
Diencephalon 
Brainstem
Cerebellum 
Cerebrum
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Figure 1.3: A model of the brain depicting the cerebral lobes [Taken from Bear et al., 1996].  
 
Beneath the cortex of the cerebrum lies a dense mass of white matter, the corpus 
collosum, which connects the left and right halves of the brain. The white matter relays 
impulses within a hemisphere, between the two hemispheres and from the cerebrum to 
other parts of the brain or spinal cord [Tortora and Grabowski, 1996]. The cerebrum also 
contains three functional areas (Figure 1.4). The sensory area receives and interprets 
sensory information such as touch, pain, temperature, sight and taste. The motor areas 
control movement of a specific group of muscles. The association areas are concerned 
with the integration and further processing of sensory information [Silverthorn, 2001].  
 
  
Figure 1.4: A figure of the human brain depicting various functional lobes 
[Taken from http://www.gazzaro.it/g/Language%20in%20the%20brain_file/sensory_motor.gif ].  
 
The cerebrum contains several clusters of neurons termed the basal ganglia which are 
connected to each other. The nuclei (clusters of nerve cells) of the basal ganglia consist 
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of the striatum (caudate and putamen) and the globus pallidus (Figure 1.5). The basal 
ganglia are involved in the timing and amplitude of movement.  
 
Figure 1.5: A representation of the location and components of the striatum [Taken from Bear et 
al., 1996]. 
 
The limbic system is a group of structures in the cerebrum that includes the 
hippocampus and amygdala and is involved in emotion and memory. Maintaining the 
physiological and anatomical structure of the cerebrum is essential for normal 
functioning. Abnormalities in development or trauma to the cerebrum or structures in the 
cerebrum cause abnormal or impaired movement, cognitive and sensory dysfunction. 
Disease of the basal ganglia is associated with movement disorders which are 
characterised by increased or reduced movements.  
 
1.1.2 The cerebellum 
 
The cerebellum is the second largest part of the brain. Much like the cerebrum, the 
surface consists of highly convoluted grey matter with deeper white matter arranged like 
branches of a tree [Van De Graaff, 2001]. The cerebellum has afferent and efferent 
connections to the pons, medulla, spinal cord and midbrain. The primary function of the 
cerebellum is to co-ordinate movements by comparing the intended movement with the 
actual movement being made. It is also an essential contributor to the maintenance of 
posture and balance. Action tremor in limbs is a common feature in a dysfunctional 
cerebellum [Watts and Koller, 1997].  
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1.1.3 The diencephalon  
 
The diencephalon consists predominantly of the thalamus and hypothalamus. The 
thalamus consists of grey matter organized in clusters and is the principle relaying 
station for sensory impulses from the efferent regions [Tortora and Grabowski, 1996]. 
The hypothalamus is located below the thalamus and contains four regions which serve 
specific functions, thereby contributing to the overall homeostasis of the body. It is 
essential for homeostasis because it secretes hormones that control the release of other 
hormones from the pituitary gland [Tortora and Grabowski, 1996]. The hypothalamus 
plays a role in the integration of the autonomic nervous system such as controlling blood 
flow and breathing. It also regulates body temperature, thirst, food intake and maintains 
sleeping patterns.  
 
1.1.4 The brainstem  
 
The brainstem consists of the medulla oblongata, pons and midbrain (mescencephalon). 
The brainstem relays sensory information to the thalamus and cerebral cortex. It 
contains nuclei of cranial nerves and therefore receives stimuli for balance, hearing, 
swallowing, head/shoulder and tongue movements.  
 
All these structures play an important role in the normal functioning of the CNS. Damage 
or disease in these components may lead to movement and cognitive impairment. 
 
1.2  Dementia 
Dementia refers to the progressive decline in cognitive ability that occurs due to loss or 
impairment of brain cell function. It is not a specific disease but rather a term used to 
describe a group of symptoms caused by disorders or trauma to the brain.  Individuals 
suffering from dementia have diminished or impaired brain functions beyond what is 
normally expected in the natural aging process.  It has been estimated that when 
maturity is reached, individuals lose 0.5% of their brain volume per year and this 
percentage increases every year from the onset. However, there are cases when 
dementia is severe, rapidly progressive and occurs early in life. In these cases dementia 
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is normally due to a disease or disorder and is of interest in the present study [Watts and 
Koller, 1997]. 
Dementia manifests in affected people as a loss of memory and difficulty with speech 
and understanding. Other brain functions that are impaired are problem solving, 
perception of time and place and other cognitive abilities. Dementia occurs 
predominantly in individuals over 65 years of age. In the year 2000, it was estimated that 
dementia afflicted some 25 million people worldwide, mostly in the developing countries 
[Wimo et al., 2006]. The estimated number of people affected by dementia globally is 
shown in Table 1.1 [Wimo et al., 2006]. 
 
Table 1.1: Estimated number of people with dementia worldwide [Wimo et al., 2006]. 
 
Dementia is predominantly observed in cases of Alzheimer’s disease (AD), vascular 
dementia, dementia with Lewy Bodies, alcohol/drug related dementia and 
Frontotemporal Dementia (FTD). Less common causes of dementia are Creutzfeld-
Jakob disease (CJD), Parkinson’s disease (PD), Huntington’s disease (HD) and head 
trauma [Harvey et al., 2003]. In a majority of cases, there are no effective treatments for 
the dementia, although drugs blocking acetyl cholinesterase have been shown to 
improve cognitive function in Alzheimer’s disease and Dementia with Lewy Bodies 
[Flicker, 1999]. 
 
Inherited disorders in which dementia is a prominent symptom are of importance in the 
present study. Furthermore, many of these inherited dementias also manifest with 
abnormal movements. A summary of a few of these disorders are discussed in the 
subsequent sections. 
 
Continent  Number of cases ( million)  % of total  
Asia  11.87 46.5 
Europe 7.43 29.1 
North America 3.08 12.1 
Latin America 1.69 6.6 
Africa 1.25 4.9 
Oceania  0.21 0.8 
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1.3 Movement disorders 
 
A movement disorder can refer to two situations, the first being an involuntary or 
abnormal movement that occurs while an individual is conscious. Secondly, it can also 
be used to describe a syndrome that has abnormal movements as a prominent 
symptom. Abnormal movements can be distinguished according to their clinical 
presentation, i.e. the amplitude of the movement, velocity, posture, rhythm and the ability 
to suppress the movement. Movement disorders fall into two broad categories namely 
Hyperkinesias which refer to the excessive movement of body parts and Hypokinesias 
which is a decrease in voluntary or autonomic movements [Watts and Koller, 1997]. 
 
1.3.1 Hyperkinesias  
 
 Dystonia refers to an abnormal movement characterised by continuous muscle 
contraction. It presents as repetitive movements or abnormal posture and can be 
present in different areas of the body simultaneously but commonly involves a particular 
body part [Pulst, 2003].  
 
Tremor is defined as involuntary oscillations of a body part. It can occur at different 
frequencies and is either prominent when the body is at rest or when maintaining a 
posture. Intention tremor is the most common form of tremor and is characterised by 
oscillations which increase as the hand or foot reaches a particular target [Pulst, 2003]. 
 
Myoclonus is described as a sudden shock-like movement. It is often a sign of cerebral 
dysfunction and is associated with abnormalities in the cortex of the cerebrum. Cortical 
myoclonus is associated with epileptic seizures. Action myoclonus refers to myoclonic 
movements while performing a precise movement [Watts and Koller, 1997]. 
 
Chorea manifests as arrhythmic, jerky movements of low amplitude that usually occur in 
the limbs. It may also present in the face as awkward grimaces and in children, as 
fidgety movements. It is a prominent symptom in Huntington’s disease [Watts and Koller, 
1997]. 
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1.3.2 Hypokinesias  
 
Bradykinesia is generally described as a reduction in speed during repetitive movements 
or general slowness in performing voluntary actions. Other signs include reduced facial 
expression and blinking [Pulst, 2003].  
 
Rigidity is stiffness in muscles during passive movements. It often occurs in joints, 
especially in the lower limbs. This is commonly a symptom of Parkinson’s disease [Watts 
and Koller, 1997]. Parkinsonism is a broad term that refers to a range of movement 
disorders including tremor, rigidity, bradykinesia and loss of postural reflexes [Watts and 
Koller, 1997]. 
 
Movement disorders can occur as the sole symptom in a disease or in conjunction with 
other symptoms. The latter is usually the case in neurodegenerative diseases where 
dementia and other neurological signs frequently accompany the movement disorder. 
There are a number of inherited diseases that manifest with dementia and movements 
disorders which are relevant to this study and will be discussed in the following sections.  
 
1.4 Mitochondrial DNA and disease 
 
Mitochondria are the powerhouse of the cell, generating energy in the form of adenosine 
triphosphate (ATP) to drive cellular processes. Mitochondrial DNA (mtDNA) is 
extrachromosomal DNA that plays an important role in the physiology of the cell and in 
many different human diseases.  
 
The mitochondrial genome is 16569bp in size and comprised of approximately 93% 
coding DNA. This genome codes for 37 genes (Figure 1.6) which consists of 13 
polypeptides which constitute the mitochondrial respiratory chain (OXPHOS) system as 
well as the necessary RNA for the translation of these polypeptides (two ribosomal 
RNAs and 22 transfer RNAs) [Strachan and Read, 1996]. There are hundreds of copies 
of mitochondria in each cell (polyploidy) and this feature plays an important role in the 
pathogenicity of mitochondrial diseases. 
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Figure 1.6: A circular representation of the mitochondrial genome indicating the 37 genes [Taken 
from www.mitomap.org].  
 
Although mtDNA polymerase has a proof-reading mechanism, random polymorphisms 
occur frequently due to a high rate of replication and the absence of protective histones 
in the replication process. Furthermore, reactive oxygen molecules that are generated 
during ATP production causes oxidative damage that result in sequence variants. These 
variations can be disease-causing mutations or result in predisposition to disease in four 
ways. Typical mitochondrial syndromes may occur where mutations in mtDNA result in a 
specific disease. Secondly, a high load of mutated mtDNA in the mother can result in a 
clinical syndrome in subsequent generations. Thirdly, the natural aging process 
incorporates mutations into the mtDNA and thereby predisposes aged individuals to 
disease. Finally, chromosomal mutations that affect mitochondrial ribosomal proteins 
can result in translational defects in mitochondria [Strachan and Read, 1996]. 
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Mitochondrial mutations can either be homoplasmic (in which all copies of the 
mitochondria will have the mutation) or heteroplasmic (in which only some copies of the 
mitochondria will be affected). In most cases of heteroplasmic mutations, the number of 
mutant copies must exceed a certain threshold before the disease manifests 
phenotypically [Strachan and Read, 1996]. Due to heteroplasmy, some mutations will 
only be expressed in certain tissues or systems where the mutational load is highest. 
Similarly, the disease may only be present in some of the progeny and absent in others. 
Homoplasmic mutations, however, will be transmitted to all progeny although they may 
not all display exactly the same phenotypic features of the disease [Strachan and Read, 
1996]. 
 
Mitochondrial DNA is uniparental and passed through generations via the maternal line. 
During oocyte development, only some of the mitochondria from the mother are 
transferred to the egg cells and the progeny will therefore have a limited selection of the 
mitochondrial load that the mother had. Consequently, a pattern of maternal inheritance 
of the disorder is essential in recognizing and diagnosing mitochondrial diseases [Taylor 
and Turnbull, 2005]. 
 
1.5 The influence of non-genetic factors in neurodegenerative disorders 
 
The aetiology of many neurodegenerative disorders is multifactorial in that it involves 
both genetic susceptibility and environmental interactions, which influence the course of 
the disease. While the genetic mutation may cause the susceptibility to a certain 
disorder, it is only with the exposure to other risk factors that the disease manifests.  
Common environmental risk-factors in neurodegenerative diseases include chemical 
exposure, oxidative stress, vitamin deficiency and exposure to heavy metals. Other risk-
factors include age, gender, lifestyle habits such as smoking and drug abuse as well as 
the presence of metabolic disorders. For example, the increased exposure to heavy 
metals such as organic aluminium in water was associated with the occurrence of AD 
[Gauthier et al., 2000]. In addition, Parkinson’s disease (PD) has been associated with 
the exposure to pesticides in rural areas [Abbott et al., 2003]. Another study found an 
association between PD and rural populations, proposing that the increased incidence of 
PD may be due to neurotoxins in the water [Priyadarshi et al., 2001]. 
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It is important to recognise these risk factors as avoiding them may reduce or delay the 
onset of symptoms. Furthermore, these risk factors may alter the clinical phenotype of 
the disease.  
 
 1.6  Inherited disorders displaying dementia and movement disorders 
 
Cases of familial dementia and movement disorders have been found to be due to 
mutations in both mitochondrial and nuclear genes. The pedigree of the family in the 
present study showed a tendency for maternal transmission of the disorder.  Whether 
this was a chance occurrence or not was unknown at the time of this study and it was 
therefore assumed that mutations in either mitochondrial or nuclear genes could be 
responsible for these symptoms. Given this, both mitochondrial and nuclear 
neurodegenerative disorders are discussed in the following sections.  
 
1.6.1 Mitochondrial diseases associated with movement abnormalities and 
dementia 
 
1.6.1.1 Myoclonic Epilepsy with Ragged-Red Fibres (MERRF; MIM 545000)  
 
MERRF is commonly caused by mutations in the transfer RNA (tRNA) genes of the 
mitochondria resulting in ragged- red fibres in muscle tissue and abnormally shaped 
mitochondria. The clinical symptoms are myoclonus, seizures, ataxia, and myopathy. 
The severity and rate of progression of the disease varies amongst different cases but 
myoclonus is normally the initial symptom [Berkovic et al., 1989]. The age at onset 
(AAO) ranges from 7-50 years with most cases occurring in childhood after a normal 
early development [Hirano and DiMauro, 1992]. 
 
The prevalence rate is quite low with estimations of 0-1.5/100 000 in Finland [Remes et 
al., 2005] and 0.25/100 000 in Northern Europe [Chinnery et al., 2000]. However, the 
disease is clinically heterogeneous, making it difficult to diagnose and these estimates 
might be biased.  
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 Four point mutations (A8344G, T8356C, G8363A and G8361A) in the MTTK gene, 
encoding tRNA lysine, collectively account for 90% of MERRF cases with the A8344G 
mutation accounting for approximately 80% of those cases [Shoffner et al., 1990].  The 
remaining 10% of reported cases is due to other MTTK point mutations or single base 
and larger deletions. Some of the reported mutations may result in additional symptoms 
not found in typical MERRF. For example in two families, affected individuals harbouring 
the T8356C mutation showed symptoms of MELAS, another mitochondrial disorder 
[Zeviani et al., 1993]. 
 
Although the mechanism of pathogenesis has not been determined, analysis of cells 
containing the A8344G mutation showed decreased tRNA lysine production [Enriquez et 
al., 1995]. It is not clear whether there is a correlation between the amount of mutant 
mitochondria and the severity of the disease [Berkovic et al., 1989]. 
 
1.6.1.2 Mitochondrial myopathy, Encephalopathy, Lactic acidosis and 
Stroke-like episodes (MELAS; MIM 540000)  
 
MELAS is a well characterised multisystem disorder that manifests phenotypically with 
subacute-stroke-like episodes, encephalopathy with seizures and dementia. Additional 
symptoms include short stature, recurrent headaches and vomiting. The initial symptoms 
may include exercise intolerance and limb weakness that usually presents in early 
childhood [Hirano et al., 1992]. However, there are rare cases where the AAO is in the 
fourth decade of life. 
 
Although MELAS is predominantly associated with mutations in the mitochondrial 
tRNAs, there are several causative mutations in other mitochondrial genes such as the 
genes encoding the Complex I subunit [Goto et al., 1992] and MT-ND5 gene [Crimi et 
al., 2003]. However, it has been estimated that 80% of reported cases of MELAS are 
due to an A-G transition at position 3243 in the MTTL1 gene on the mitochondrial 
genome. A study in Finland found the prevalence of MELAS due to the A3243G 
mutation to be 16.3 /100 000 [Majamaa et al., 1997].  
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As with MERRF the symptoms vary in different cases and there are some cases in 
which the symptoms of MELAS and MERRF overlap, making it difficult to make a distinct 
diagnosis [Zeviani et al., 1993].  
 
1.6.1.3 Familial multisystem degeneration associated with parkinsonism 
(LHON-variant) (MIM 516003) 
 
Lebers’ hereditary optic neuropathy (LHON) presents in teenagers and adults as acute 
or subacute loss of vision or complete blindness. The disease is caused by mutations in 
mtDNA and there are currently 18 allelic variants. However, the most common cause of 
LHON is the G11778A mutation in the MT-ND4 gene. In Asia, more than 90% of LHON 
patients harbour this mutation [Mashima et al., 1993].  
 
The 11778G>A mutation, previously only associated with LHON families, was identified 
as the cause of a maternally inherited multisystem degeneration disease characterised 
by parkinsonism in one family [Simon et al., 1999]. The symptoms varied dramatically 
between affected individuals. In addition to prominent parkinsonism, affected members 
also displayed akinesia, rigidity, dysarthria, dystonia and dementia. 
 
1.6.2  Non-mitochondrial inherited diseases manifesting with dementia and 
movement disorders 
 
1.6.2.1 Prion diseases (MIM 1766540) 
 
Prion diseases can occur in both human and animals. Furthermore, the disease can be 
acquired from animals or may appear sporadically or be inherited. Most cases are 
sporadic or acquired but about 10-15% of prion diseases are inherited [Windl et al., 
1999]. More than 30 point mutations and insertions in the prion protein gene (PRPN) 
have been implicated as the cause of inherited prion diseases [Mead, 2006]. A study of 
four genes associated with early onset (EO) dementia  showed that mutations in the 
PRPN  gene were the most frequent cause of EO dementia for those four genes [Finckh 
et al., 2000]. 
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There are three clinically distinct inherited phenotypes of prion diseases, namely 
Creutzfeldt-Jakob disease (CJD) [Brown et al., 1994], Gerstmann-Straussler-Scheinker 
syndrome (GSS) [Hainfellner et al., 1995] and Fatal Familial Insomnia (FFI) [Lugaresi et 
al., 1986]. Although the symptoms may be markedly heterogeneous, the disease is 
typically characterised by slowly progressive ataxia, hallucinations, and myoclonus. In 
the case of CJD, rapidly progressive dementia occurs while in cases of GSS dementia 
occurs in the later stages of the disease. There are only four frequently occurring 
mutations in the PRPN gene that leads to inherited prion disease, namely E200K, 
D178N, P102L and OPRI. In a report on 492 cases of prion disease, 350 of the cases 
were due to these four mutations [Mead, 2006]. 
 
The E200K mutation is by far the most commonly occurring mutation for inherited prion 
disease. Clinically it manifests as typical CJD with muscular rigidity and myoclonus being 
prominent features [Brown et al., 1986]. The mean AAO is 58 years although this differs 
in various studies [Brown et al., 1994]. 
 
The phenotype of prion disease caused by the D178N mutation has been described as 
CJD-like. In addition to CJD symptoms, affected individuals also suffer from insomnia 
and severe myoclonus. In 72 reported cases the AAO ranged from 20-71 years with a 
median AAO of 50 years [Pocchiari et al., 1998]. 
 
The insertion of three octapeptide repeats (OPRI mutation) in the N-terminal of the 
PRPN is also a common cause of inherited prion disease. The AAO is in the fourth 
decade and the condition presents clinically as myoclonus, ataxia and chorea with 
cortical dementia as the main feature [Mead, 2006].  
 
The P102L mutation follows a GSS pattern of disease, with slowly progressive ataxia 
and dementia in later stages of the disease. In 52 reported cases the AAO ranged 
between 25-70 yrs [Young et al., 1997]. 
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1.6.2.2 Early onset Parkinson’s disease (PD; MIM 168600) 
 
Idiopathic Parkinson’s disease (PD) is defined as a slowly progressive 
neurodegenerative disease characterised by loss of dopaminergic neurons and the 
presence of Lewy bodies (eosinophilic inclusion bodies containing ubiquitin and α 
synuclein aggregations). The degeneration of dopaminergic neurons causes a decrease 
of dopaminergic input to the striatum resulting in movement abnormalities [Marras and 
Tanner, 2003]. The initial symptoms are bradykinesia, tremor and rigidity while 
symptoms that appear as the disease progresses include dementia and dysarthria. PD is 
largely a disorder of the aged so the incidence and prevalence of the disease increases 
dramatically in individuals over 50 years of age. PD that occurs in individuals in which 
the AAO is younger than 50 years is considered to be early onset PD and is of interest in 
the present study. PD can occur sporadically or follow a Mendelian or non-Mendelian 
pattern of inheritance.  
 
PD has been noted to be the second most common neurodegenerative disease globally 
[Okubadejo et al., 2006]. The prevalence of PD has been estimated in various 
population groups but to date has not yet been established in South Africa. The 
prevalence differs in different population groups. A higher prevalence rate was reported 
in Caucasians compared to the Asian or African populations [Wood et al., 2005]. A 
gender bias has also been implicated with males having a slightly higher burden than 
females. However, all these estimates can be biased as there is no diagnostic test for 
PD during life and clinical diagnoses could be inaccurate [Marras and Tanner, 2003].    
 
Although inherited PD may only contribute to about 5% of PD cases worldwide [Oliveri et 
al., 2001], great strides have been made in understanding the genetics of PD and has 
resulted in the identification of a number of mutations in at least five genes that have 
shown to cause PD while many other genes have been implicated by association studies 
[Tan and Jankovic, 2006]. To date three genes, namely DJ1, PINK1 and PARK2, have 
been found to be responsible for autosomal recessive early onset (AAO<40years) PD 
[Gasser, 2005]. Mutations in the PARK2 (Parkin) gene account for 50% of familial and 
70% of sporadic cases of early onset PD [Lucking et al., 2000 and Mata et al., 2004]. 
Similarly, in a study of 73 families which had at least one member with early onset PD, 
49% were shown to have mutations in the PARK2 gene [Lucking et al., 2000].  
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Clinically, PD caused by mutations in PARK2 differs from typical idiopathic PD in that 
dystonia is more common, the progression of the disease may be slower and the AAO 
can be very young (<20years) but may also be older. Unlike other cases of PD, the 
presence of Lewy bodies is rare [Takahashi, 1994]. PARK2 is located at the 
chromosomal position 6q25.2-q27 and codes for an E3 ubiquitin ligase. Its function is to 
tag proteins for degradation via the ubiquitin pathway [Wood et al., 2005]. There are 
currently more than 100 mutations in PARK2 that cause PD. Of these, more than 50 are 
point mutations while deletions, duplications and exon rearrangements account for the 
remainder [Tan and Skipper, 2007].  
 
1.6.2.3 Familial Encephalopathy with Neuroserpin Inclusion Bodies 
 (FENIB; MIM 604218) 
 
Serine proteases are enzymes that catalyse the hydrolysis of peptide bonds and play a 
role in intestinal digestion and blood coagulation. During neurogenesis they assist with 
cell migration and axon development. In adulthood they assist in neuropeptide 
processing, neural survival, neural structural processing and also play a role in learning 
and memory processes [Molinari et al., 2003].  
 
Serpins are a family of serine protease inhibitors and neuroserpins form part of this 
family but are expressed solely in neurons. Neuroserpins are normally expressed in the 
late stages of neurogenesis where they are postulated to assist with synaptogenesis 
[Osterwalde et al., 1996].  
 
Mutations in neuroserpins have been identified as the cause of an autosomal dominantly 
inherited neurodegenerative disease termed Familial Encephalopathy with Neuroserpin 
Inclusion Bodies (FENIB) [Davis et al., 2002]. The disease is characterised by dementia, 
myoclonus and the presence of eosinophilic inclusion bodies (Collin’s Bodies) in the 
cerebral cortex [Molinari et al., 2003]. Biochemical analysis of inclusions that were 
purified from post-mortem brains showed that they were periodic acid Schiff (PAS) 
positive but ubiquitin and α-synuclein negative and that the major constituent was the 
neuroserpin protein, SERPINI1. 
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Several point mutations have been identified in the SERPINI1 gene although only two, 
S49P and S52R, are common [Davis et al., 2002]. The phenotype of the S49P mutation 
was first described in a Caucasian family in the United States (US). The affected 
members presented in the fifth decade of life with initial symptoms of cognitive decline, 
response regulation difficulties, memory and visio-spatial abnormalities. The later stages 
were characterised by severe progressive dementia and action myoclonus [Molinari et 
al., 2003]. The S52R mutation was also reported in a Caucasian family in the US. In 
addition to the above mentioned symptoms, affected family members also suffered from 
epilepsy but the AAO in this family was in the third decade of life.  
 
There have been a number of proposed mechanisms of pathogenesis. Thus far, all the 
point mutations causing FENIB have been found in the “shutter” region of the functional 
site of the inhibitor. Molecular models of these point mutations show a distinct 
conformational change in the overall shape of the protein which makes the protein more 
prone to aggregation. In addition, the degree to which the mutated form tends to 
aggregate correlated with severity of the disease [Molinari et al., 2003]. As with other 
neurodegenerative diseases, it is generally accepted that the presence of aggregations 
plays a detrimental role in neuronal dysfunction. The pathogenesis of FENIB is likely to 
be due to the precipitation of mutant neuroserpin [Davis et al., 2002].  
 
1.6.3  Repeat expansion disorders 
 
Repeat expansion mutations are known to cause a number of neurodegenerative and 
neuropsychiatric disorders. Trinucleotide repeat expansions, in particular, are 
responsible for a vast amount of neurodegenerative diseases with motor disco-
ordination. Triplet repeat expansions can be classified as type I or type II depending on 
where the repeat expansion occurs in the DNA sequence. Type I disorders refers to 
those conditions in which the repeat lies in a coding region of a gene and therefore 
codes for functional amino acids. Type II disorders refer to conditions in which the repeat 
occurs in a non-coding region [Margolis et al., 1997].  
 
Polyglutamine diseases refers to a group of diseases caused by CAG or CAA repeat 
expansions associated with the production of long polyglutamine (polyQ) tracts. 
Although there are many proposed mechanisms of pathogenicity for diseases caused by 
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these mutations, the generally accepted mechanism of pathogenesis is that mutated 
transcripts containing polyQ tracts aggregate and form inclusions in the cell leading to 
cellular degradation. These intranuclear inclusions, which are usually immuno-positive 
for the mutated protein, have become hallmarks for polyglutamine disease [Neri, 2001]. 
Other theories propose that the mutant protein containing polyQ tracts has a 
conformational change that leads to abnormal cellular distribution of the protein which is 
toxic to the cell [Neri, 2001]. Another theory suggests that the mutant polyQ tracts 
interact with short polyQ tracts that normally occur in transcription factors, thereby 
affecting transcriptional regulation.  
 
Features of repeat expansion disorders include anticipation and repeat instability 
[Stevanin et al., 2000]. Anticipation refers to the ability of larger repeats to expand even 
further in successive generations. Repeat instability is the phenomenon whereby larger 
numbers of repeats have an unstable transmission in subsequent generations thereby 
causing repeats to be expanded into the pathogenic range in offspring of parents with 
large repeats [McInnis, 1996].  
 
In the following sections a number of different neurodegenerative disorders caused by 
repeat expansions will be discussed.  
 
1.6.3.1 Spinocerebellar Ataxias  
 
Spinocerebellar Ataxias (SCAs) are inherited neurodegenerative diseases characterised 
by limb or gait ataxia and dysarthria. The majority of SCAs are autosomal dominantly 
inherited. Over the past 14 years more than 28 genetically distinct types have been 
identified and there are still many cases of SCA for which a genetic cause or the affected 
gene has not been identified [Pulst, 2003]. 
 
In general, the prevalence rate of SCAs has been estimated to be three cases in every 
100 000 people but this is a tentative estimation based on studies in isolated regions 
[Michalik et al., 2004]. A true reflection of the prevalence rate is affected by rare 
subtypes not being included in many of the population studies. Furthermore, the 
subtypes in which a chromosomal region was implicated but the exact genetic mutation 
is unknown, makes it difficult to identify these subtypes [Watts and Koller, 1997]. A direct 
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comparison between regional occurrences of subtypes is hindered due to founder 
effects which creates a genetic bias. The presence of founding individuals in a 
population has a profound effect on the geographic occurrence of a particular subtype, 
for example SCA type 2 (SCA 2) in Cuba [Estrada et al., 1999]. From a global 
perspective, SCAs 1, 2, 3, 6 and 7 seem to be the most common types, representing 50-
80% of the known cases. In South Africa the most common type is SCA 1 [Ramesar et 
al., 1997], although cases of SCA types 2, 3, 6, and 7 have been reported [Bryer et al., 
2003].  
 
In addition to ataxia and dysarthria, affected persons may also display symptoms such 
as dementia, oculomotor disturbances, epilepsy, myoclonus and cognitive impairment 
[Pulst, 2003]. The neuropathological effects of SCAs vary amongst subtypes with a few 
morphological features that are present in most, if not all, types. These features typically 
include atrophy and loss of neurons in brain regions involved in movement and co-
ordination such as the cerebral cortex, purkinje cells, cerebellum and the striatum. 
Immunohistochemistry of neurons may show intranuclear aggregations containing 
polyglutamine tracts in many of the subtypes, while in others cytoplasmic inclusions are 
present [Schöls et al., 2004]. The clinical overlap between different subtypes makes it 
difficult to classify the subtypes clinically so generally they are classified using molecular 
methods. 
 
SCAs are caused by a variety of mutations, predominantly repeat expansions but point 
mutations have also been implicated in some subtypes [van Swieten et al., 2003]. Six of 
the characterised types of SCAs (types SCA1, SCA2, SCA3, SCA6, SCA7 and SCA17) 
are caused by CAG repeat expansions in coding regions of the respective genes and the 
number of repeats that lead to pathogenesis varies between subtypes [Schöls et al., 
2004]. In these cases the CAG repeats are generally thought to form polyglutamine 
tracts which bind with other proteins to form aggregates that are toxic to the cell thereby 
causing cellular dysfunction or death.  Another sub-type (SCA12) is due to a CAG repeat 
expansion in the 5’ non-coding region of the PPP2RB gene. A penta-nucleotide repeat 
expansion of (ATTCT) has been implicated in SCA 10 whereas point mutations in 
FGF14 and C γPKCγ have been shown to be causal in two cases of familial SCA.  
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1.6.3.2 Dentatorubral-Pallidoluysian Atrophy (DRPLA; MIM 125370) 
 
Dentatorubral-Pallidoluysian Atrophy (DRPLA) is a rare neurodegenerative disease 
characterised by cerebellar ataxia, choreo-athetosis, myoclonic epilepsy and dementia. 
DRPLA is distinguished from SCAs by the significant neuronal loss in the dentatorubral 
and pallidoluysian systems [Naito and Oyanagi, 1982]. In addition to the general 
symptoms, individuals with early onset DRPLA (<20years) also present with signs of 
progressive myoclonus epilepsy (PME). Late onset cases are clinically different, with 
most patients displaying choreo-athetosis and psychiatric disturbances [Ikeuchi et al., 
1995].  
 
DRPLA is caused by an unstable CAG repeat in the ATN1 gene located on chromosome 
12p13. Unaffected individuals have 3 to 36 repeats whereas in affected individuals the 
repeats range from 49-88 [Schöls et al., 2004]. The number of repeats is directly 
associated with the severity and AAO of the disease. Furthermore, anticipation has been 
observed in several cases [Komure et al., 1995].  
 
DRPLA occurs predominantly in Japan with a prevalence rate of two to four per million 
although cases in other ethnic groups have been noted [Lee et al., 2001]. The genetic 
mutation in an African American family affected with a neurodegenerative disorder, 
termed Haw River Syndrome, was later found to be the CAG expansion in Atrophin1 
(ATN1) gene and is thus considered the same disorder. However, the Haw River 
Syndrome cases showed a slightly different phenotype in that they had calcification of 
globus palladius and no myoclonic seizures [Burke et al., 1994]. 
 
The pathogenic mechanism of the disease is unknown and there are many theories 
surrounding it. Mutant ATN1 is expressed at similar levels to the wild type protein 
indicating that transcription efficiency is not altered. This concurs with the theory that 
polyglutamine tracts produced by CAG repeat expansions in the ATN1 gene are 
pathogenic to the cell and result in cell death [Onodera et al., 1995].  
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1.6.3.3 Huntington’s disease (HD; MIM 143100) 
 
 Huntington’s disease (HD) is an autosomal dominantly inherited disease caused by a 
CAG repeat expansion in the IT15 gene on chromosome 4p16.3. HD manifests as a 
progressive neurodegenerative disorder involving chorea, impaired cognitive ability and 
psychiatric disturbances. Affected individuals have an average of 20 years survival 
following the onset of clinical symptoms. HD accounts for approximately 90% of cases of 
chorea with a genetic aetiology [Schneider et al., 2007].  
 
HD is a late onset disease where the AAO is usually in the fourth decade of life, more 
specifically between 35-44 years of age. The early stages of disease are characterised 
by neurological disturbances, impaired voluntary movements and motor disco-ordination 
which progresses to a final stage of profound dementia and prominent chorea ultimately 
leading to death [Schneider et al., 2007]. Neuropathological examination of the brains of 
deceased HD patients showed severe degeneration of selective neurons in the striatum 
[Cowan and Raymond, 2006]. Intracellular inclusions containing mutant IT15 protein 
were also present.  
 
The prevalence rates varies in different population studies with estimates of four to eight 
per 100 000 cases in North America and Europe. However, the prevalence rates of HD 
in Japan, Norway and Finland are much lower [Schneider et al., 2007].  
 
The CAG repeat occurs in Exon 1 of the IT15 gene. The repeat codes for polyglutamine 
and HD therefore, falls into the category of Type I polyglutamine disorders. Unaffected 
individuals may have up to 26 repeats while the effect of 27-35 repeats are considered 
intermediate in that individuals with this range of repeats are not expected to exhibit the 
Huntington’s phenotype but their mutant allele is prone to expand in to the pathogenic 
range in subsequent generations [Semaka et al., 2006]. Reduced penetrance was 
demonstrated for cases in which the repeats were between 36 and 39 while repeats of 
greater than 40 are considered pathogenic. As with other repeat expansion disorders, 
the phenomenon of anticipation has been observed in many cases of HD. 
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1.6.3.4 Huntington’s disease-like 2 (HDL2; MIM 606438) 
 
Huntington’s disease-like 2 (HDL2) is a rare neurodegenerative disease characterised 
by movement abnormalities, selective neuronal degeneration and severe, progressive 
dementia. A hallmark of this disease is the presence of intranuclear inclusion bodies and 
selective atrophy in the cerebrum, while the cerebellum remains relatively unaffected. 
Clinically, the disease appears similar to HD but unlike HD it is caused by a repeat 
expansion in an alternatively spliced exon of the Junctophilin-3 (JPH3) gene [Walker et 
al., 2003].  
          
The discovery of HDL2 
 
 About 1% of HD-like cases are not due to the HD mutation. It has been proposed that 
the study of diseases that have a HD phenotype but are negative for the HD expansion 
may provide clues to the pathogenic mechanism of HD. 
 
Given this, in 2001, Margolis et al., described a family (pedigree W) with an HD-like 
phenotype who were negative for HD, SCA (types 1-3, 6-8 and 12), DRPLA, 
Huntington’s disease-like 1 and mutations in the TBP gene [Margolis et al., 2001]. The 
family was of African American descent and resided in South Eastern United States. The 
proband, a female, presented at 26 years of age with weight loss and disco-ordination 
which steadily progressed. After 10 years of disease the proband was severely 
demented and completely bedridden. The presentation of this disease was similar for all 
the cases in this family [Margolis et al., 2001].  
 
The MRI scans of the proband showed severe atrophy of the striatum and the cerebral 
cortex while the cerebellum was relatively unaffected. Microscopical analysis of brain 
tissue showed selective neuronal degeneration particularly of medium spiny neurons in 
the striatum. Furthermore, intranuclear inclusions were detected that stained with IC2 
antibodies which are proposed to be selective for long polyglutamine tracts but may also 
stain any form of aggregated protein. A positive reaction was also observed for staining 
with anti-ubiquitin antibodies but not with α-synuclein and anti-Huntington antibodies. 
The inclusions were predominantly present in the cortex. 
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It was suspected that the disease may be due to a repeat expansion because most 
repeat expansion disorders result in neuropsychiatric disorders [Margolis et al., 1997]. 
To ascertain the identity of the causative mutation the genomic DNA of several family 
members was analysed using the repeat expansion detection (RED) assay which 
detects any CTG/CAG repeats longer than 40 in an individual’s genome [Holmes et al., 
2001]. The flowchart (Figure1.7) displays the process that led to the identification of the 
HDL2 mutation.  
 
The RED assay detected a CTG/CAG repeat expansion of 50-60 repeats in all affected 
family members. Furthermore, this expanded tract was absent in all unaffected family 
members. In order to characterise this repeat the genomic DNA of one affected family 
member was subjected to digestion with EcoRI and the resulting DNA fragments were 
separated on a gel and the gel was then cut into 50 slices. The DNA fragments was 
extracted from the slices and a RED assay was performed on the extracted DNA in 
order to isolate fragments in which long CAG/CTG repeats were present.  
 
The fragments that were positive for the RED assay were cloned and the resulting library 
was probed with oligos that were specific for long CAG tracts. Clones that contained 
long repeats were subjected to direct sequencing. A 6kb clone that contained this 55-60 
repeats was identified and the regions flanking the repeat were used to design primers 
that would amplify the repeats in order to determine the repeat sizes in other family 
members. 
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Pedigree W was described with symptoms similar to HD but 
HD negative. 
It was suspected that the family had a repeat expansion 
disorder like SCAs or HD so genomic DNA (gDNA) was 
collected from family members and a RED Assay, which 
detects CAG/CTG repeat expansions, was performed. 
An unexplained (not due to SCA, DRPLA etc.) CAG/CTG tract 
of 50-60 repeats was found in all affected and no unaffected 
family members. 
gDNA of an affected family member was digested with EcoR1, 
the fragments were electrophoresed, the gel was sliced into 
50 pieces and DNA was extracted. RED ASSAY was 
performed on DNA from each slice. RED positive slices were 
cloned and the library was screened with (CAG)15 probes. 
Plasmids with long repeats were extracted and sequenced. 
 
 A 6kb region containing 55 CAG/CTG repeats was cloned. 
The sequences flanking the repeats were used to design 
primers to determine repeat length. 
The sequence was BLASTed against 
GenBank database.   
The sequence was mapped to JPH3 
gene on chromosome 16q23-24. Repeats ranged from 51-57 in 
affected Pedigree W 
members. Complete 
segregation of repeat 
expansion and disease in the 
family was shown. 
The repeat length was 
determined in 98 unaffected, 
unrelated individuals as well as in 
175 HD individuals and 330 
individuals with movement 
disorders.  
When two (CTG)8  primers anneal 
adjacent to each other along the 
template DNA, they ligate to each other. 
After 500 PCR cycles the longest oligo 
corresponded to the longest CAG/CTG in 
the genome of the individual.  
 
PCR products underwent electrophoresis 
and were probed with (CTG) 8 probes. 
Bands produced corresponded to long 
CAG/CTG tracts. The presence of 30-40 
repeats was expected as controls.  
 
gDNA was incubated with (CAG) 10 
primers, underwent electrophoresis and 
were probed with (CTG)8 primers. 
Figure 1.7: Schematic diagram of the process leading to the identification of the HDL2 mutation.  
METHOD OF REPEAT EXPANSION 
DETECTION (RED)  
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The repeat length of 13 individuals from the family (pedigree W) was determined. The range 
of pathogenic repeats in affected family members was 51-57 triplet repeats. The diversity of 
repeat length in three sibships indicated that the repeat was most likely unstable during 
vertical transmission [Holmes et al., 2001]. To further support the pathogenic aetiology of 
the repeat, the repeat length was determined in 175 individuals with HD, 98 unaffected and 
unrelated individuals as well as in 330 individuals with unknown movement disorders.  In 
this study [Holmes et al., 2001] the unexpanded alleles for all the individuals ranged from 6 
to 27 triplet repeats with a mode of 13 repeats (Figure 1.8).  
 
 
Figure 1.8: Graph representing the repeat length in JPH3 gene for 603 individuals (Black bars 
represents individuals with movement disorders of unknown aetiology, grey bars represents the 
control individuals) [Taken from Holmes et al., 2001].  
 
Expanded alleles, ranging from 44 to 50 repeats, were detected in four individuals of 
African American descent (unrelated to pedigree W), with a family history of an HD-like 
disorder but were negative for the HD mutation. In addition, an allele of 49 repeats was 
found in a Moroccan woman and a repeat expansion of 35 triplets was identified in an 
individual with a sudden onset of cerebellar signs [Holmes et al., 2001].  
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Complementary DNA (cDNA) containing this repeat had previously been mapped to 
chromosome 16 [Margolis et al., 1997]. To further characterise the repeat a 125kb contig 
containing the repeat was created from DNA of an affected pedigree W member. The 
contig was compared to the dbEST database and analysed using GENSCAN. The 
contig, with the repeat in the CAG orientation, did not match any ESTs in the database 
nor did GENSCAN predict any transcripts for this orientation of the repeat. However, in 
the CTG orientation the repeat was localised to the JPH3 gene, between Exons 1 and 2 
[Nishi et al., 2000]. The 125 kb contig included Exon 1 which allowed for the localisation 
of the repeat to 760 nucleotides 3’ to the end of Exon 1.  
 
Four factors lend support to the fact that the repeat lies in a variably spliced exon in the 
JPH3 gene. Firstly, a polyadenylation signal was identified 281 nucleotides 3’ to the 
repeat. Secondly, GENSCAN predictions displayed a transcript where Exon 1 is spliced 
to a terminal exon containing the repeat. Thirdly, two Expressed Sequence Tags (EST’s) 
from retinoblastoma and lung carcinoid tissue (BE042890 and BE779067) were 
identified which show Exon 1 spliced to the terminal exon containing the repeat. Lastly, 
the authors used RT-PCR on normal brain mRNA and found that this alternatively 
spliced transcript could exist in different forms due to the orientation of the splice 
acceptor sites. In these three forms the repeat can either code for polyalanine, 
polyleucine or lie in the 3’ untranslated region (Figure 1.9). 
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Figure 1.9: (a) Graphical structure of full length JPH3. The exons are indicated by grey blocks, 
location of the polyadenylation signal (AATAA) and the repeat are indicated. (b) Published JPH3 
mRNA transcript. (c-e)  Depicts the alternatively spliced versions of the JPH3 transcripts with 
exon 1 spliced to exon 2A and the different splice acceptor sites which causes the repeat to code 
for polyalanine, polyleucine or fall into the 3’ UTR [Taken from Holmes et al., 2001].  
 
Population studies of HDL2 
 
Since the discovery of HDL2 a steady increase in cases has been identified worldwide. 
Thus far, most of the reported cases are in individuals of Black African ancestry 
[Margolis et al., 2006]. An exception to these cases was a HDL2 positive individual from 
Morocco [Holmes et al., 2001] and a family from Mexico [Stevanin et al., 2003]. 
However, these individuals were later found to originate from areas in their respective 
countries that was colonised by Black Africans [Margolis et al., 2006]. Furthermore, a 
preliminary report had indicated 7 of 20 Black patients from South Africa had tested 
positive for HDL2 [Krause et al., 2002].  
 
No patients with an HDL2 repeat expansion were found in a study done on 1600 
Caucasian patients with HD-like symptoms from Austria and Germany [Bauer et al., 
2002]. Of this cohort 147 patients had a family history of HD-like symptoms. The repeats 
in this cohort ranged from 10 -27 triplets with modes of 14 and 16 repeats (Figure 1.10) 
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Figure 1.10: Determination of JPH3 repeat length in 1600 Caucasian individuals from Germany 
and Austria [Adapted from Bauer et al., 2002]. 
 
 A study done on individuals from Japan and North America with HD-like symptoms was 
also carried out. Out of 538 of the North American cases, six were positive for HDL2 but 
none of the 44 Japanese cases were positive for HDL2 [Margolis et al., 2004].  
 
Characterisation of the HDL2 repeat 
 
In order to determine the risk for developing HDL2, the repeat sizes were determined in 
a healthy population of Serbia and Montenegro. In this study, a cohort of 198 unrelated 
“healthy” controls was typed [Keckarevic et al., 2005]. No pathogenic repeat expansions 
were found and the alleles ranged from 11-18 repeats with a bimodal pattern of 
distribution with peaks at 14 and 16 repeats, results which were similar to those obtained 
by Bauer et al. [2002].  
 
The repeat length and age of onset is correlated in HDL2 as in other repeat expansion 
disorders [Margolis et al., 2004]. For example, in 24 HDL2 cases an increase in repeat 
length resulted in a younger age of onset (Figure 1.11). 
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Figure 1.11: The JPH3 repeat length is correlated with the age of onset [Taken from Margolis et 
al., 2004]. 
 
A repeat expansion of more than 43 repeats has been determined to be pathogenic, 
whereas repeats of between 40 and 43 are considered to be incompletely penetrant 
[Margolis et al., 2004]. Moreover, repeats of 33-35 have been reported to be unstable in 
vertical transmission. The phenotypic effects of repeats in this range have however not 
been established as an individual with 35 repeats developed Cogan’s Syndrome, which 
is an auto immune disease [Margolis et al., 2004]. 
 
Neuropathology of HDL2 
 
From a neuropathological perspective the disease mimics HD in that the caudate and 
putamen are severely atrophied in the late stages of the disease (Figure 1.12 A and D) 
[Margolis et al., 2006]. As in HD (Figure 1.12 B and E) the cerebrum was severely 
atrophied while the cerebellum remained relatively unaffected. The examination of four 
HDL2 brains showed severe atrophy of the striatum, particularly the caudate and the 
putamen while mild atrophy of the globus pallidus was observed [Margolis et al., 2006].  
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Figure 1.12: (A) and (D) MRI scans of an HDL2 case after 10 years disease duration. (B) and (E) 
MRI scans of HD brain after 12 years disease duration. (C) and (F) normal control at 43 years old 
[Taken from Margolis et al., 2003]. 
 
 As in HD, a hallmark of this disease is the presence of intranuclear inclusions. However 
these inclusions did not stain with anti-Huntington antibodies but were positive for 
staining with IC2 antibodies [Rudnicki et al., 2007]. 
 
Summary of the clinical presentation of HDL2 
 
Early clinical signs of the disease include weight loss, personality changes, imbalance 
and poor motor co-ordination. In later stages of the disease the patients exhibit 
choreiform movements, rapidly progressive dementia, rigidity and dystonia which 
culminate in a completely bedridden state within 10 -15 years of onset [Margolis et al., 
2004]. The age of onset has been estimated to be in the third to fourth decade of life with 
the earliest age of onset in a boy of the Mexican pedigree who reported to display 
choreiform movements and psychiatric disturbances at the age of 12 [Margolis et al., 
2004]. An HDL2 family with acanthocytosis has also been reported [Walker et al., 2002]. 
Although affected family members followed the general disease course, 30- 35% 
acanthocytosis was detected on peripheral blood smears of the three affected family 
members.  
 
 
  
31
 
The Junctophilin-3 gene 
 
The Junctophilin-3 gene is a member of a conserved family of proteins called 
Junctophilins. The Junctophilins play a role in the structure of junctional membrane 
complexes by regulating the Ca2+ influx [Takeshima et al., 2000]. Junctional complexes 
are structures that form between the sarcaoplasmic /endoplasmic reticulum and the 
plasma membrane in all excitable cells. The complexes are thought to provide functional 
cross talk between the plasma membrane and Ca2+ dependent ion channels.  
 
Four human Junctophilin subtypes have been identified. Blot hybridisation techniques 
were used to localise the mouse orthologues of the subtypes to their respective 
expression tissues. Junctophilin-1 (JP1) was localised to skeletal tissue and knock-out 
mouse models exhibited neonatal death [Nishi et al., 2003]. Junctophilin-2 (JP2) was 
expressed in both heart and skeletal muscle in mice [Nishi et al., 2003] and also lung 
and stomach tissue that indicates expression in smooth muscle [Takeshima et al., 2000]. 
Knock out mouse models showed disruption in normal Ca2+ transients in cardiac 
myocytes which ultimately resulted in embryonic lethality [Nishi et al., 2000].  
 
Junctophilin-3 (JPH3) is predominantly expressed in the brain and possibly the testis 
(Figure 1.13). A northern blot analysis of JP3 (the mouse ortholgue of JPH3) detected a 
4.4Kb fragment in mouse brain tissue and a smaller fragment in the testis [Nishi et al., 
2003]. The JP3 probes did not hybridize to any other tissues in this study.  
 
 
Figure 1.13: Northern Blot of JP3 in mouse tissues [Taken from Nishi et al., 2003]. 
 
Knockout mouse models of JP3 showed impaired motor co-ordination but no other 
morphological abnormalities. In addition, normal hearing, emotional and learning abilities 
were observed [Nishi et al., 2003].  It was noted that the phenotype seen in these mice 
was, surprisingly, not as severe as the presentation of HDL2 in humans. Junctophilin-4 
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(JP4) may have similar functions as JP3 because JP4 was also shown to be expressed 
solely in the brain (Figure 1.14 G) and displayed co-localized expression with JP3 in 
mouse brains (Figure 1.14 A–F) [Nishi et al., 2003]. It has been proposed that JP4 may 
assist in carrying out JP3 functions in the knockout mouse models and that may be the 
reason for the phenotype in the knockout mice being less severe than that observed in 
HDL2 cases [Margolis et al., 2006].  
 
 
Figure 1.14: (A-F) Dark-field photographs showing similar expression patterns of JP3 and JP4 in 
adult mouse brains. (G) Northern blot of JP4 in mouse tissues [Taken from Nishi et al., 2003]. 
 
The mechanism of pathogenesis for HDL2 is unknown although a number of theories 
have been postulated. One theory explores the possibility that RNA foci are formed in 
the brains of HDL2 patients as in myotonic dystrophy type 1 (DM1) [Brook et al., 1992]. 
As in DM1, RNA containing repeat expansions form aggregations which are toxic to the 
cell.  In HDL2, it was proposed that an RNA gain of function mechanism contributes to 
the pathogenesis of the disease because no mutant protein was found in the 
intranuclear inclusion bodies. In addition, the pathogenic repeat may fall into an 
untranslated region possibly explaining why the aggregation of mutant protein is not 
solely responsible for the disease [Rudnicki et al., 2007].  
 
To investigate the possibility of RNA–gain of function mutation the authors first 
attempted to identify the JPH3 transcript in post-mortem brain using the Fluorescent in 
situ hybridisation (FISH) technique with probes specific to Exon 2A [Rudnicki et al., 
 
(G) 
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2007]. Once the foci were identified, the composition of the foci was determined and was 
shown to contain RNA transcripts in which Exon 1 was present. Both these results 
showed negative reactions in post mortem HD brains. Further analysis showed that the 
foci may contain other splice variants. Secondly, all inclusions were in neurons with the 
inclusion in the striatum having a brighter appearance in dark-field microscopy than 
those in the frontal cortex indicating that the striatum may be more severely affected 
than the frontal cortex [Rudnicki et al., 2007].  
 
Another proposed mechanism suggests that the disease may be due to a loss of 
function. This theory is based on the fact that the phenotypes of knockout mouse models 
are not as severe as the disease in humans. Furthermore, it was hypothesised that an 
increase of alternative spliced transcript expression in affected individuals could 
decrease the expression of full length JPH3 thereby causing a more severe phenotype.   
 
1.7 Aims and objectives of the present study   
 
The primary aim of the present study was to identify the pathogenic mutation underlying 
dementia and movement disorders in a South African family of Mixed Ancestry. The 
investigation involved a clinical and molecular analysis of affected and unaffected, at-risk 
family members.  
 
Ultimately the identification of the disease-causing mutation in this family would provide 
the option of informed genetic counselling and pre-symptomatic genetic testing for at-risk 
family members. In the long term, the identification of this mutation may contribute to the 
understanding of the patho-physiology involved in this neurological disorder.  
 
 
 
 
 
 
 
 
  
34
 
CHAPTER TWO: MATERIALS AND METHODS 
 
2.1 Study participants 
 
In the present study, a self-reported Mixed Ancestry family presenting with dementia and  
movement disorders of unknown aetiology was investigated. The proband (5657) 
presented at Tygerberg Hospital with severe dementia and a movement disorder. A 
subsequent review of his family history revealed that several family members spanning 
three generations had also displayed similar symptoms and had died of the disorder. 
Figure 2.1 depicts the pedigree of the family investigated (hereafter referred to as  
Family R). The pedigree was constructed based on data obtained from other unaffected 
family members, a close family friend as well as hospital records. 
  
Figure 2.1: Pedigree of the affected family, Family R. Genomic DNA was available for individuals 
5760, 5555, 5657, 6341,and 6188. The solid arrow indicates the proband, 5657 and the 
diamonds symbolise unknown gender. 
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Later, another family member (5760) was also identified with dementia and a movement 
disorder. A study was undertaken to identify the disease-causing mutation segregating in 
this family. In addition, two family members who had affected parents but were clinically 
unaffected at the time of this study (individuals 6341 and 6188, aged 35 and 36 years 
respectively) were also recruited. As indicated, most of the affected individuals are 
deceased hence no DNA was available for them. Due to the late age of onset of the 
symptoms, many of the fourth generation family members could not partake in this 
study, as they were too young and asymptomatic. For these reasons, DNA of only five 
family members was available (5555, 5657, 5760, 6188, and 6341). 
 
In 2006, a complete neurological examination was performed on the proband (5657) and 
his uncle (5760) (Table 2.1). This examination included a Mini-Mental State Examination  
(MMSE) which detects and measures the extent of dementia [Folstein et al., 1975]. 
Once corrected for age and the level of schooling, a MMSE score ranging from 20-26 
(out of 30) is indicative of mild dementia while scores between 10-19 indicates moderate 
dementia. An MMSE score of less than 10 signifies severe dementia [Crum et al., 1993]. 
An electroencephalogram (EEG) to detect problems in the electrical activity of the brain 
was also performed. Somatosensory evoked potentials (SEP) measured the electrical 
activity of the sensory cortex in response to peripheral sensory stimuli. Jerk-locked 
averaging (JLA) was performed, which measured the brain activity preceding brisk 
involuntary movements such as those observed in patients with myoclonus.  JLA in 
conjunction with SEP was used to classify this family’s movement disorder [Barrett, 
1992] Magnetic Resonance Imaging (MRI) was employed to detect any structural 
alterations in their brains. 
 
 According to Tygerberg Hospital’s medical records, another affected member (5555) 
had reported with similar symptoms in the period during 1993-1995 and had then been 
clinically examined. Unfortunately the examination was not as thorough as that of 
individuals 5657 or 5760. A summary of the clinical examination is reported (Table 2.1).  
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       Table 2.1: Summary of the neurological examination of affected individuals. 
Symptoms 5760  5555 5657 
Age of onset 48 years 25 years 39 years 
Year of examination 2006 1993-1995 2006 
Dementia 
 
Present Present Present 
MMSE1 14 ND 13 
Psychiatric symptoms 
 
Dementia only Echolalia 
Disinhibited 
Aggressive 
Hallucinations, 
paranoid 
delusions 
Reduced facial expression Yes No Yes 
Hyperreflexia No No Yes 
Increased tone 
 
Yes No Yes 
Bradykinesia Yes No Yes 
Postural tremor Yes (low 
amplitude) 
No Yes (prominent) 
Rest tremor No No Intermittent 
Cerebellar signs 
 
Within normal 
limits 
No Probably normal 
Abnormal posture Yes No Yes 
Chorea 
 
No Yes No 
EEG2 Normal ND Normal 
SEP3 Normal ND Enlarged 
JLA4 No cortical spike ND ND 
 
1) Mini-Mental State Examination (MMSE)  
2) Electroencephalogram (EEG)  
3) Somatosensory evoked potentials (SEP)  
4) Jerk-locked averaging ( JLA) 
        Not determined (ND) 
 
Ethical approval for this study was provided by the University of Stellenbosch, 
Committee for Human Research (reference number: N06/05/089). For Family R, 
informed consent (Appendix 1) was obtained to collect blood samples for the genetic 
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analysis. These samples were collected during the time in which the family members 
were examined at Tygerberg Hospital. 
 
Blood was also collected from a number of control individuals, representing the Mixed 
Ancestry, Caucasian and Black South African sub-populations. Samples from 60 
Caucasian individuals and 51 from each of the Black and Mixed Ancestry populations 
were obtained. 
 
2.2  Exclusion of known loci by the National Health Laboratory Service   
 
Prior to this study, the DNA of one affected individual had been analysed by the National 
Health Laboratory Service (NHLS -Groote Schuur Inherited Metabolic Diseases). This 
laboratory screened for mutations on the mitochondrial genome, which commonly cause 
MELAS, MERRF and Leigh’s Disease (Table 2.2). In addition, other known loci were 
screened by NHLS/University of Cape Town (UCT) Human Genetics Research Unit, 
(Institute of Infectious Disease and Molecular Medicine, University of Cape Town). 
These included the loci for Huntington’s disease (HD) and Spinocerebellar Ataxia (SCA) 
types 1, 2, 3, 6 and 7.   
 
Table 2.2: Known mutations causing neurodegenerative disorders.  
Disorder  Mutation 
Myoclonus Epilepsy and Ragged-Red Fibres (MERRF) A8344G 
Deletion 8356-8851 
Mitochondrial myopathy ,Encephalopathy, Lactic acidosis and 
Stroke-like episodes (MELAS) 
A3243G 
T3271C 
Leigh’s disease  G13513A 
G14459A 
T8993C 
T9176C 
Huntington’s disease (HD) Repeat expansion in the IT15 
gene 
Spinocerebellar Ataxia (SCA) Repeat expansions at the SCA 
types 1, 2, 3, 6 and 7 loci 
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These loci were all negative for mutations and hence excluded as the cause of the 
disorder in this family. 
 
2.3  Selection of candidate genes 
  
Several disorders are known to cause the symptoms that Family R presented with 
(Introduction: Section 1.6). These disorders were therefore likely candidates to screen 
for and are listed below (Table 2.3).  
  
Table 2.3: Candidate disorders selected to be screened and the symptoms involved in each 
disease. 
(1) Myoclonus Epilepsy and Ragged-Red Fibres (2) Mitochondrial myopathy, Encephalopathy, Lactic acidosis and Stroke-
like episodes (3) Ragged red fibres (4) Familial multisystem degeneration associated with parkinsonism (5) Gerstmann-
Straussler-Scheinker syndrome (6) Parkinson’s disease (7) Familial  Encephalopathy with Neuroserpin Inclusion Bodies 
(8) Spinocerebellar ataxias (9) Dentatorubral-Pallidoluysian Atrophy (10) Huntington’s disease (11) Huntington’s disease-
like 2  (*) symptom present 
 
As mentioned in Section 2.2 the common mutations associated with MELAS, MERRF, 
Leigh’s disease and five loci for SCA and HD were already excluded as being the 
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mutations underlying the disorder in this family. Candidate genes were selected to be 
screened for pathogenic mutations on the likelihood of these genes being implicated in 
neurological diseases (Tables 2.4 A and B). The selected candidate genes were divided 
into mitochondrial (Table 2.4 A) and nuclear (Table 2.4 B) genes.  
 
Table 2.4 A: List of all mitochondrial genes selected as candidate genes to be screened. 
DM, Diabetes Mellitus; MECM, Mitochondrial Encephalocardiomyopthy; ME, Mitochondrial Encephalopathy; MM, 
MERRF/MELAS overlap 
Table 2.4 B: List of nuclear genes selected to be screened and associated diseases.   
Mitochondrial 
gene 
Coding for  Position on 
mitochondria 
 Associated Diseases 
MTTF  tRNA phenyl alanine 577-647 MM; MELAS; MERRF: Nephritis   
 
MTTL1  tRNA leucine 1 3230-3304 MM, MELAS, MERRF, Deafness, DM 
MTTI tRNA isoleucine 4263-4331 MM, MECM, 
MTTQ tRNA glutamine 4329-4400 MELAS 
MTTM tRNA methionine 4402-4469 MM, 
MTTK tRNA lysine 8295-8364 MERRF, ME 
MT-ATP8 ATP synthase 
subunit 
8366-8572  
MT-ND4  NADH de-
hydrogenase subunit  
10760-12137 Familial multisystem degeneration with 
Parkinsonism (LHON variant) 
MTTH tRNA histidine 12138-12206 MERRF, MELAS, cerebral oedema 
MTTS2  tRNA serine 2 12207-12265  
MTTL2 tRNA leucine 2 12266-12336 MM 
Gene  Chromosomal 
location  
Type of mutation Associated 
disorder  
Serpini1  
(PI12)  
3q26.1 S49P and S52R point mutations FENIB 
Atrophin1 
(ATN1) 
12p13 CAG repeat expansion in exon  DRPLA  
Parkin  
(PARK2)  
6q25.2-q27 Point mutations /deletions / 
exon rearrangements/ 
duplications/insertions 
Early onset PD 
Junctophilin-3 
(JPH3 )  
16q24.3 CTG/CAG repeat expansion in exon2 A  HDL2  
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2.4  DNA extraction  
 
All blood samples were collected in EDTA tubes and stored at 4ºC until further use. DNA 
was extracted from whole blood using a modified phenol/chloroform method by Mrs Ina 
Le Roux (MAGIC Lab, Tygerberg Campus, Stellenbosch University) [Corfield et al., 
1993] (Appendix 3). The method involves the separation of genomic DNA from cellular 
debris by a phenol/chloroform solution. All DNA samples were diluted to approximately 
200ng/µl and this was the working concentration for all subsequent reactions.  
 
2.5  Primer design 
 
The Human Mitochondrial DNA Revised Cambridge Reference Sequence (rCRS) 
[www.mitomap.org] was used as a reference sequence to design the six primer sets 
used to amplify the mitochondrial candidate genes (Table 2.5). In some cases, more 
than one gene could be screened with one set of PCR primers, for example, the MTTI; 
MTTQ and MTTM genes were amplified with one primer set. 
 
Primers were designed to amplify nine genes encoding mitochondrial tRNAs, the 
ATP8ase gene and a region of the MT-ND4 gene. These genes were selected for 
screening because they had all been previously noted to harbour mutations causing 
movement disorders and/or dementia. In some cases the primers amplified genes that 
were in close proximity to the selected regions. For this reason the MT- ATP8, MTTS2 
as well as regions of the MT-ND1 and MT-ND2 genes were also screened. Table 2.5 
summarises the details of the primer sets designed to amplify candidate genes, including 
their positions on the genome, the genes that were screened and the PCR conditions. 
 
Primers to amplify nuclear regions were designed based on the reference sequences in 
the NCBI database [www.ncbi.nlm.nih.gov]. The primers used in the PARK2 study were 
designed for another study in our laboratory. All 12 exons, including the promoter region, 
of the PARK2 gene were amplified using PCR primers that are listed in Table 2.6. Exon 
12 was too large to PCR-amplify with one set of primers so two primer sets (12 A and B) 
were designed to amplify this exon. The primers designed for the JPH3 study (Table 2.7) 
were based on reference sequences from ensembl database [www.ensembl.org]. 
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All primers (except those used in the PARK2 investigation) were designed using Primer3 
programme V.02 [http://frodo.wi.mit.edu/cgibin/primer3/primer3_www.cgi]. The primers 
were designed at least 30bp upstream and downstream to the 5’ and 3’ ends of target 
regions respectively.  
The only settings that were changed in Primer3 for the primer designing were:  
• Primer melting temperature (Tm):  
     Minimum 50ºC, Optimum 55ºC, Maximum 60ºC  
• Maximum Tm difference =10ºC 
• Primer GC%:  Minimum = 40ºC , Optimum = 50ºC, Maximum = 60ºC 
• Minimum primer length was set as 18bp and the maximum was 22bp 
 All the other parameters were used at the default settings.  
 
The melting point temperature of the primers (Tm) was manually calculated using the 
following formula:  
Tm = 4ºC (G+C) + 2ºC (A+T) 
The primer annealing temperature (Ta) of each primer set was calculated as 2ºC-5ºC 
less than the primer with the lower Tm. Primers were synthesized by Inqaba Biotechnical 
Industries (Pty) Ltd. Fluorescently-labelled primers were synthesized at the Synthetic 
DNA Laboratory (Department of Cellular and Molecular Biology, University of Cape 
Town, South Africa) using standard phosoramidite techniques with an Oligo 1000M DNA 
Synthesizer (Beckman Instruments Inc.). The fluorescent label, FAM-6, was covalently 
attached to the non-reactive 5’ end of the primers.
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Table 2.5: List of the primers designed for this study including PCR conditions. Mitochondrial primers are listed in blue and primers for nuclear 
genes are in black.   
 
Primer Set Sequence  Expected 
fragment size 
Gene Position  
on the gene 
Annealing 
Temperature (ºC) 
Additives  Labelled  
MTTF 
Forward 
 
Reverse 
 
AATACAACCCCCGCCCATC 
 
GGGGATGCTTGCATGTGTA 
 
222bp 
MTTF 486-505 
690-708 
 
55 
None  None  
MTTL1 
Forward 
 
Reverse 
 
GCCTTCCCCCGTAAATGATA 
 
CGTTCGGTAAGCATTAGG 
 
218bp 
Mt-ND1 
partially 
3163-3182 
3363-3381 
 
 
52 
None  None  
MTTI, Q, M 
Forward 
 
Reverse 
 
GATTCCGCTACGACCAACTC 
 
GCTTAGCGCTGTGATGAGTG 
 
397bp 
MTTI,MTTQ 
MTTM Q 
MT-ND2 ( partially) 
4142-4161 
4519-4538 
 
60 
None  None  
MT-ND4 
Forward 
 
Reverse 
 
CACGGGCTTACATCCTCATT 
 
GGAGAACGTGGTTACTAGCACA 
 
207bp 
MT-ND4 
(partially) 
11714-11733 
11898-11920 
 
60 
None  None  
MTTH, S2, L2 
Forward 
 
Reverse 
 
ACACCTATCCCCCATTCTCC 
 
AACGAGGGTGGTAAGGATGG 
 
333bp 
MTTH, 
MTTS2, 
MTTL2 
12076-12095 
12389-12408 
 
58 
None  None  
MTTK, MT-ATP8 
Forward 
 
Reverse 
 
ATGCCCATCGTCCTAGAATC 
 
TTTGGAGGTGGGGATCAATA 
 
428bp 
MT-Atp8 ase 8204-8222 
8612-8631 
 
55 
None  None  
PI 12 
Forward 
 
Reverse 
 
CCTCCCAACATATCCTTCCA 
 
GGGTTTCCTAATCCTTCTAGCC 
 
 
491bp 
SERPINI1 53301-53320 
 
 
53770-53791 
 
58 
None  None  
DRPLA rpt 
Forward 
Reverse 
 
CCTCTTAGCCAACAGCAATG 
AGACATGGCGTAAGGGTGTG 
 
~250 bp- 350bp 
CAG repeat in  
Atrophin1  
 
1586-1606 
 
1817-1836 
 
58 
None  6-FAM 
HDL2 
Forward 
 
Reverse 
 
 
GGAATCTCGTCTTTCAGTGG 
 
TGAGGAGTGGATATCGGAGAG 
 
~250-300bp  
CTG/CAG repeat in 
Junctophilin-3  
1274-1294 
 
 
 
1496-1516 
 
58 
DMSO 6-FAM 
42
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Table 2.6: Primers and PCR conditions for the screening of the PARK2 gene.  
 
 
Region   Forward primer  Reverse primer   Annealing 
temp (ºC) 
Product size 
(bp)  
Additives  
PROMOTER 
 
ATCCAGATGTTTGGCAGCTC CGGCTCTCCTGGGTTAAATC 55 351 Formamide 
EXON 1 
 
GAACTACGACTCCCAGCAG CCCGTCATTGACAGTTGG 55 300 Formamide  
EXON 2  
 
CACCATTTAAGGGCTTCGAG TCAGGCATGAATGTCAGATTG 55 313 None  
EXON 3  
 
TCTCGCATTTCATGTTTGACA GCAGACTGCACTAAACAAACA 55 364 None  
EXON 4 
 
GCTTTAAAGAGTTTCTTGTC TTTCTTTTCAAAGACGGGTGA 55 299 None 
EXON 5  
 
GGAAACATGTCTTAAGGAGT TTCCTGGCAAACAGTGAAGA 55 223 None 
EXON 6  
 
CCAAAGAGATTGTTTACTGTG GGGGGAGTGATGCTATTTTT 55 280 None 
EXON 7  
 
CCTCCAGGATTACAGAAATTG GTTCTTCTGTTCTTCATTAGC 55 232 None 
EXON 8  
 
GGCAACACTGGCAGTTGATA GGGGAGCCCAAACTGTCT 55 232 None 
EXON 9  
 
TCCCATGCACTGTAGCTCCT CCAGCCCATGTGCAAAAGC 55 297 None 
EXON 10  
 
CAAGCCAGAGGAATGAATAT GGAACTCTCCATGACCTCCA 55 272 None 
EXON 11 
 
CCGACGTACAGGGAACATAAA GGCACCTTCAGACAGCATCT 55 300 None 
EXON 12A 
 
TCTAGGCTAGCGTGCTGGTT GCGTGTGTGTGTGTGTTTGA 55 296 Formamide  
EXON 12B 
 
ACATCCTGGGGGAGCATAC GCTCTGCTGTCTTGTGTGGA 55 237 None  
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Table 2.7: Primers and PCR conditions used in the analysis of mRNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*ND: Not determined 
gDNA: Genomic DNA  
Primer Set Sequence  Expected 
fragment size 
Gene Annealing 
Temperature 
(ºC) 
Additives  
HBB  
Forward  
Reverse 
 
ACACAACTGTGTTCACTAGC 
ACCGAGCACTTTCTTGCCAT 
 
 
(mRNA) 248bp 
(gDNA) 377bp 
 
β-Haemoglobin 
 
 
55 
 
 
None 
JPH3 Full length set A 
Forward 
Reverse 
 
TACTCGGACGGAGGGACC 
 
GGTACTCCAGCCCGTTTTC 
 
928bp 
 
Exon 2-3 JPH3  
 
 
ND* 
 
None 
JPH3 Full length set B 
Forward 
Reverse 
 
AAGTCCAGTACGGGCTCAG 
 
CCACTTTCTAAGCTCGTGTC 
 
530bp 
 
Exon 4-5 
JPH3 
(partially) 
 
 
56 
 
None 
JPH3 Alternatively spliced 
Forward 
Reverse 
 
CTACTCGGACGGAGATGC 
 
AGGAGTGGATATCGGAGAGT 
 
 
181bp 
 
Alternatively 
spliced JPH3 
mRNA 
 
 
56 
 
None 
44
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2.6  DNA quantification 
 
DNA and primers were quantified and analysed using the NanoDrop® ND 1000 –UV-Vis 
Spectrophotometer (NanoDrop Technologies, Inc. USA) according to manufacturer’s 
instructions. The NanoDrop® employed UV/VIS spectrophotometry to accurately 
determine nucleic acid concentration in a sample which is recorded in ng/ul. It also 
measured the purity and quality of a nucleic acid sample by measuring the ratio of 
absorbance at 260nm and 280nm. The 260/280 ratio for good quality, purified DNA is 
~1.8. A deviation in this ratio is normally indicative of contaminants, such as salts or 
phenol, in a sample.    
[www.nanodrop.com/techsupport/nd-1000-users-manual.pdf] 
 
2.7  Polymerase chain reaction  
 
PCR amplification was performed in a standard reaction mixture of 50µl on a 
GeneAmp® PCR system 2720 Thermal (Applied Biosystems). Each PCR reaction 
contained 0.1µg template DNA; 20pmol of each primer; 2.5mM (0.05mM of each) dNTP 
(dATP; dTTP; dCTP; dGTP) (Bioline  Ltd, London, UK), 0.1 Units (U) BIOTAQ™ DNA 
Polymerase (Bioline Ltd, UK); 1XNH4 Buffer (Bioline Ltd, London, UK);1.5mM MgCl2 and  
Sterile Injection water (Fresenius Kabi) to a final volume of 50µl.  
 
In some cases (Tables 2.5, 2.6 and 2.7), additives such as Dimethyl sulphoxide (DMSO) 
or formamide were used to facilitate the amplification process. In such cases 5% of the 
final volume contained the respective additive. 
 
The PCR cycling regime was as follows:  
An initial denaturing step of 94°C for five minutes followed by 35 cycles of denaturation 
at 94°C for 30 seconds, varying annealing temperature (Table 2.5, 2.6 and 2.7) for 30 
seconds and extension at 72°C for 45 seconds. The 35 cycles was followed by a final 
extension step of 72°C for 5 minutes. 
 
For colony PCR, sterile techniques were used to pick single colonies as template DNA. 
The initial denaturing step was extended to ten minutes to ensure that the colonies 
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would burst and release the DNA. Thereafter, PCR amplification was performed as 
described above. All PCR products were stored at 4°C until further use. 
 
2.8  Gel electrophoresis 
 
All PCR products and DNA was visualised using agarose gel electrophoresis. Gels were 
made up to 2% (w/v) by dissolving 1g of agarose (Whitehead Scientific, South Africa) in 
50ml of 1X Sodium Borate (SB) buffer (Appendix 2) at a high temperature. Once the 
solution had cooled down, 5µl of 1µg/µl Ethidium Bromide was added to the solution. 
Ethidium bromide binds to DNA molecules and allows the DNA to be visualised under 
ultra violet (UV) light. Ethidium bromide is a carcinogen and should be used with caution. 
Later in the study, SYBR Green I Nucleic Acid Gel Stain® (Roche Applied Sciences) 
was used according to manufacturer’s specifications, to replace the use of Ethidium 
bromide. SYBR Green I Nucleic Acid Gel Stain® serves the same purpose as Ethidium 
bromide but is not thought to be carcinogenic and thus minimised the risk of danger to 
the user.  
 
Prior to loading a sample onto a gel, 1µl of Bromophenol Blue (Appendix 2) loading dye 
was added to 8µl of each sample. In all cases 2µl of 100bp DNA ladder (Promega, USA) 
was co-electrophoresed with the samples on the gel as a size standard. 
  
The samples were resolved by electrophoresis at 250 volts (V) for 10-20 minutes in 
1XSB running buffer. The samples were viewed under UV illumination (Transilluminator 
model LMS-26E, USA) and photographed using a Sony graphic system UP-860CE 
(Sony Corporation, Japan).  
 
2.9  Purification of PCR products 
 
In some cases PCR products were purified for downstream processes. For sequencing, 
DNA was purified using Exonuclease I (USB Corporation, USA) and Shrimp Alkaline 
Phosphatase (Roche Applied biosciences) according to manufacturer’s instructions. 5U 
of Shrimp Alkaline Phosphatase and 5U of Exonuclease I was added to 8µl of PCR 
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product. The mixture was then incubated at 37ºC for 15 minutes followed by 80ºC for 15 
minutes to deactivate the enzymes.  
 
The concentration and purity of the PCR products were checked using the Nanodrop® 
according to manufacturer’s specifications. The samples were then diluted down to the 
desired concentration using sterile distilled water. 
 
For cloning purposes the appropriate DNA fragment was excised from an agarose gel 
using a sterile scalpel and placed in a sterile Eppendorf tube. The fragment was then 
purified using the GFX™ PCR DNA and gel band purification kit (Amersham Pharmacia 
Biotech, New Jersey, USA) according to manufacturer’s instructions.    
 
2.10  Direct sequencing 
 
Automated direct sequencing [Mattocks et al., 2000] was performed using the BigDye 
Terminator Sequence Ready Reaction kit version3.1 (Applied Biosystems, USA) and 
resolved on an ABI 3130X ® Genetic Analyzer (Applied Biosystems, USA). The primers 
used for sequencing were diluted to 1.1µM and the PCR products were diluted to 
20ng/µl. The sequencing data was analysed using BioEdit version 7.0.5 software 
[www.mbio.ncsu.edu/BioEdit/page2.html].  
 
2.11  Genotyping on an ABI 3130xl® Genetic Analyzer  
 
For parts of this study, fluorescently labelled primers were used for automated 
genotyping of samples on the ABI Prism 3130XF® Genetic Analyzer (Applied 
Biosystems, USA). GeneScan-500 LIZ size standard was used as a size marker, which 
can determine fragments of 75- 500bp in size. The data was analysed using 
GeneMapper ® V3.7 software (Applied Biosystems, USA). The software sizes the peaks 
based on the internal size standard and analyses the peaks based on user-defined 
parameters.  
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2.12  Single Strand Conformational Polymorphism (SSCP) Analysis  
 
Single Strand Conformational Polymorphism (SSCP) Analysis [Orita et al., 1989] was 
used as a mutation detection method for screening the PARK2 gene. The method 
involves separating double stranded DNA and then rapidly cooling it so that the single 
stranded DNA form secondary structures to create a unique banding pattern when 
subjected to electrophoresis on a polyacrylamide gel (Appendix 4). The gel is then silver 
stained [Gottlieb and Chavko, 1987] (Appendix 5) in order to detect the bands formed by 
DNA. Changes in the DNA sequence will then be seen as a shift in the banding pattern. 
 
Certain conditions may be altered in order to obtain optimal results. In this study, one 
such optimisation was employed by varying the percentage of polyacrylamide and urea 
in the gel (Appendix 4). The samples were run on both 8% and 10% polyacrylamide gels 
at 4ºC, 70 Watts overnight on an ‘in-house” manufactured electrophoresis system. 
Samples in which a shift was observed were sequenced to determine the exact 
sequence variation.  
 
2.13  Genetic ancestry testing  
 
Genetic Ancestry testing was performed by the MRC/NHLS/WITS Human Genomic 
Diversity and Disease Research Unit (HGDDRU) Johannesburg, South Africa. The 
method uses Y–chromosome analysis to determine the paternal lineage and sequencing 
of regions in the mitochondrial genome to resolve the maternal lineage of the individual.  
 
Family R member, 5760, was used in this study as a representative of the family. The 
detection of various single nucleotide polymorphisms (SNPs) and short tandem repeats 
(STRs) on the Y-chromosome created a haplogroup for the individual. The resolved 
haplogroup was compared against a database containing 42000 males worldwide 
[www.yhrd.org/index.html].  
 
Sequencing of regions of the mitochondrial genome resolved the maternal haplotype for 
5760. This profile was compared to 33 haplogroups recognized world wide and then 
grouped to a particular sub-haplogroup.   
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2.14  Cloning and transformation 
 
Following DNA quantification, purified PCR products were cloned into the pGEM®-T 
Easy cloning vector using the pGEM®-T Easy Vector Systems cloning kit (Promega, 
USA) as specified by the manufacturer’s instructions. Three ligation reactions were set 
up in which 1:1, 1:3 and 1:5 vector to PCR product ratios were used.  
 
Competent E. coli DH5α cells were prepared using the method described by Sambrook 
and Russell (Appendix 6) [Sambrook and Russell, 2001]. 3µl-5µl Of the respective 
ligation reactions were used to transform 200µl of thawed competent cells via heat 
shocking. This process entailed incubating tubes containing the cells and the ligation 
mixture on ice for 20-30 minutes. The mixtures were then placed at 42ºC for 45 seconds 
only, followed by incubation at room temperature for 2 minutes. 2ml Luria Bertani Broth 
(Appendix 2) was added to the cells and the cells were incubated on a shaker at 37ºC 
for 60 minutes. Thereafter, 200µl of this mixture was plated onto Luria Bertani (LB)agar 
(Appendix 2) containing 15mM Isopropyl-beta-D-thiogalactopyranoside (ITPG), 100µg/ml 
ampicillin and 5mg/ml 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-GAL). 
The plates were then incubated overnight at 37°C. 
 
The following day, a number of blue and white single colonies were picked and placed 
into separate sterile 15ml Falcon tubes containing 5ml LB broth. These tubes were 
incubated at 37ºC on a shaker overnight to allow cells to express the vector. The 
following day the tubes were spun down at 15000rpm and the supernatant was 
removed. The isolation of plasmid DNA from the cells was attained using GeneJET™ 
Plasmid Miniprep Kit (Fermentas Life Sciences, UK) according to manufacturer’s 
instructions. The plasmids were subjected to colony PCR, with insert specific primers 
followed by direct sequencing to determine whether they contained the correct insert. 
 
2.15  Lymphocyte separation and transformation  
 
Lymphocytes were cultured by Mrs Ina Le Roux using an “in-house” method. Blood of 
two affected family members were collected in heparin tubes. Heparin tubes prevent the 
coagulation of blood by inhibiting thrombin in the coagulation cascade. Lymphocytes 
were isolated from the whole blood and transformed (immortalised) to provide a 
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permanent source of DNA and RNA of the patients. This was achieved by initiating 
transformations of lymphocytes, with Epstein-Barr virus infection using an optimised 
protocol (Appendix 7). The cell pellet was then spun down and stored at -20ºC until 
further use.  
 
2.16 RNA isolation and cDNA synthesis  
 
RNA was isolated from the patients’ transformed lymphocytes using TRIzol ® reagent 
(Invitrogen Life Technologies) in a modified protocol (Appendix 8) [Chomczynski and 
Sacchi,  1987]. In addition, RNA from 21 pooled foetal brains was purchased (Clonetech, 
USA). The foetuses had spontaneously aborted at 26-40 weeks and the RNA was 
extracted from fresh brain tissue. The purity of foetal brain RNA was analysed and both 
the 260/280 and the 28S/18S ratios showed that the RNA was of good standard (Figure 
2.2). Generally a ratio of 1.8 is considered good quality.   
 
 
Figure 2.2: Electropherogram indicating the qualitative analysis of the purchased foetal brain 
RNA.  
The quality and quantity of the lymphocyte RNA was appraised by automated 
electrophoresis on the Experion™ Automated Electrophoresis System using RNA 
StdSens Analysis Kit (Bio-Rad Laboratories Inc) according to manufacturer’s 
instructions. The kit employs the use of LabChip microfluidic technology to detect, 
quantify and analyse the quality of RNA. To ensure that the isolated RNA was free of 
genomic DNA, the samples were treated with TURBO DNA-Free ™ kit (Ambion) 
according to manufacturer’s instructions. Furthermore, the QuantiTect® Reverse 
18S 
28S 
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Transcription Kit (Qiagen) also contained a genomic DNA removal buffer which was 
used according to manufacturer’s instructions.  
 
After the successful removal of the majority of genomic DNA contaminants, cDNA 
synthesis of lymphocyte and foetal brain RNA was carried out as using the QuantiTect® 
Reverse Transcription Kit according to manufacturer’s instructions. The kit provides a 
mixture of polyA and random oligos that anneals to a number of places on the RNA. The 
RNA –dependent polymerase then transcribes the first strand of cDNA which is an exact 
copy of the RNA (Figure 2.3). 
 
 
Figure 2.3 Steps of 1st strand cDNA synthesis using polyA oligos [Adapted from 
www.qiagen.com].  
 
The viability and purity of cDNA was evaluated by PCR with mRNA specific primers 
designed to amplify the Beta Haemoglobin gene (HBB). The HBB gene was used as a 
housekeeping gene for subsequent reactions. The primers were designed to amplify 
both genomic and mRNA HBB transcripts. However, in genomic DNA the primers 
produced a fragment of 377bp whereas in cDNA an amplicon of 248bp was produced 
(Figure 2.4). This further allowed isolated cDNA to be checked for genomic DNA 
contamination. 
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1 ACATTTGCTT CTG ACACAAC TGTGTTCACT AGC AACCTCA AACAGACACC ATGGTGCATC 
       61 TGACTCCTGA GGAGAAGTCT GCCGTTACTG CCCTGTGGGG CAAGGTGAAC GTGGATGAAG 
      121 TTGGTGGTGA GGCCCTGGGC AGGCTGCTGG TGGTCTACCC TTGGACCCAG AGGTTCTTTG 
      181 AGTCCTTTGG GGATCTGTCC ACTCCTGATG CTGTTATGGG CAACCCTAAG GTGAAGGCTC 
      241 ATGGCAAGAA AGTGCTCGGT GCCTTTAGTG ATGGCCTGGC TCACCTGGAC AACCTCAAGG 
      301 GCACCTTTGC CACACTGAGT GAGCTGCACT GTGACAAGCT GCACGTGGAT CCTGAGAACT 
      361 TCAGGCTCCT GGGCAACGTG CTGGTCTGTG TGCTGGCCCA TCACTTTGGC AAAGAATTCA 
      421 CCCCACCAGT GCAGGCTGCC TATCAGAAAG TGGTGGCTGG TGTGGCTAAT GCCCTGGCCC 
      481 ACAAGTATCA CTAAGCTCGC TTTCTTGCTG TCCAATTTCT ATTAAAGGTT CCTTTGTTCC 
      541 CTAAGTCCAA CTACTAAACT GGGGGATATT ATGAAGGGCC TTGAGCATCT GGATTCTGCC 
      601 TAATAAAAAA CATTTATTTT CATTGC 
 
       1  ACATTTGCTT CTGACACAAC TGTGTTCACT AGCAACCTCA AACAGACACC ATGGTGCATC 
       61 TGACTCCTGA GGAGAAGTCT GCCGTTACTG CCCTGTGGGG CAAGGTGAAC GTGGATGAAG 
      121 TTGGTGGTGA GGCCCTGGGC AGgttggtat caaggttaca agacaggttt aaggagacca 
      181 atagaaactg ggcatgtgga gacagagaag actcttgggt ttctgatagg cactgactct 
      241 ctctgcctat tggtctattt tcccaccctt agGCTGCTGG TGGTCTACCC TTGGACCCAG 
      301 AGGTTCTTTG AGTCCTTTGG GGATCTGTCC ACTCCTGATG CTGTTATGGG CAACCCTAAG 
      361 GTGAAGGCTC ATGGCAAGAA AGTGCTCGGT GCCTTTAGTG ATGGCCTGGC TCACCTGGAC 
      421 AACCTCAAGG GCACCTTTGC CACACTGAGT GAGCTGCACT GTGACAAGCT GCACGTGGAT 
      481 CCTGAGAACT TCAGGgtgag tctatgggac gcttgatgtt ttctttcccc ttcttttcta 
      541 tggttaagtt catgtcatag gaaggggata agtaacaggg tacagtttag aatgggaaac 
      601 agacgaatga ttgcatcagt gtggaagtct caggatcgtt ttagtttctt ttatttgctg 
      661 ttcataacaa ttgttttctt ttgtttaatt cttgctttct ttttttttct tctccgcaat 
      721 ttttactatt atacttaatg ccttaacatt gtgtataaca aaaggaaata tctctgagat 
      781 acattaagta acttaaaaaa aaactttaca cagtctgcct agtacattac tatttggaat 
      841 atatgtgtgc ttatttgcat attcataatc tccctacttt attttctttt atttttaatt 
      901 gatacataat cattatacat atttatgggt taaagtgtaa tgttttaata tgtgtacaca 
      961 tattgaccaa atcagggtaa ttttgcattt gtaattttaa aaaatgcttt cttcttttaa 
     1021 tatacttttt tgtttatctt atttctaata ctttccctaa tctctttctt tcagggcaat 
     1081 aatgatacaa tgtatcatgc ctctttgcac cattctaaag aataacagtg ataatttctg 
     1141 ggttaaggca atagcaatat ctctgcatat aaatatttct gcatataaat tgtaactgat 
     1201 gtaagaggtt tcatattgct aatagcagct acaatccagc taccattctg cttttatttt 
     1261 atggttggga taaggctgga ttattctgag tccaagctag gcccttttgc taatcatgtt 
     1321 catacctctt atcttcctcc cacagCTCCT GGGCAACGTG CTGGTCTGTG TGCTGGCCCA 
     1381 TCACTTTGGC AAAGAATTCA CCCCACCAGT GCAGGCTGCC TATCAGAAAG TGGTGGCTGG 
     1441 TGTGGCTAAT GCCCTGGCCC ACAAGTATCA CTAAGCTCGC TTTCTTGCTG TCCAATTTCT 
     1501 ATTAAAGGTT CCTTTGTTCC CTAAGTCCAA CTACTAAACT GGGGGATATT ATGAAGGGCC 
     1561 TTGAGCATCT GGATTCTGCC TAATAAAAAA CATTTATTTT CATTGC 
 
 Figure 2.4: Position of HBB primers on mRNA (A) and on genomic DNA (B) producing 
differently sized products (Black arrows indicate the positions and orientation of the primers). (A) 
Each exon is in a different colour. (B) Exons are in uppercase, while introns are in black 
lowercase.  
 
2.17  Sequence alignments  
 
Alignments were carried out using the Multiple Sequence Alignment programme by 
ClustalW [http://align.genome.jp] under the default settings. Alignments between two 
sequences were also performed using the BLAST (bl2seq) tool on the NCBI database 
[http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi] with the “filter” tool disabled which 
allows for repeats to be aligned. Input sequences were obtained from either the 
NCBI GenBank [http://www.ncbi.nlm.nih.gov/Genbank/] or Ensembl databases 
[http://www.ensembl.org/index.html] and are listed in Table 2.8. 
(A)  
(B) 
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Table 2.8: List of all sequences and accession numbers used in the analysis of the JPH3 gene. 
Description Sequence ID Accession number Database 
Contig from foetal brain cDNA U80757.1 GI: 2565083 
 
dbEST 
Contig from retinoblastoma BE779067.1 GI: 10200265 
 
dbEST 
Contig from lung carcinoid BE042890.1 GI:8359943 
 
dbEST 
Genomic DNA sequence of human 
JPH3 gene  
NC_000016.8   GI:51511732 
 
GenBank 
mRNA of full length JPH3  in 
humans 
NM_020655.2   GI:21704282), GenBank 
Protein of full length JPH3 
transcript in humans 
 
 
ENSP00000284262   ensembl 
mRNA of alternatively spliced  
JPH3 gene in human  
 
 ENST00000301008 ensembl 
Protein sequence of alternatively 
spliced  JPH3 in humans 
ENSP00000301008 ENSP00000301008 ensembl 
Genomic sequence of Mus 
musculus  
Junctophilin-3 gene (mouse JP3) 
NC_000074.5    
GI:149361523 
 
GenBank 
Junctophilin-3 (JP3), mRNA 
sequence of mouse JP3 gene  
NM_020605.2   GI:118130503 
 
GenBank  
Protein sequence of mouse JP3  NP_065630.1   GI:10181142 GenBank 
Genomic sequence of JPH3 in Pan 
troglodytes (Chimpanzee) 
 ENSPTRG00000008447 ensembl 
mRNA sequence of the full length 
JPH3 gene of Chimpanzee   
 ENSPTRT00000015560 ensembl 
Protein sequence of the full length 
JPH3 gene of Chimpanzee   
 ENSPTRP00000053372 ensembl 
mRNA sequence of alternative 
spliced JPH3 in chimpanzee  
 ENSPTRT00000060083  ensembl 
Protein sequence of alternative 
spliced JPH3 in chimpanzee 
 ENSPTRP00000053371 ensembl 
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2 .18  Statistical analysis  
 
Statistical analysis was performed in consultation with Dr. Lize van der Merwe 
(Biostatistics Unit, Medical Research Council of South Africa). Statistical tests from 
packages of the open-source programming environment R (R development core team) 
were used. The non-parametric Kolmogorov-Smirnov test [www.R-project.org] and 
Fishers’ test was used to analyse the repeat distributions in the population studies. 
Furthermore, the binomial distribution test was used to appraise the probability of 
maternal inheritance in the analysis of the pedigree. The observed heterozygosity was 
calculated as:                              Number of heterozygotes 
Number of individuals  
 
2.19  Real-time PCR on LightCycler® 1.5 Instrument   
 
In conjunction with conventional PCR, real-time PCR on the LightCycler® 1.5 Instrument 
(Roche Applied Sciences, Germany) was used to amplify regions of the HBB and JPH3 
genes from foetal brain and lymphocyte cDNA. Real-time PCR is recognised as a much 
more sensitive and rapid PCR process than conventional PCR and Ethidium Bromide 
staining. It produces results in real time (as the amplification process is happening). The 
method uses a fluorescent dye, in this case SYBR Green I, which integrates into double 
stranded DNA as the amplicons are formed and gives off a fluorescent signal that is 
detected by the instrument during the extension step of each cycle. The 
LightCycler®FastStart DNA Master PLUS SYBR Green I kit (Roche Applied Sciences) was 
used to prepare the PCR reactions according to manufacturer’s instructions. Real-time 
PCR was attempted for the amplification of foetal and lymphocyte cDNA and was used 
as a qualitative and quantative means to determine whether the transcript could be 
detected in both tissues. LightCycler Software 4.0 was used for the analysis of the 
results.  A melt curve analysis was also performed on the samples. For melt curve 
analysis the reaction is slowly heated to 95ºC which causes double stranded amplicons 
to separate and the dye to be released. A rapid decrease in fluorescence is recorded by 
the software which then creates a characteristic curve for a particular sequence. The 
melt curve analysis is used to detect any non-specific products in the reaction as each 
product has a unique curve. 
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CHAPTER THREE: RESULTS 
 
This section is divided into two sub-sections. The first part deals with identifying the 
genetic cause of the disease in the family. The second section reports the results of the 
analysis of the HDL2 locus. 
 
Section A: Investigation of the causative mutation 
 
3.1 Pedigree analysis  
 
Statistical analysis of the pedigree (Figure 2.1) indicated that there was a strong 
possibility that this disease could have a maternal pattern of inheritance. It was therefore 
hypothesised that the disease might be due to a mutation on the mitochondrial genome. 
A statistical analysis using a binomial distribution calculation showed that there was a 
1:400 probability that this disorder was maternally linked. 
 
Generally the symptoms displayed by affected family members were severe, progressive 
dementia and movement disorders. A neurological examination of 5657, 5760 and 5555 
was performed. It was determined that 5657 and 5760 shared similar mental states but 
their respective movement disorders differed. The proband, 5657, had cortical 
myoclonus while his uncle, 5760, had predominantly parkinsonian features. Individual 
5555 had prominent chorea on examination but none of the other features were 
reported.  
 
3.2  Investigation of mitochondrial candidate genes  
 
Due the potentially maternal bias of the disease segregation in Family R, several 
mitochondrial genes were selected as candidate genes to screen. A literature search on 
the mitochondrial genome showed that there were many mutations in this genome that 
could be the cause of dementia and a movement disorder. Most of the mitochondrial 
mutations associated with dementia occur in genes that encode transfer RNAs (tRNA). 
For this reason several mitochondrial genes were selected (Table 2.4 A, page 39) to be 
screened for known or novel mutations. 
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The amplification of selected regions of the mitochondrial genome was successful for all 
study participants. A fragment of the expected size was produced for each primer set 
(Figure 3.1). 
 
 
Figure 3.1: A 2% agarose gel representing the electrophoresis of PCR products yielded from the 
6 sets of primers used to amplify selected regions of the mitochondrial genome. In many cases 
more than one gene was amplified with one set of primers. (Lane 1: MTTK and MT-ATP8ase, 
lane 2:  MTTI; MTTQ and MTTM, lane 3:  MTTH; MTTS2 and MTTL2, lane 4: MTTF, lane 5:  
MTTL1 and lane 6: MT-ND4) .The lane marked M contains a 100bp ladder with the sizes 
indicated by the red arrows. The lane marked C represents a 450bp fragment as an additional 
sizing control.  
 
Initially, the PCR products of two affected individuals namely, 5657 and 5760 were 
sequenced to screen for possible pathogenic mutations. The mitochondrial genome is 
highly polymorphic and the sequence varies widely between different ethnic groups. For 
this reason DNA of an ethnically matched unaffected individual was sequenced as a wild 
type (WT control). The Human Mitochondrial DNA Revised Cambridge Reference 
Sequence (rCRS) [www.mitomap.org] was used as the reference sequence.   
 
When performing the sequence analysis of these family members, the WT control and 
the rCRS , five sequence variants in the MTTF, MT-ND1, MTTI and MT-ND2 genes were 
identified. To confirm whether these variants were indeed disease-causing they would 
have to segregate in all affected individuals and be absent in unaffected family 
members. For this reason the PCR products produced by primer sets MTTF and MTTI 
500bp 
400bp 
300bp 
200bp 
M        C             1            2        3         4          5           6    
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were sequenced in additional family members. Figures 3.2-3.6 represents the 
sequencing of the variants found in the PCR products. 
 
(A) Wild type control 
  
 
(B) 5657 
  
 
Figure 3.2: Represents a section of the chromatograph produced by the sequencing of the MTTI, 
MTTQ, MTTM and MT-ND1 genes. The solid red arrow indicates a homoplasmic G to A change 
in the sequence. This position corresponds to the position 4206 in the MT-ND1 gene on the 
mitochondrial genome. (A) WT control and (B) an affected family member (5657) of Family R. 
 
(A) Wild type control 
 
(B) 5657 
 
 
Figure 3.3: Chromatographs depicting the homoplasmic T to C change in the sequence 
(indicated by the solid red arrows). This corresponds to the position 4232 on the mitochondrial 
genome, which is in the MT-ND1 gene. (A) WT control and (B) member 5657 of Family R. 
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(A) Wild type control  
 
(B) 5657 
 
 
Figure 3.4: Chromatographs depicting the homoplasmic C to T change in the sequence 
(indicated by the solid red arrows). This corresponds to the position 4312 on the mitochondrial 
genome which is in the MT-TI gene. (A) WT control and (B) member 5657 of Family R. 
 
 
(A) Wild type control 
  
(B) 5657 
 
 
 Figure 3.5: Chromatographs depicting the homoplasmic C to T change in the sequence 
(indicated by the solid red arrows). This change corresponds to the position 4505 on the 
mitochondrial genome which is in the MT-ND2 gene. (A) WT control and (B) member 5657 of 
Family R.  
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(A) Wild type control  
 
(B) 5657: Forward primer sequence  
 
 
(C) 5657: Reverse primer sequence 
 
 
Figure 3.6: Results obtained from automated sequencing displaying the heteroplasmic polyC 
tract at position 568 which is in the control region on the mitochondrial genome (indicated by the 
solid red arrows). (A) The polyC tract in the WT control consisting of 6C’s. (B) The polyC tract in 
member 5657 of Family R where the polyC tract had expanded and was heteroplasmic. (C) The 
same polyC tract of 5657 sequenced with the reverse primer and reverse complemented using 
the programme BioEdit. 
 
From this investigation three novel variants were determined at positions 4206, 4232 
and 4505 on the mitochondrial genome.  These variants were deposited in the Mitomap 
database [www.mitomap.org] under the reference numbers listed in Table 3.1. The other 
two variants were known variants and have not been associated with disease. All the 
sequence variants are unlikely to be pathogenic because these variants have not 
  
60
 
previously been associated with the symptoms observed in this family. Furthermore, 
mitochondrial DNA is highly variable and prone to polymorphisms due to the high rate of 
replication, the absence of protective histones and exposure to reactive oxygen 
molecules that cause oxidative damage. It would therefore be difficult to prove the 
pathogenicity of the novel variants. The variant observed at position 4206 occurred only 
in the WT control. No sequence variants were determined for any of the other candidate 
genes investigated. Furthermore the G11778A mutation in the MT-ND4 gene, causing 
Leber’s Hereditary Optic Neuropathy (LHON) was not found in any of the affected family 
members. 
 
In summary, this investigation indicated that it was unlikely that these mitochondrial 
genes were the cause for disease in this family.   
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Table 3.1:  A list of sequence variants observed in comparison with the rCRS and WT control sequence. 
 
*rCRS: the Human Mitochondrial DNA Revised Cambridge Reference Sequence.  
** The variant at position 568 is an expanded polycytosine tract in a non-coding region. The polyC tract is unstable and can therefore not be accurately counted. 
***The accession numbers of the variants as provided by the Mitomap database.  
ND, not determined. 
4206 Change in the control. 
4312 Change was in a non-coding region. 
 
 
 
Position on 
mitochondrial 
genome 
Gene 
symbol 
rCRS* WT 
control 
5657 5760 5555  6188 6341 Homoplasmic Synonymous/ 
Non-
synonymous 
Amino acid 
changes 
Known/ 
Novel 
Reference: 
568** MT-TF 6C’s 6C’s ND ND ND ND ND No NA NA Known Sternberg et al., 
2001 
4206 MT-
ND1 
A G A A A A A Yes Synonymous L300L 
TTA-TTG 
Novel 20061030001*** 
4232 MT-
ND1 
T T C C C C C Yes Non-
synonymous 
I 309T 
ACT-ATT 
Novel 20061030002*** 
4312 MT-TI C C T T T T T Yes NA NA Known Moraes et al., 
1993 
4505 MT-
ND2 
C C T T T T T Yes Synonymous T12T 
ACC-ACT 
Novel 20061030003*** 
61
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3.3   Investigation of the PARK2 gene 
 
Mutations in the PARK2 gene have previously been associated with early onset 
parkinsonism [Tan and Skipper, 2007]. As members of Family R exhibited parkinsonian 
features, the PARK2 gene was screened for any known or novel mutations. The PCR 
amplification was successful for all the exons as well as the promoter region (Figure 3.7). 
 
       
    
 
    
 
Figure 3.7: Representative 2% agarose gel showing the PCR amplification of the promoter and 
all the exons of the PARK2 gene. The lane marked M contains a 100bp ladder with 
corresponding sizes indicated by the red arrows. The lane marked P contains the promoter region 
while lanes marked X1-X12B represent Exons 1-12.  
 
SSCP analysis was performed on the PCR-amplified products to screen for sequence 
variations in the PARK2 gene. Any shifts in the banding pattern (compared to the 
controls) were indicative of a variation in the DNA sequence. Two affected family 
members (5657 and 5760) were screened in conjunction with two control samples (WT1 
and WT2) of individuals of Mixed Ancestry. Four mobility shifts were identified and direct 
sequencing was performed to identify the sequence variants. 
 
  P      X1     X2     X3     X4     X5     X6      M 
  X7      X8      X9    X10  X11   X12A  X12B   M 
 
400bp 
300bp 
200bp 
100bp 
 
400bp 
300bp 
200bp 
100bp 
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Figure 3.8 shows a shift in banding pattern in Exon 8 and subsequent direct sequencing 
results (Figure 3.9). 
 
  
Figure 3.8: SSCP gel representing a shift in the banding pattern in Exon 8. The black arrow 
indicates a shift in banding pattern in sample 5657.  
(A) 
 
(B) 
 
Figure 3.9: A chromatograph depicting the heterozygous C>T polymorphism in Exon 8 of the PARK2 gene. 
(A) Represents a WT control while (B) represents member 5657 of Family R.  
 
Figures 3.9(A) and (B) depicts the chromatographs produced by sequencing of the Exon 
8 from proband 5657 as well as a WT control. In Figure 3.9(B) the solid red arrow 
indicates the position of the C>T change in individual 5657. In the figure it is clearly 
shown that both thymine (T) and cytosine (C) are present which was indicative of a 
heterozygous change. Furthermore, the C>T change has been identified as IVS8 + 
48C>T, a known polymorphism in Exon 8 [Kay et al., 2007]. 
 
A mobility shift was observed in Exon 10 for individual 5657 (data not shown). The 
subsequent sequencing result is shown (Figure 3.10).  
 
 
5657       5760        WT1      WT2 
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(A) 
 
           (B)  
 
Figure 3.10: A chromatograph depicting the heterozygous G>C polymorphism in Exon 10 of the 
PARK2 gene. (A) Represents a WT control while (B) represents member 5657 of Family R.  
 
Figure 3.10 depicts the chromatographs produced by sequencing of Exon 10 from 
sample 5657 as well as a WT control. In Figure 3.10(B), the solid red arrow indicates the 
position of the G>C change in 5657. Both guanine (G) and cytosine were present which 
was indicative of a heterozygous change. Furthermore, this G>C change also altered the 
amino acid sequence by substituting a valine for leucine at position 380 and is a known 
polymorphism in the PARK2 gene [Kay et al., 2007]. 
 
Furthermore, a band shift was observed for individual 5657 in the SSCP analysis of 
Exon 11 (data not shown) and the PCR product was therefore sequenced (Figure 3.11).   
 (A) 
 
(B) 
 
Figure 3.11: A chromatograph depicting the heterozygous G-A polymorphism in Exon 11 of the 
PARK2 gene. (A) Represents a WT control while (B) represents member 5657 of Family R.  
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In Figure 3.11(B), the solid red arrow indicates a G>A polymorphism. As in the case of 
the V380L polymorphism, mentioned above, this change was also heterozygous due to 
the presence of both guanine and adenosine (A) residues at this position. This produced 
a non-synonymous change in the amino acid sequence, substituting aspartic acid for an 
asparagine at position 394 (D394N). This has previously been reported as a known 
polymorphism [Lincoln et al., 2003].  
  
A band shift was also observed for individual 5657 in the SSCP analysis of the promoter 
region of PARK2 (data not shown) and the PCR product was analysed by direct 
sequencing (Figure 3.12).   
(A) 
 
(B) 
 
Figure 3.12: A chromatograph depicting the heterozygous A-G polymorphism in the promoter of 
the PARK2 gene. (A) Represents a WT control while (B) represents member 5657 of Family R. 
  
In Figure 3.12 (B), the solid red arrow indicates an A>G polymorphism. This change was 
heterozygous due to the presence of both guanine and adenosine residues at this 
position. This polymorphism is in the 5’ UTR and is a known polymorphism [West et al., 
2002]. 
 
Table 3.2 summarizes all the changes observed in PARK2 gene for family member 5657 
by both SSCP analysis and automated sequencing. 
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Table 3.2: A summary of all the variations observed in PARK2 gene for individual 5657. 
Exon/Region Sample number  Change in 
sequence  
Known 
polymorphism  
Reference: 
Exon 8  5657 C>T  IVS8+48 C>T Kay et al., 2007 
Exon 10 5657 G>C V380L Kay et al., 2007 
Exon 11  5657 G>A D394N Lincoln et al., 2003 
Promoter  5657 A>G -227A>G  West et al., 2002 
 
No other changes in SSCP or sequencing were observed for the other affected family 
member. Furthermore, the variants found in this investigation were excluded as 
pathogenic because they are known polymorphisms. In addition, SSCP was proven to 
be a successful mutation detection method as it enabled the detection of four known 
polymorphisms. From this investigation it was determined that no pathogenic point 
mutations or small insertions or deletions were identified in the PARK2 gene for affected 
Family R members.   
 
3.4  Investigation of the locus for Familial Encephalopathy with 
Neuroserpin Inclusion Bodies (FENIB) 
 
Two point mutations in the SERPINI1 (also known as PI12) gene, located at position 
3q26.1 have been implicated in FENIB. Patients harboring either of these mutations 
manifest with dementia and myoclonus, similar to the clinical features observed in Family 
R. For this reason, two mutations associated with FENIB (S49P and S52R) were 
screened in affected Family R members.  
 
After successful PCR amplification of the template DNA, automated sequencing of the 
PCR product was performed in order to detect the presence of two point mutations. The 
sequencing results of 5657 (Figure 3.13) show the positions at which these mutations 
occur (indicated by red arrows).   
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Figure 3.13: Sequencing results of 5657 obtained from automated sequencing with PI12 forward 
primer. The solid red arrows indicate the positions of the mutations. 
 
For the S49P mutation the T at position 239 on the chromatograph changes to C while 
the A at position 248 changes to a C for the S52R mutation (Figure 3.13, indicated by 
solid red arrows). From the sequencing results it could be determined that neither the 
S49P nor the S52R mutations were present. Therefore, the disorder in this family is not 
due to these two mutations in the PI12 gene.  
 
3.5  Investigation of the locus for Dentatorubral-Pallidoluysian Atrophy 
(DRPLA)  
 
DRPLA is caused by an unstable expansion of a CAG repeat in the Atrophin1 (ATN1) 
gene located at the chromosomal position 12p13. The number of repeats in unaffected 
individuals ranges from 3 to 36 and affected individuals are reported to have repeats 
ranging from 49 to 88 [Schöls et al., 2004].   
  
Patients harbouring the mutation causing DRPLA and affected Family R members 
display similar symptoms such as dementia and myoclonus. For this reason Family R 
members were tested for the DRPLA disease-causing expansion. In addition, an 
unaffected individual was typed as a negative control. No positive control for DRPLA was 
available at the time for analysis and comparison.  
 
The DRPLA repeat expansion was screened using fluorescently labelled primers and 
electrophoresis on the ABI. The primers were designed to amplify the CAG repeat and 
produce a fragment of approximately 247bp (which corresponds to 14 repeats) in 
unaffected individuals. In the case of affected individuals, the fragment would be greater 
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than 356 bp, which corresponds to 49 or more repeats.  The genotyping results of the 
control and 5657 are displayed (Figure 3.14). 
 
 
 
 
 
Figure 3.14: (A) The electropherogram of genotyping results of an affected Family R member 
(5657) and (B) represents the results of an unaffected individual.  
 
Initially, DNA of only the proband (5657) of Family R was available for study and 
genotyping of the DRPLA CAG repeat produced a single peak in the normal range for 
this individual (Figure 3.14 A) . The unaffected control produced two peaks within the 
normal range (Figure 3.14 B). It could not be determined whether 5657 was homozygous 
at this locus or whether 5657 was heterozygous and the repeat expansion was possibly 
too large to be PCR- amplified. Later, when DNA of another family member (5760) 
became available, this sample was also genotyped and this showed two alleles in the 
unaffected range (Figure 3.15).    
 
Figure 3.15: The electropherogram of genotyping results of an affected Family R member (5760). 
  
By sizing the PCR fragments on the ABI Genetic Analyzer, the number of repeats could 
be calculated by applying the following formula:   
 Number of repeats = (size of fragment) bp - 205bp* 
3 
(B) 
 
(A) 
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*where 205bp is the length of the PCR fragment excluding the CAG repeat      
E.g.: number of repeats = 248bp – 205bp  
3 
                                             = 14.3 (rounded off to 14 repeats)  
Table 3.3 summarizes the size of the fragments found in two of the affected individuals 
and an unaffected control. 
 
Table 3.3: The size of the fragments and number of repeats for each of the individuals typed at 
the DRPLA locus.  
Sample              Allele 1 Allele 2 
5657 248bp   14 repeats  248bp  14 repeats 
5760 248bp  14 repeats 259bp 18 repeats 
Unaffected control 227bp 7 repeats 250bp 15 repeats 
 
As the number of repeats at the DRPLA locus was in the normal range for both affected 
individuals it was concluded that this family did not have DRPLA 
 
3.6 Investigation of the locus for Huntington’s disease-like 2 (HDL2)  
 
Huntington’s disease-like 2 (HDL2) is caused by a triplet repeat expansion in the 
Junctophilin-3 (JPH3) gene. This CTG/CAG repeat occurs in an alternatively spliced 
exon in the JPH3 gene on chromosome 16q24.3. In the case of affected individuals the 
repeat is more than 40 repeats. In the case of unaffected individuals a mean of 14-16 
repeats has been reported [Holmes et al., 2001]. 
 
HDL2 is characterised by severe progressive dementia, motor disco-ordination, 
psychiatric symptoms and chorea. As many of these symptoms were present in the 
affected members of Family R, the locus for HDL2 was investigated.  
 
 Fluorescently- labelled primers were designed to amplify the CAG/CTG repeat which 
produced an amplicon of approximately 242bp (14 repeats) in unaffected individuals and 
more than 320bp (more than 40 repeats) in affected individuals (Figure 3.16). 
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1261 tcagtgagag ccca ggaatc tcgtctttca gtggctgcat cgttttcacc attagttgag 
 
1321 ggaatcgatc tgtgccttca ttctaagatg ccaccgcatt cggggcagag ccggggccgg 
 
1381 aagccaggga gctgcctgct gctgctgctg ctgctgctgc tgctgctgct gctgctgtaa 
 
1441 gatggtttct gtgcagggaa ccttggccgg ctctgcagct gcccgcctgc ctggactctc 
 
1501 cgatatccac tcctcagtgc acctgacacg catggagccg gtcctttcct ggaagccaga 
 
Figure 3.16: The positions and orientation of the primers for amplification of the CTG/CAG repeat 
on the JPH3 gene. The sequence in yellow represents the forward primer while the sequence in 
grey is the sequence on which the reverse primer is based. The pink region is the CTG triplet 
repeat sequence. 
 
 
Figure 3.17: An agarose gel representing the amplification of a wild type control (unrelated Mixed 
Ancestry individual) (WT), a Family R member (5657) and a HDL2 positive control sample 
(HDL+). Lane M contains 100bp size marker and the sizes are indicated by red arrows. 
 
DNA from an HDL2 positive individual was obtained from the National Health Laboratory 
Service (NHLS) Molecular Diagnostic Laboratory and used as a positive control in this 
investigation (Figure 3.17). The PCR product of an affected Family R member as well as 
an unrelated negative control is also shown (Figure 3.17). 
 
For the HDL2 positive sample, two bands are visible indicating two different sized alleles. 
The bigger fragment would indicate an expanded allele and the smaller fragment would 
be indicative of an allele in the normal range. The same pattern is observed for the 
affected family member (5657), which would be indicative of a possible repeat 
expansion. Whether this expansion is in the disease-causing range could only be 
confirmed by accurately sizing the repeats by genotyping on an automated genetic 
analyser. The fluorescently labelled primers, designed to amplify the repeat, were used 
   WT     5657        HDL+      M  
400bp 
 
300bp 
 
200bp 
 
 
 
100bp 
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to amplify the DNA of Family R members and genotyped on an ABI 3130xl to determine 
the number of repeats for each individual (Figure 3.18).  
 
 
 
 
 
 
 
 
 
 
Figure 3.18: Electropherograms indicating the size of the repeats in the JPH3 gene. (A) 
Unaffected WT control of Mixed Ancestry, (B) HDL2 positive individual, (C), (D) and (E) are 
affected members of Family R (5657, 5760 and 5555 respectively). 
(D) 5760 
(B) HDL2  
Positive  
control  
(E) 5555 
(A) Wild  
type 
356bp 
344bp 241bp 
241bp 
247bp 
241/241bp 
344bp 247bp 
(C) 5657 
377bp 
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From the sizing of the PCR fragments the amount of repeats was calculated using the 
following formula:   
 Number of repeats = (size of PCR fragment) bp - 200bp* 
      3 
*Where 200bp is the length of the PCR product excluding the CTG repeat 
 
Example: Number of repeats = 241 - 200bp 
  3 
= 13.6 repeats 
 = 14 repeats (rounded up)   
 
The triplet repeat ranges for Family R members was determined and has been 
summarised (Table 3.4).The results indicate that three Family R members, namely 5657, 
5760 and 5555 had repeats within the pathogenic range. The two unaffected family 
members (6188 and 6341) had repeats in the normal range. It was therefore concluded 
that the disease segregating in this family is HDL2. 
 
Table 3.4: A summary of repeat sizes for Family R members.  
* Values are rounded up 
In the case of repeat expansion diseases such as HDL2, the causative repeat is usually 
unstable and prone to expand. Due to this the repeat length may vary between various 
cells in an individual. Furthermore, the electropherograms produced by the ABI were not 
very intense for the expanded repeats producing small peaks (Figure 3.18). This may 
leave room for error in determining the exact length of repeats. It is vital to establish the 
exact number of repeats in an individual as a difference of one repeat can determine 
whether an individual is in the pathogenic or intermediate range.    
Sample number  Allele 1 Allele 2 Pathogenic (Y/N) 
 
Size of 
PCR 
fragments* 
Number of 
repeats 
Size of 
PCR 
fragments* 
Number of 
repeats 
 
5657 242                         14 356                         52 Yes  
5760 242                         14 344                         49 Yes 
6188 242                         14 242                         14 No 
6341 242                         14  245                         15 No 
5555  248                         16 377                         59 Yes 
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In order to accurately determine the number of CTG repeats, the expanded allele was 
cloned and sequenced. This was performed by PCR-amplification of sample 5760 and 
electrophoresing the PCR product on an agarose gel to separate the fragments. The 
larger fragment (representing the expanded allele) was excised from the gel and purified. 
The purified fragment was then ligated into a pGem® - T Easy vector. Three different 
vectors: insert ratios were tested, 1:1; 1:3 and 1:5. These ligations were used to 
transform competent E coli DH5α cells which were grown until blue and white colonies 
could be clearly observed (Figure 3.19).  
 
 
Figure 3.19: A representative LB-agar plate indicating blue and white colonies. 
 
Table 3.5 summarises the amount of colonies produced by 200µl of transformed cells. It 
was noted that a vector: insert ratio of 1:1 produced no colonies. A vector: insert ratio of 
1:3 produced the most colonies but was ineffective as single colonies could not be 
picked. The 1:5 ratio, however, produced single colonies. Individual colonies were 
therefore, picked from the 1:5 ratio plates and were subjected to colony PCR.  
 
Table 3.5: Number of colonies produced per 200µl of transformed cells. 
Ratio vector : insert 
DNA 
Number of blue 
colonies/200µl 
Number of white 
colonies/200µl 
1:1  None 4  
1:3 116 TNTC* 
1:5 18 54 
*TNTC: too numerous to count. 
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In order to determine whether the correct insert was taken up by the clone, colony PCR 
was performed with the HDL2 primers. Colony -PCR of several white colonies, using the 
HDL2 primers, did not reveal a colony with an appropriately-sized insert. As numerous 
blue colonies were observed on the plates, (and as the protocol recommends) colony- 
PCR with HDL2 primers was performed on a few of these blue colonies to determine 
whether any of these colonies contained the insert (Figure 3.20).  
 
 
        
Figure 3.20: Agarose gel representing colony-PCR with HDL2 primers. The lane marked M 
contains a 100bp ladder with sizes indicated by red arrows. Lane W: random white colony, lane 
B2: blue colony 2 and lane B1: blue colony 1. 
 
Figure 3.20 is a representative gel of the colony- PCR results for two blue colonies and a 
randomly selected white colony. One blue colony (B2) produced a fragment of 
approximately 400bp, which is the expected fragment size and another blue colony (B1) 
contained a fragment of roughly 250bp while the white colony did not amplify. This 
indicates that the blue colonies contained the insert which is possible because the 
pGem® - T Easy vector contains a multiple cloning site with a α-peptide coding region of 
the β-galactosidase gene. This region is disrupted when the insert is taken up by the 
plasmid. This process usually results in the formation of white colonies for clones that 
contain the insert and blue colonies for clones that do not have the insert. However, 
cases have been reported where blue colonies could also contain insert DNA 
[www.promega.com]. This occurs when the insert DNA is a multiple of 3bp and is then 
cloned in-frame to the Lac-Z gene thereby not disrupting its function and resulting in blue 
colonies containing the insert.  Moreover, the 250bp fragment found in colony B1 is the 
smaller allele. When excising DNA from the gel, the 250bp fragment usually moves  
 
 
 
400 bp  
300bp 
200bp 
 M              W          B2       B1    
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faster through the gel but there may be traces of this fragment in the part of the gel that 
was excised which was expected to only contain the expanded allele.  
 
The colony plasmid containing the 400bp fragment (which roughly corresponds to the 
expanded allele of 5760) was purified and subjected to direct sequencing using the 
HDL2 forward primer. Sequencing analysis revealed that the correct fragment was 
inserted into the pGem® - T Easy at the expected position, and that individual 5760’s 
expanded allele was confirmed to be 49 CTG repeats (Figure 3.21). 
 
 
 
Figure 3.21: Sequencing results of the blue colony (B2) containing ~400bp insert, which 
corresponds to 49 CTG repeats. The beginning and end of the expanded repeat is indicated by 
solid red arrows. 
 
These cloning results confirmed that the CTG repeats (Table 3.4) were correctly sized. 
The irregular peaks observed at positions 110-120 and 180-190 (Figure 3.21) on the 
chromatograph are a result of dye terminators from the sequencing kit that were not 
completely removed during the post-sequencing step.  
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3.7  Genetic ancestry testing  
 
HDL2 has previously only been found in individuals of Black African Ancestry. In order to 
confirm the families’ self-reported ancestry a partial genetic ancestry test was performed 
on one of the family members. DNA of an affected male Family R member (5760) was 
analysed by the MRC/NHLS/WITS Human Genomic Diversity and Disease Research 
Unit (HGDDRU) to determine his lineage.  
 
The genetic analysis of the mitochondrial genome was used to determine the maternal 
lineage for individual 5760. The resolved haplogroup, L1d1, is associated with the 
Khoisan population but is also present in the Bantu speaking population. This 
haplogroup implies an origin in Khoisan population before the arrival of Bantu speakers 
in South Africa. In addition, this haplogroup was observed at a frequency of 12% in 
Coloured individuals, 8% in Whites and 6% in Jews of South Africa. 
 
From Y-chromosome analysis to determine the paternal lineage, it was shown that 5760 
belonged to the Y-chromosome Haplogroup FG-M213. This haplogroup is mainly found 
in European and Asian populations [Semino et al., 2000]. Upon further analysis of the y-
chromosome it was shown that the genetic profile produced for 5760 exactly matched 40 
other individuals from a world wide survey of 42000 males [www.yhrd.org]. Furthermore, 
one of the 40 individuals was also of South African Mixed Ancestry [Soodyall, personal 
communication].  This gives us a strong indication that 5760 and other members of 
Family R can be considered as Mixed Ancestry individuals as this profile is typical of 
what can be found in the lineage of a South African Mixed Ancestry individual which is a 
maternal lineage from indigenous Africans and a partial European paternal lineage 
[Bardien et al., 2007]. This indicates that for clinicians in South Africa, HDL2 should not 
only be considered in HD-like phenotype patients of Black African ancestry but in cases 
of Mixed Ancestry as well.  
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Section B:  Analysis of the Junctophilin-3 (JPH3) gene 
 
3.8 Distribution of the CTG/CAG repeat lengths in South African sub-
populations.  
 
As previously mentioned HDL2 has thus far only been found in individuals classified as 
having African ancestry. This led to the question of whether individuals of African 
ancestry could possibly have larger alleles that are prone to expand into the pathogenic 
range, thereby predisposing them to develop HDL2.  
 
In this part of the study, the distribution of JPH3 CTG/CAG repeat length in the Black, 
Mixed Ancestry and Caucasian South African sub-population groups was investigated.  
A total of 51 individuals (representing 102 alleles) of each of the Mixed Ancestry and 
Black groups and 60 (representing 120 alleles) of the Caucasian group was genotyped.  
 
The repeat was in Hardy Weinberg equilibrium for all three subgroups (p=1, Permutation 
test). However, the distribution of alleles differed amongst the three groups. 11 Different 
alleles were observed in the Black cohort and they ranged from 8 to 19 repeats. The 
Mixed Ancestry group had 9 different alleles, ranging from 8 to 21 repeats while the 
Caucasian cohort had only 7 different alleles ranging from 13 to 27 repeats (Figure 3.22 
A and B). This indicates less diversity at this locus in the Caucasian group in comparison 
to the other sub-populations.  
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Figure 3.22: Bar graph (A) and line graph (B) displaying the frequency of alleles in South African 
sub-populations.  
A 
B 
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The observed heterozygosity was calculated as 88.4% for Black population, 76.4% for 
the Mixed Ancestry population and 62.4% for Caucasian. This further establishes that 
less diversity is observed in the Caucasian cohort compared to the other two groups. 
 
Furthermore, the difference in repeat distribution in this study was statistically significant 
between the Caucasian and Black group (P= 0.0014) but not significant between the 
Black and Mixed Ancestry (P=0.3788, two-sided) nor between the Mixed Ancestry and 
the Caucasian groups (P=0.3186).   
 
The most common allele (mode) for all three groups was the allele containing 14 
repeats, as has been shown for other population studies in Germany, France, 
Montenegro and Scandinavia [Bauer et al., 2002; Keckarevic et al.,2005; Stevanin et al., 
2003]. The allele containing 16 repeats was also fairly common for all three sub-
populations as had been noted in previous population studies. However, the frequency 
of alleles containing 14 repeats differs dramatically between subgroups. Considering the 
distribution of the 14 repeats allele in the different population groups can provide a 
measure of whether this difference is significant. 
 
Figure 3.23 depicts the distribution of alleles containing 14 repeats amongst the different 
population groups. This graph groups the alleles as 14/14 (homozygous pair of alleles 
with 14 repeats); 14/other (one allele of 14 repeats) and other/other (alleles that does not 
contain 14 repeats). 
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Figure 3.23: Bar graph displaying the frequency of alleles containing 14 repeats.  
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For the 14 repeat allele, the Caucasian cohort has the highest homozygosity (32%) and 
also has the highest frequency (55% from Figure: 3.22). The Black cohort, however 
shows the opposite with the least homozygosity (4%) and least overall frequency (25% 
from Figure: 3.22) of this allele. The Mixed Ancestry group falls in the middle with a 
frequency of  12 %  for 14/14 genotype  and 33% frequency in general (from Figure: 
3.22). By applying the Fishers’ test it was found that the distribution of the 14 repeat 
allele differed significantly (P-value=0.0001788) between the three different groups.   
 
3.9 Sequence alignments of the Junctophilin-3 gene 
 
For many genes, similar gene organisation is observed across species [Guryev et al., 
2006]. This implies a functional importance for the regions of the gene that are 
conserved. In order to determine whether a gene or part of a gene is vital for the survival 
of a cell it has to further be conserved throughout species. The JPH3 gene exists in 
variably spliced forms and the HDL2 pathogenic repeat is thought to be present in an 
alternatively spliced exon termed Exon 2A. To determine the degree of conservation 
between the alternatively spliced and full length transcripts around the repeat, the mRNA 
and protein sequences of the full length and alternatively spliced version were aligned 
(Figure 3.24). For the alignments “*” indicates a single conserved residue. A “: “indicates 
a “strongly” conserved group (according to ClustalW  score test) while a “.” indicates that 
a “weak” group is conserved. 
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Full length mRNA       AGAGCAAGGGGAAGTGGGTGTACAAGGGCGAGTGGACGCACGGATTCAAGGGGCGCTACG 
Alternatively spliced  AGAGCAAGGGGAAGTGGGTGTACAAGGGCGAGTGGACGCACGGATTCAAGGGGCGCTACG 
                       ************************************************************ 
 
Full length mRNA       GGGTGCGGGAGTGCGCGGGCAACGGGGCCAAATACGAAGGGACCTGGAGCAACGGGCTGC 
Alternatively spliced  GGGTGCGGGAGTGCGCGGGCAACGGGGCCAAATACGAAGGGACCTGGAGCAACGGGCTGC 
                       ************************************************************ 
 
Full length mRNA       AGGACGGCTACGGGACCGAGACCTACTCGGACGGAGGGACCTACCAGGGCCAGTGGGTCG 
Alternatively spliced  AGGACGGCTACGGGACCGAGACCTACTCGGACGGAGAT----------GCCACCGCATTC 
                       ************************************            ****  *  *   
 
Full length mRNA       GTGGCATGCGCCAGGGCTACGGCGTCCGGCAGAGCGTCCCGTATGGCATGGCCGCGGTCA 
Alternatively spliced  GGGGCA-GAGCCGGGGC--CGGAAGCCAG-GGAGCTGCCTGC-TGCTGCTGCTGCTGCTG 
                       * **** * *** ****  ***   ** *  ****  ** *  **     ** ** *    
 
Full length mRNA       TC-CGCTCACCCCTGAGGACGTCCATCAACTCCCTGCGCAGCGAGCACACCAACGGCACG 
Alternatively spliced  CTGCTGCTGCTGCTGCTGCTGTAAGATGG-TTTCTGTGCAGGGAACCT-----TGGC-CG 
                          *     *  ***  *  **        *  *** **** ** *        *** ** 
 
Full length mRNA       GCGCTGCATCCCGACGCCTCTCCGGCGGTGGCCGGCAGCCCGGCCGTGTCCCGCGGGGGC 
Alternatively spliced  GCTCTGCAGCTGCCCGCCTGCCTGG-ACTCTCCGATATCCACTCCTCAGTGCACCTGA-- 
                       ** ***** *    *****  * **   *  ***  * **   **      * *  *    
 
Full length mRNA       TTCGTGCTCGTGGCCCACAGTGACTCCGAGATCCTCAAGAGCAAGAAGAAGGGGCTGTTT 
              Alternatively spliced   ------------------------------------------------------------ 
 
 
Full length protein      MSSGGRFNFDDGGSYCGGWEDGKAHGHGVCTGPKGQGEYTGSWSHGFEVLGVYTWPSGNT 
Alt spliced protein      MSSGGRFNFDDGGSYCGGWEDGKAHGHGVCTGPKGQGEYTGSWSHGFEVLGVYTWPSGNT 
                         ************************************************************ 
 
Full length protein      YQGTWAQGKRHGIGLESKGKWVYKGEWTHGFKGRYGVRECAGNGAKYEGTWSNGLQDGYG 
Alt spliced protein      YQGTWAQGKRHGIGLESKGKWVYKGEWTHGFKGRYGVRECAGNGAKYEGTWSNGLQDGYG 
                         ************************************************************ 
 
Full length protein      TETYSDGGTYQGQWVGGMRQGYGVRQSVPYGMAAVIRSPLRTSINSLRSEHTNGTALHPD 
Alt spliced protein      TETYSDG---------------------------------------------DATAFGAE 
                         *******                                             :.**: .: 
 
Full length protein     ASPAVAGSPAVSRGGFVLVAHSDSEILKSKKKGLFRRSLLSGLKLRKSESKSSLASQRSK 
Alt spliced protein     PGPEARELPAAAAAAAAAAAAAVRWFLCREPWPALQLPACLDSPISTPQCT--------- 
                        ..* .   **.: .. . .* :   :*  :    :: .   .  : ..:..          
 
Full length protein     QSSFRSEAGMSTVSSTASDIHSTISLGEAEAELAVIEDDIDATTTETYVGEWKNDKRSGF 
Alt spliced protein     ------------------------------------------------------------ 
 
Figure3.24:  Alignment of human alternatively spliced and full length mRNA (A) and protein (B) around  
the CTG repeat (highlighted in yellow). 
 
(B) 
(A) 
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It was observed that the protein and mRNA sequences of the full length and alternatively 
spliced transcript are fully conserved for the first exon (blue sequences, Figure 3.24 A 
and B). As expected, the second exons (red sequences, Figure 3.24 A and B) were 
completely different. The second exon of the alternatively spliced transcript (Exon 2A) is 
a terminal exon which contains the CTG repeats coding for a polyalanine tract 
(highlighted in yellow). The alternatively spliced version is also much shorter and 
consists of only 186 amino acids (AA) while the full length transcript is 748 AA in length. 
As expected this data verifies that the CTG/CAG repeat is not present in the mRNA or 
protein sequence of the full length JPH3 but exists in an alternatively spliced version of 
the gene.  
 
The conservation of a region of a gene across species indicates the importance of that 
region. For instance the MORN domains of the JPH3 gene are highly conserved in 
mouse and nematode [Nishi et al., 2000]. The genomic sequences of human and mouse 
is highly conserved until the CTG repeat (Figure 3.25 A) because the repeats are 
interestingly not present in the mouse JP3 gene. However, the genomic sequence of the 
Pan troglodytes (Chimpanzee) contained the repeats (Figure 3.25 B, highlighted in 
yellow). 
 
In addition, the chimpanzee genomic sequence in the Ensembl [www.ensembl.org] 
database has a larger number of repeats repeat (23 repeats) at this position compared 
to the human consensus sequence (14 repeats). Despite this, the sequences upstream 
and downstream of the repeat are highly conserved between humans and chimpanzees 
(Figure.3.25 B). 
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Human GI:51511732   CCCAGGAATCTCGTCTTTCAGTGGCTGCATCGTTTTCACCATTAGTTGAG 
Mouse GI:94471605   CCCAGGAATCTGGCCATTCAGTGGCTGAATCATTTTCACCTTTAGTTTAG 
                    *********** * * *********** *** ******** ****** ** 
 
Human GI:51511732_> GGAATCGATCTGTGCCTTCATTCTAAGATGCCACCGCATTCGGGGCAGAG 
Mouse GI:94471605   GGAATCGCTCTGCGCCTCCAGTGTAAGATGCCACCACAGTCAGGGCAGAG 
                    ******* **** **** ** * ************ ** ** ******** 
 
Human_ GI:51511732> CCGGGGCCGGAAGCCAGGGAGCTGCCTGCTGCTGCTGCTGCTGCTGCTGC 
Mouse GI:94471605   CCGGTGCCGGAAGCCAGGCAACTACCAG---------------------- 
                    **** ************* * ** ** *                       
 
Human_ GI:51511732> TGCTGCTGCTGCTGCTGTAAGATGGTTTCTGTGCAGGGAACCTTGGCCGG 
Mouse GI:94471605   -----------------TGTGATGGTTTCTGTTCAGA-AGTCCCGGTTGG 
                                     *  ************ ***  *  *  **  ** 
 
Human GI:51511732_> CTCTGCAGCTGCCCGCCTGCCTGGACTCTCCGATATCCACTCCTCAGTGC 
Mouse GI:94471605   CTTGGCAGCCTTC-----------ACTCCAATGTCACCACTCCTCAGCAG 
                    *************           ****     *  ***********  
 
    Human genomic JPH3   CGTTTTCACCATTAGTTGAGGGAATCGATCTGTGCCTTCATTCTAAGATG 
    Chimp genomic JPH3   CGTTTTCACCATTAGTTGAGGGAATCGATCTGTGCCTTCATTCTAAGATG 
                          ************************************************** 
 
    Human genomic JPH3  CCACCGCATTCGGGGCAGAGCCGGGGCCGGAAGCCAGGGAGCTGCCTGCT 
    Chimp genomic JPH3  CCACCACATTCGGGGCAGAGCCGGGGCCGGAAGCCAGGGAGCTGCCTGCT 
                         ***** ******************************************** 
 
    Human genomic JPH3  GCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG------------- 
    Chimp genomic JPH3  GCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGC 
                        *************************************              
 
    Human genomic JPH3  --------------TAAGATGGTTTCTGTGCAGGGAACCTTGGCCGGCTC 
    Chimp genomic JPH3  TGCTGCTGCTGCTGTAAGATGGTTTCTGTGCAGGGAGCCTTGGCCGGCTC 
                                       ************************************                 
 
    Human genomic JPH3  TGCAGCTGCCCGCCTGCCTGGACTCTCCGATATCCACTCCTCAGTGC 
    Chimp genomic JPH3  TGCAGCTGCCCGCCTGCCCGGACTCTCCGATATCCACTCCTCAGTGC 
                         ***********************************************                    
 
                                                                                       
Figure 3.25: (A) An alignment of human and mouse genomic sequence of the JPH3 gene 
around the CTG/CAG repeat. (B) Alignment of human and chimpanzee genomic DNA around 
the repeat. The CTG repeat is highlighted in yellow.  
 
As in humans, an alternatively spliced version of the JPH3 gene which contained the 
repeat was identified in the chimpanzee but not in mice. This sequence was aligned 
to the alternatively spliced human sequence to determine whether the transcripts 
were similar (Figure 3.26 A and B). 
  
(A) 
(B) 
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 (A) 
 
chimp_alt mRNA      GGGTGCGGGAGTGCGCGGGCAACGGGGCCAAATACGAAGGGACCTGGAGCAACGGGCTGC 
Hum_alt mRNA        GGGTGCGGGAGTGCGCGGGCAACGGGGCCAAATACGAAGGGACCTGGAGCAACGGGCTGC 
                    ************************************************************ 
 
 
chimp_alt mRNA      AGGACGGCTACGGGACCGAGACCTACTCGGACGGAGATGCCACCACATTCGGGGCAGAGC 
Hum_alt mRNA        AGGACGGCTACGGGACCGAGACCTACTCGGACGGAGATGCCACCGCATTCGGGGCAGAGC 
                    ******************************************** *************** 
 
chimp_alt mRNA      CGGGGCCGGAAGCCAGGGAGCTGCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 
Hum_alt mRNA        CGGGGCCGGAAGCCAGGGAGCTGCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 
                    ************************************************************ 
 
chimp_alt mRNA      CTGCTGTAAGATGGTTTCTGTGCAGGGAGCCTTGGCCGGCTCTGCAGCTGCCCGCCTGCC 
Hum_alt mRNA        CTGCTGTAAGATGGTTTCTGTGCAGGGAACCTTGGCCGGCTCTGCAGCTGCCCGCCTGCC 
                    **************************** ******************************* 
 
chimp_alt mRNA      CGGACTCTCCGATATCCACTCCTCAGTGCACCTGACACGCACGGAGCCGGTCCTTTCCTG 
Hum_alt  mRNA       TGGACTCTCCGATATCCACTCCTCAGTGCACCTGA------------------------- 
                    **********************************  
         
  (B)      
 
human_alt_prot      MSSGGRFNFDDGGSYCGGWEDGKAHGHGVCTGPKGQGEYTGSWSHGFEVLGVYTWPSGNT 
chimp_alt_prot      -------------------------------------------SHGFEVLGVYTWPSGNT 
                                                               ***************** 
 
human_alt_prot      YQGTWAQGKRHGIGLESKGKWVYKGEWTHGFKGRYGVRECAGNGAKYEGTWSNGLQDGYG 
chimp_alt_prot      YQGTWAQGKRHGIGLESKGKWVYKGEWTHGFKGRYGVRECAGNGAKYEGTWSNGLQDGYG 
                    ************************************************************ 
 
human_alt_prot      TETYSDGDATAFGAEPGPEARELPAAAAAAAAAAAAAVRWFLCREPWPALQLPACLDSPI 
chimp_alt_prot      TETYSDGDATTFGAEPGPEARELPAAAAAAAAAAAAAVRWFLCREPWPALQLPACPDSPI 
                    **********:******************************************** **** 
 
human_alt_prot      STPQCT 
chimp_alt_prot      STPQCT 
                    ****** 
 
 
 
Figure 3.26: (A) Alignment of human and chimpanzee alternatively spliced JPH3 mRNA and (B) protein.  
The repeat is highlighted in yellow. 
 
 
Figure 3.26 confirms that the human and chimpanzee alternatively spliced versions 
of JPH3 are well conserved across these two species. In addition the CTG repeats in 
the mRNA and protein are of equal lengths as opposed to the genomic sequence 
where the chimpanzee gene had more repeats. Furthermore, Exon1 (blue sequence, 
Figure 3.26 B) of the human protein is slightly longer than that of the chimpanzee.  
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Finally, an analysis of the protein sequence for the full length transcripts was needed 
to show whether the Junctophilin-3 was conserved across species. This indicates the 
importance of the gene to the functioning of these organisms. The protein sequences 
used were the full length transcripts of human, chimpanzee and mouse Junctophilin-
3 gene (Figure 3.27).  The protein sequence similarity between the human and 
chimpanzee sequences were 89%. The human and mouse sequences displayed 
90% similarity while the mouse and chimpanzee sequences displayed 99% 
similarity. From these alignments it was concluded that JPH3 full length transcript, 
which does not contain the pathogenic repeat is highly conserved between human, 
mouse and chimpanzee implying that the full length protein has an important function 
across diverse species. 
 
Chimp_Prot      -------------------------------------------SHGFEVLGVYTWPSGNT 
Human_prot      MSSGGRFNFDDGGSYCGGWEDGKAHGHGVCTGPKGQGEYTGSWSHGFEVLGVYTWPSGNT 
Mouse_prot      MSSGGRFNFDDGGSYCGGWEDGKAHGHGVCTGPKGQGEYTGSWSHGFEVLGVYTWPSGNT 
                                                           ***************** 
 
 
Chimp_Prot      YQGTWAQGKRHGIGLESKGKWVYKGEWTHGFKGRYGVRECAGNGAKYEGTWSNGLQDGYG 
Human_prot      YQGTWAQGKRHGIGLESKGKWVYKGEWTHGFKGRYGVRECAGNGAKYEGTWSNGLQDGYG 
Mouse_prot      YQGTWAQGKRHGIGLESKGKWVYKGEWTHGFKGRYGVRECTGNGAKYEGTWSNGLQDGYG 
                ****************************************:******************* 
 
 
Chimp_Prot      TETYSDGGTYQGQWVGGMRQGYGVRQSVPYGMAAVIRSPLRTSINSLRSEHTNGTALHPD 
Human_prot      TETYSDGGTYQGQWVGGMRQGYGVRQSVPYGMAAVIRSPLRTSINSLRSEHTNGTALHPD 
Mouse_prot      TETYSDGGTYQGQWVGGMRQGYGVRQSVPYGMAAVIRSPLRTSINSLRSEHTNGAALHPD 
                ******************************************************:***** 
 
 
Chimp_Prot      ASPAVAGSPAVSRGGFVLVAHSDSEILKSKKKGLFRRSLLSGLKLRKSESKSSLASQRSK 
Human_prot      ASPAVAGSPAVSRGGFVLVAHSDSEILKSKKKGLFRRSLLSGLKLRKSESKSSLASQRSK 
Mouse_prot      ASPAVAGSPAVSRGGFVLVAHSDSEILKSKKKGLFRRSLLSGLKLRKSESKSSLASQRSK 
                ************************************************************ 
 
 
Chimp_Prot      QSSFRSEAGMSTVSSTASDIHSTISLGEAEAELAVIEDDIDATTTETYVGEWKNDKRSGF 
Human_prot      QSSFRSEAGMSTVSSTASDIHSTISLGEAEAELAVIEDDIDATTTETYVGEWKNDKRSGF 
Mouse_prot      QSSFRSEAGMSTVSSTASDIHSTISLGEAEAELAVIEDDIDATTTETYVGEWKNDKRSGF 
                ************************************************************ 
 
 
Chimp_Prot      GVSQRSDGLKYEGEWASNRRHGYGCMTFPDGTKEEGKYKQNILVSGKRKNLIPLRASKIR 
Human_prot      GVSQRSDGLKYEGEWASNRRHGYGCMTFPDGTKEEGKYKQNILVGGKRKNLIPLRASKIR 
Mouse_prot      GVSQRSDGLKYEGEWVSNRRHGYGCMTFPDGTKEEGKYKQNVLVSGKRKNLIPLRASKIR 
                ***************.*************************:**.*************** 
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Chimp_Prot      EKVDRAVEAAERAATIAKQKAEIAASRTSHSRAKAEAALTAAQKAQEEARIARITAKEFS 
Human_prot      EKVDRAVEAAERAATIAKQKAEIAASRTSHSRAKAEAALTAAQKAQEEARIARITAKEFS 
Mouse_prot      EKVDRAVEAAERAATIAKQKAEIAASRTSHSRAKAEAALTAAQKAQEEARIARITAKEFS 
                ************************************************************ 
 
Chimp_Prot      PSFQHRENGLEYQRPKRQTSCDDIEVLSTGTPLQQESPELYRKGTTPSDLTPDDSPLQSF 
Human_prot      PSFQHRENGLEYQRPKRQTSCDDIEVLSTGTPLQQESPELYRKGTTPSDLTPDDSPLQSF 
Mouse_prot      PSFQHRENGLEYQRPKHQMSCDDIEVLSTGTPLQQESPELYRKGTTPSDLTPDDSPLQSF 
                ****************:* ***************************************** 
 
 
Chimp_Prot      PTSPTATPPPAPATRNKVAHFSRQVSVDEERGGDIQMLLEGRAGDCARSSWGEEQTGGSR 
Human_prot      PTSPAATPPPAPAARNKVAHFSRQVSVDEERGGDIQMLLEGRAGDCARSSWGEEQAGGSR 
Mouse_prot      PASPTSTPPPAPASRTKMAHFSRQVSVDEERSGDIQMLLEGRGGDYARNSWGEEKAGASR 
                *:**::*******:*.*:*************.**********.** **.*****::*.** 
 
Chimp_Prot      GVRSGALRGGLLVDDFRTRGSGRKQPGNPKPRERRTESPPVFTWTSHHRASNHSPGGSRL 
Human_prot      GVRSGALRGGLLVDDFRTRGSGRKQPGNPKPRERRTESPPVFTWTSHHRASNHSPGGSRL 
Mouse_prot      GIRSGALRSGQPTEDFRTRGSGHKQPGNPKPRERRTESPTTFSWTSHHRAGNPCSGGPKL 
                *:******.*  .:********:****************..*:*******.* ..**.:* 
 
Chimp_Prot      LELQEEKLSNYRMEMKPLLRMETHPQKRRYSKGGACRGLGDDHRPEDRGFGVQRLRSKAQ 
Human_prot      LELQEEKLSNYRMEMKPLLRMETHPQKRRYSKGGACRGLGDDHRPEDRGFGVQRLRSKAQ 
Mouse_prot      LEPDEEQLSNYKLEMKPLLRMDACPQDTHPQRRRHSRGAGGDR-----GFGLQRLRSKSQ 
                ** :**:****::********:: **. : .:   .** *.*:     ***:******:* 
 
Chimp_Prot      NKENFRPASSAEPAVQKLASLRLGG-AEPRLLRWDLTFSPPQKSLPVALESDEENGDELK 
Human_prot      NKENFRPASSAEPAVQKLASLRLGG-AEPRLLRWDLTFSPPQKSLPVALESDEENGDELK 
Mouse_prot      NKENLRPASSAEPTVQKLESLRLGDRPEPRLLRWDLTFSPPQKSLPVALESDEETGDELK 
                ****:********:**** *****. .***************************.***** 
 
Chimp_Prot      SSTGSAPILVVMVILLNIGVAILFINFFI 
Human_prot      SSTGSAPILVVMVILLNIGVAILFINFFI 
Mouse_prot      SSTGSAPILVVMVILLNIGVAILFINFFI 
                ***************************** 
 
            Figure 3.27: An alignment of the full length protein transcripts of chimpanzee, human and mouse 
           Junctophilin-3. 
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3.10  Investigation of JPH3 mRNA isoforms 
 
JPH3 messenger RNA (mRNA) exists in multiple transcripts due to alternative splicing. 
The pathogenic repeat which causes HDL2 is expressed in an alternatively spliced 
mRNA transcript which consists of two exons. To validate the presence of this mRNA 
transcript, primers were design to specifically amplify the alternatively spliced transcript. 
In addition, primers to amplify the full length predominant transcript were also designed 
(Figure 3.28 A and B).  
 
GTCTCCAGCGGGAGCGCGAGACGCTGGTCAGGCTCCGCGGCGCAGCTCGAAAAGGAATAA 
TCGCCCCCGATTGACTGAAATTCCTCCGGAGCCGGCGCCGCGGCCGCCCGCGCCCGAGAC 
CGCGCTCCGGGGCCGCGTCCTCCTCTCCTCCGGAAAACGCTCGCGACCCAGGGCCGCCGG 
CGGCCGCGACTCTGCTGTGTCGATCGCCTGAGTCCGTTTTCACCGTTTGCGGGATCTGGA 
ACCGAGTTACATGCATGTCCAGTGGGGGCAGGTTTAATTTTGACGACGGAGGGTCCTACT 
GTGGAGGCTGGGAGGACGGCAAGGCGCACGGCCATGGCGTCTGCACCGGCCCCAAGGGCC 
AAGGCGAATACACCGGCTCGTGGAGCCACGGCTTCGAGGTGCTGGGCGTCTACACCTGGC 
CCAGCGGCAACACGTACCAGGGCACCTGGGCGCAGGGCAAGCGCCACGGCATCGGCCTGG 
AGAGCAAGGGGAAGTGGGTGTACAAGGGCGAGTGGACGCACGGATTCAAGGGGCGCTACG 
GGGTGCGGGAGTGCGCGGGCAACGGGGCCAAATACGAAGGGACCTGGAGCAACGGGCTGC 
AGGACGGCTACGGGACCGAGACCTACTCGGACGGAGGGACCTACCAGGGCCAGTGGGTCG 
GTGGCATGCGCCAGGGCTACGGCGTCCGGCAGAGCGTCCCGTATGGCATGGCCGCGGTCA 
TCCGCTCACCCCTGAGGACGTCCATCAACTCCCTGCGCAGCGAGCACACCAACGGCACGG 
CGCTGCATCCCGACGCCTCTCCGGCGGTGGCCGGCAGCCCGGCCGTGTCCCGCGGGGGCT 
TCGTGCTCGTGGCCCACAGTGACTCCGAGATCCTCAAGAGCAAGAAGAAGGGGCTGTTTC 
GGCGCTCGCTGCTGAGTGGGCTGAAGCTGCGCAAGTCGGAGTCCAAGAGCAGCCTGGCCA 
GCCAACGCAGCAAGCAGAGCTCCTTTCGCAGCGAGGCGGGCATGAGCACCGTCAGCTCCA 
CGGCCAGCGACATCCACTCCACCATCAGCCTGGGCGAGGCTGAGGCCGAGCTGGCGGTCA 
TCGAGGACGACATCGACGCCACCACCACCGAGACCTACGTGGGCGAGTGGAAGAACGACA 
AACGCTCCGGCTTCGGCGTGAGCCAGCGCTCGGACGGGCTCAAGTACGAGGGCGAGTGGG 
CCAGCAACCGGCGCCATGGCTACGGCTGCATGACCTTCCCGGACGGCACCAAGGAGGAGG 
GCAAGTACAAGCAGAACATCCTCGTCGGCGGCAAGCGCAAGAACCTCATCCCCCTGCGGG 
CCAGCAAGATCCGCGAGAAGGTGGACCGCGCCGTTGAGGCCGCTGAGCGGGCCGCCACCA 
TCGCCAAGCAGAAGGCTGAGATCGCGGCTTCCAGGACCTCCCACTCTCGGGCAAAGGCCG 
AGGCAGCCCTCACAGCAGCTCAGAAAGCCCAGGAGGAGGCGCGGATCGCCAGGATCACTG 
CCAAAGAGTTCTCCCCTTCCTTCCAGCACCGGGAAAACGGGCTGGAGTACCAGAGGCCGA 
AGCGTCAGACCTCCTGTGACGACATCGAGGTGCTGTCCACCGGGACACCCCTGCAGCAGG 
AGAGCCCCGAGCTGTACCGCAAGGGCACCACTCCCTCCGACCTGACCCCCGACGACAGCC 
CCCTGCAGAGCTTCCCCACCAGCCCCGCGGCCACCCCGCCGCCCGCGCCCGCCGCCAGGA 
ACAAGGTCGCCCACTTCTCGAGGCAGGTGTCGGTGGACGAGGAGCGGGGCGGGGACATCC 
AGATGCTCCTGGAGGGCCGGGCCGGGGACTGCGCCCGCAGCAGCTGGGGCGAGGAGCAGG 
CCGGGGGCTCCAGGGGTGTCCGCAGCGGTGCCCTGCGCGGCGGCCTGCTCGTGGATGACT 
TCCGCACCCGAGGTTCGGGCCGCAAGCAGCCCGGGAACCCCAAGCCGCGGGAGCGGCGGA 
CGGAGTCACCCCCCGTGTTCACGTGGACTTCCCACCACCGGGCCAGCAACCACAGCCCCG 
GAGGCTCCAGGCTGCTGGAGCTGCAGGAGGAGAAGCTGAGCAACTACCGGATGGAGATGA 
AACCCTTGCTGAGGATGGAGACGCATCCCCAGAAAAGACGCTACAGCAAGGGCGGCGCCT 
GCCGGGGCTTGGGGGACGACCACCGCCCCGAGGACCGGGGCTTCGGGGTGCAGAGACTGC 
GGTCCAAGGCCCAGAACAAGGAGAACTTCAGGCCGGCCTCCTCCGCGGAGCCCGCCGTGC 
AGAAACTGGCGAGCCTGCGGCTGGGCGGGGCCGAGCCCCGGTTGCTGCGTTGGGACTTGA 
CCTTCTCCCCGCCCCAGAAATCCTTGCCTGTCGCTCTAGAGTCCGACGAGGAGAATGGGG 
ATGAGCTCAAGTCCAGTACGGGCTCAGCGCCTATCCTGGTGGTCATGGTGATCTTGCTCA 
ACATCGGAGTCGCCATTCTGTTTATTAACTTTTTCATCTGATGAGATGTCGCGGTAGCAA 
AAATAGAGAAAGGGTAGAAAAAAGGGACATTAAAATTAAAAGCAAAACCACAAGAAGGGA 
AAGACCGCAACTCGGACAGCCCAGCGACTTCCAAGTCCTCTCACAGAAGAACCACACGAT 
TGGGTATCACTCACAGTTTGCCTTTTTTTCTGGGTAATGTTTTTTGGATTTTAGCCAAAA 
TTCTTTGCTTGTATAACACTCTGCTGTGTGGCATGGCAGAAGGAGGCCAGCACGCAGCCC 
CTCCAGCTCCACGTGGAGACAGAAGGGATCCCGGCACATCAGTGGTAACAGCGGACGTTG 
TCCTCGTGGTCACACGTCCCGTCTTGGGTGTGGATGGAGGGCAGCCCGGGGCAGAGCCTC 
AGCCCCGCGGCCCCTGAGTGGCAGGGCTGACTCCCGTCGACACGAGCTTAGAAAGTGGAT 
TCACTGCTTTCTCTGTCTAGAACAGACGGGTGACAAGTATGGGCAGGAGGCATGGGGCAG 
GGTGGCCCACCCCAGTGGGCAGTAGCCTGGCCTTTTTCTGTGTGAGATCTGTGCTGCACA 
CCTGAGGGAGGGGGAGGGATCGGCCACCTCCTCCCTGTGAGACGGATGCAGGTCCTTCCC 
(A) 
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TCTTCTCGGCACTGCCCCCGGCCTTCCATGAGAAGCCGACTCCCCACACCGAGTTTTAAA 
GCAAAGCCCTTTTCTTCTGCTGCCCACTCACTGTGGGTCCCATTCGGCTGTTTCCCCCAC 
CAGACCCCAGGGAAGCCGGGGCCCACTCCGATCCGCCTGGGCTCAGCTAAGCACGGAAGC 
CAAGGGGGCTGTGCCGTGGAGCTGGGCTCGCGCCGGGGCTCTGGGTGTGTGCGCTTGGCG 
TGCAGGGTGGACGCGTGGGGTTCCGTGTCCCCAGCAGTGAGGGCCCTAGAGGACGCCTTC 
TCCCATGGTTACTGATCTCCACGGGTTTTCACATCTCTGTACTGTGCCTGCCTCAACTTC 
CCCTAACAGATATGCATATTCCTTCCAGATGCCTCAGTGCTACACCACAGTGGGCCTGGT 
CCCAGGACAGGAATGCGGTTCAAACCCAGTGGCTTGAAACTTCCTGAGAAACTGTAGCAT 
ATCCAGCCCCCTAAAATGTACAATGTAACTTGTTCAGTCCAACAAAAACAGGTTCCTTAT 
GTTTCTGCCTTCTCCACCAGGGTCGCTCCATCACCCAAACAAAAGAACAAGGTTTGCCAG 
GATGTCCGAGTGCCCCCTGGCCCTGGCTCTCGTGTGCATGGACGTGCCTGAGGGGTCCGG 
GCACGGCCATACGCAGGACCCCTGTGCCCGGGGAGGCGCTGCAGGGATTCCCCATCCGGT 
CGTCTTGGGGCCAGCCCGTCTTATGGACTCTGCCTTGCTTTGCTTATGTTTAGCTGTTTC 
TCTGCTACCTTTCGAGCAGACTTCTTTACTACACTGCACTGGATTGCTATATTTTTAACC 
      AGAAATAAACTAAAGATTAGAGCATGTTCCAGTTAAA 
 
 
GTCTCCAGCGGGAGCGCGAGACGCTGGTCAGGCTCCGCGGCGCAGCTCGAAAAGGAATAA 
TCGCCCCCGATTGACTGAAATTCCTCCGGAGCCGGCGCCGCGGCCGCCCGCGCCCGAGAC 
CGCGCTCCGGGGCCGCGTCCTCCTCTCCTCCGGAAAACGCTCGCGACCCAGGGCCGCCGG 
CGGCCGCGACTCTGCTGTGTCGATCGCCTGAGTCCGTTTTCACCGTTTGCGGGATCTGGA 
ACCGAGTTACATGCATGTCCAGTGGGGGCAGGTTTAATTTTGACGACGGAGGGTCCTACT 
GTGGAGGCTGGGAGGACGGCAAGGCGCACGGCCATGGCGTCTGCACCGGCCCCAAGGGCC 
AAGGCGAATACACCGGCTCGTGGAGCCACGGCTTCGAGGTGCTGGGCGTCTACACCTGGC 
CCAGCGGCAACACGTACCAGGGCACCTGGGCGCAGGGCAAGCGCCACGGCATCGGCCTGG 
AGAGCAAGGGGAAGTGGGTGTACAAGGGCGAGTGGACGCACGGATTCAAGGGGCGCTACG 
GGGTGCGGGAGTGCGCGGGCAACGGGGCCAAATACGAAGGGACCTGGAGCAACGGGCTGC 
AGGACGGCTACGGGACCGAGACCTACTCGGACGGAG ATGCCACCGCATTCGGGGCAGAGC 
CGGGGCCGGAAGCCAGGGAGCTGCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 
CTGCTGTAAGATGGTTTCTGTGCAGGGAACCTTGGCCGGCTCTGCAGCTGCCCGCCTGCC 
      TGGACTCTCCGATATCCACTCCTCAGTGCACCTGA 
 
 
Figure 3.28: The positions of the primers designed to amplify the full length (A) and alternatively 
spliced (B) JPH3 transcripts are indicated by highlighted regions. Grey: full length set A, pink: full 
length set B and yellow: alternatively spliced. The different exons are indicated by the alternating 
colours. 
 
As a control a third set of primes were designed to amplify a housekeeping gene, namely 
β-Haemoglobin (HBB) gene, which was used to test the viability and quality of cDNA. 
The HBB gene is expressed in many tissues at relatively similar rates and is highly 
conserved, thereby making it a suitable housekeeping gene [Shmueli et al., 2003]. The 
primers were designed spanning a small intron thereby producing differently sized 
fragments on genomic DNA and on cDNA, which was useful in controlling for genomic 
contamination which is a major source of contamination in cDNA (Section 2, Figure 2.4). 
The primers for HBB produced a product of 377bp in genomic DNA and 248bp in cDNA 
(Figure 3.29).  
 
 
 
 
(B) 
  
89
 
 
 
Figure 3.29: Agarose gel depicting the size difference in fragments produced by HBB primers for 
genomic DNA (gDNA) and cDNA. 
 
The HBB primers were used in all subsequent PCR reactions as a control to firstly 
indicate that there was no genomic DNA contaminants in the cDNA samples and 
secondly that the cDNA was of good quality. 
 
 3.10.1 Purchased foetal brain cDNA as template  
 
The HBB, JPH3 full length and alternatively spliced JPH3 primers were tested on cDNA 
generated from foetal brain RNA which was used as a template because JPH3 is 
expressed almost exclusively in the brain. The subsequent PCR reactions of foetal brain 
cDNA using primers for the HBB gene are shown (Figure 3.30).   
 
     
Figure 3.30: Agarose gel depicting PCR products using foetal brain cDNA as template. Lane M 
contains 100bp marker. Lane 1: amplification with HBB primers, lane 2: amplification with JPH3  
full length primers (set A), lane 3: amplification with JPH3  full length primers (set B), lane 4: 
amplification with JPH3  alternatively spliced primers. 
 
 M      gDNA    cDNA  
400bp 
300bp 
200bp 
 
 
100bp 
M        1           2            3           4  
500bp 
400bp 
300bp 
200bp 
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Several attempts to optimise the JPH3 full length set A primers PCR were unsuccessful. 
Interestingly, the PCR product obtained using primers for the alternatively spliced 
isoform was correct and verified by sequencing even though, according to Margolis et 
al., [2006], the alternatively spliced version of the transcript is expressed at lower levels 
than the full length transcript (Lane 4, Figure 3.30). The full length primers were then 
redesigned across Exons 4 and 5 of the JPH3 gene which is closer to the 3’ end of the 
transcript because it was possible that the cDNA did not extend all the way to the 5’ end 
during the generation of the cDNA. The amplification with the redesigned primers (Set B, 
Lane 3), HBB primers (Lane 1) as well as the alternatively spliced primers (Lane 4) was 
successful for foetal brain cDNA (Lane 3) whereas the full length (Set A) primers were 
not (Lane 2, Figure 3.30). 
 
These PCR products were subjected to direct sequencing to confirm that the correct 
fragments were amplified and also to determine the number of repeats in the 
alternatively spliced product. 
(A) 
 
(B) 
 
Figure 3.31: (A) Chromatographs produced from the direct sequencing of foetal brain cDNA with 
JPH3 alternatively spliced reverse and (B) JPH3 full length set B primers. 
 
The foetal brain RNA was isolated from a pooled sample of foetuses and produced more 
than one transcript. Due to this the CTG repeat sizes of the different foetuses would 
differ and cause “messy” sequencing (Figure 3.31 A). The sequencing products were 
searched against the NCBI database using the BLAST search tool and were shown to 
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match the reference sequences for JPH3 full length and alternatively spliced mRNA 
transcripts.    
 
3.10.2  Patient lymphocyte cDNA as template 
  
An exploratory study to analyse the JPH3 isoforms in the affected family members was 
attempted. In this investigation RNA was isolated from transformed lymphocytes of two 
affected family members. The lymphocytes served as a substitute for brain tissue which 
was not available at the time of this study. Lymphocytes were used as a surrogate for 
brain tissue since, due to the process of illegitimate transcription, all forms of transcripts 
of every gene is expressed as mRNA at a basal level [Chelly et al., 1989].  
 
The Experion™ RNA StdSens Analysis Kit was used to determine the quality and 
quantity of the extracted RNA. Samples of the RNA from lymphocytes of family members 
5657 and 5760 were run on Experion™ automated electrophoresis system which 
separated and analysed the sample. Figure 3.32 represents the gel matrix with the 
samples that were applied to it.  
 
 
Figure 3.32: Electrophoresis of RNA isolates using the Experion™ automated electrophoresis 
system. 
 
The lane marked L contains an RNA ladder with the sizes (in bp) along the Y axis. Lane 
3 contains RNA-free water as a negative control. Lanes 1 and 2 contain the RNA 
isolated from 5657 and 5760 respectively. The red arrows indicate the 18S and 28S 
28S rRNA  
 
 
 
18S rRNA 
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ribosomal RNA (rRNA) of sample 5760. Figure 3.33 shows the graphical output of lane 2 
as generated by the Experion™ system.  
 
Figure 3.33:  Experion™ graphical output of lane 2. 
 
The graph (Figure 3.33) showed that RNA was isolated from 5760 and the peak for 28s 
was clearly defined. cDNA was generated from the isolated RNA of 5760 and used as 
template for amplification using the HBB primers as a control to determine whether the 
cDNA was viable and could be amplified. A fragment of the appropriate size was 
observed for the HBB primers (lane 2), which indicated that the cDNA was 
uncontaminated and was of good enough quality to be used in a PCR reaction. The 
cDNA was then used as template for amplification with the primers listed in Table 2.7 
(Page 44). Subsequent PCR reactions with either full length JPH3 (Lane 3 and 4) or 
alternatively spliced primers (Lane 5) were unsuccessful even after extensive attempts at 
optimising the reaction (Figure 3.34).  
 
     
Figure 3.34: Gel electrophoresis of PCR products using lymphocyte cDNA of affected HDL2 
patients. Lane M contains 100bp marker, lane 1: HBB primers on genomic DNA (control), lane 2: 
HBB primers on lymphocyte cDNA, lane 3: full length primers (set A), lane 4: full length primers 
(set B) and lane 5: alternatively spliced primers. 
18s         28s 
M    1     2      3     4    5  
400bp 
300bp 
200bp 
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3.10.3 Real-time PCR 
 
To determine whether the patient’s lymphocyte cDNA did not amplify with the JPH3  
primers because the transcripts are not being illegitimately transcribed or was just at too 
low levels to be detected, real-time PCR on a LightCycler® was attempted. Real-time 
PCR is a more sensitive PCR method which allows one to detect extremely low levels of 
template in a PCR reaction. Real-time PCR measures the amount of fluorescence 
generated by SYBR green as it is incorporated into the amplified PCR product.  
 
HBB primers 
Initially the LightCycler® reactions were performed using serial dilutions of the genomic 
DNA (1:1, 1:10 and 1:100) of the genomic DNA, using HBB primers.  
 
The genomic DNA amplification was successful with the crossing point (CP) of the 
reactions between 20-28 cycles. The optimal reaction occurred with the 1:1 template 
DNA. The melt point analysis produced peaks at 87ºC for all three dilutions indicating 
that a single product was produced (Figure 3.35). The negative control produced a CP 
value of 33 and had a different melt-curve to the genomic DNA. The agarose gel (Figure 
3.35 C) shows the respective sizes of the bands. The faint, small fragments visible in all 
the lanes are likely due to the formation of primer dimers.   
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 Figure 3.35: (A) The crossing point curve and (B) melt curve of genomic DNA (1:1 blue, 1:10 
green, 1:100 red and negative control black) amplified with HBB primers.(C) Agarose gel 
indicating the size of the PCR products. Lane M contains 100bp marker, lane 1: HBB primers on 
genomic DNA (1:1), lane 2: HBB primers on genomic DNA (1:10), lane 3: HBB primers on 
genomic DNA (1:100) and lane N: negative control. 
 
Real-time PCR using HBB primers with foetal brain and lymphocyte cDNA as template 
also produced the correct product which was verified by sequencing (Figure 3.36 A and 
B).     
 
 
Figure 3.36: Chromatograph depicting the partial sequence obtained from the direct sequencing 
of (A) lymphocyte cDNA and (B) foetal brain cDNA amplified with primers for the HBB gene. 
 
Based on these promising results, real-time PCR was attempted using primers for the 
JPH3 full length and alternatively spliced isoforms.  
 
 
 
      M            1           2           3         N   
400bp 
300bp 
200bp 
 
(A) 
(B) 
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Full-length and alternatively spliced primers 
 
Using the optimal dilutions from the HBB amplification, the amplification of foetal brain 
and lymphocyte cDNA was attempted. The crossing points of many of the runs were 
more than 30 cycles and are therefore not optimal. However some runs have been 
analysed (Figures 3.37 and 3.38).  
 
 
 
Figure 3.37: Amplification with JPH3 full length set B (A) crossing point curve and (B) melt curve 
analysis of lymphocyte cDNA, foetal brain cDNA and a negative control. 
 
(A) 
(B) 
Foetal brain cDNA 
 Foetal brain cDNA 
 
Negative control 
Lymphocyte cDNA 
Lymphocyte  cDNA 
 
Negative control 
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Figure 3.38: Amplification with JPH3 alternatively spliced primers (A) crossing point curve and 
(B) melt curve analysis of lymphocyte cDNA, foetal brain cDNA and a negative control.  
 
 From the graphs (Figures 3.37 and 3.38) it appeared that the negative controls and the 
cDNA templates have similar CP values. In addition, the melt curve analysis for the 
negative control does not differ from the cDNA templates. These results indicate that the 
exploratory real-time PCR reactions were unsuccessful and require further optimisation. 
At this stage we are unable to determine whether the JPH3 transcripts are present in 
lymphocytes. 
(A) 
(B) 
Lymphocyte cDNA 
Foetal brain cDNA 
Negative control 
Foetal brain cDNA 
Lymphocyte  cDNA 
Negative control  
  
97
 
 3. 11  Expressed Sequence Tags alignments 
 
 
To provide independent confirmation of the existence of the alternatively spliced 
transcript primers were designed to specifically amplify this repeat in lymphocyte 
RNA of the affected family and from commercial foetal brain cDNA.  Amplification 
from lymphocyte cDNA was unsuccessful. However, the foetal brain cDNA produced 
strong fragments of the expected size. This product was then sequenced and 
searched against ESTs in the dbEST database.   
 
Significant alignment was shown for 17 ESTs (Figure 3.39) however, only three 
(highlighted in green) of these ESTs contained Exon 1 spliced to an Exon 2A which 
contains the repeat.  
 
Sequences producing significant alignments:                       (Bits)  E Value 
 
gb|BI553267.1|  603193587F1 NIH_MGC_95 Homo sapiens cDNA clone...  1175    0.0 
gb|BI550632.1|  603195805F1 NIH_MGC_95 Homo sapiens cDNA clone...  1138    0.0 
gb|BM548387.1|  AGENCOURT_6573271 NIH_MGC_124 Homo sapiens cDN...   717    0.0 
gb|AA912459.1|  om52c01.s1 NCI_CGAP_GC4 Homo sapiens cDNA clon...   560    5e-157 
gb|BE042890.1|  ho30c07.x1 NCI_CGAP_Lu24 Homo sapiens cDNA clo...   527    5e-147 
dbj|DA404387.1|  DA404387 BRTHA3 Homo sapiens cDNA clone BRTHA...   523    7e-146 
dbj|DA189798.1|  DA189798 BRAMY3 Homo sapiens cDNA clone BRAMY...   361    6e-97 
gb|AI680727.1|  tx40f05.x1 NCI_CGAP_Lu24 Homo sapiens cDNA clo...   335    3e-89 
gb|U80757.1|  U80757 Human fetal brain (R.L.Margolis) Homo sap...   320    1e-84 
gb|AI299726.1|  qm97d09.x1 NCI_CGAP_Lu5 Homo sapiens cDNA clon...   292    2e-76 
gb|CN309838.1|  17000600179634 GRN_PRENEU Homo sapiens cDNA 5', m   267    1e-68 
gb|BE779067.1|  601464841F1 NIH_MGC_67 Homo sapiens cDNA clone...   241    8e-61 
gb|AW205682.1|  UI-H-BI1-adu-b-03-0-UI.s1 NCI_CGAP_Sub3 Homo s...   231    5e-58 
gb|BI547995.1|  603189433F1 NIH_MGC_95 Homo sapiens cDNA clone...   172    3e-40 
dbj|DA414512.1|  DA414512 BRTHA3 Homo sapiens cDNA clone BRTHA...   159    2e-36 
dbj|DA123472.1|  DA123472 BRACE3 Homo sapiens cDNA clone BRACE...   141    8e-31 
dbj|DA193144.1|  DA193144 BRAMY3 Homo sapiens cDNA clone BRAMY...  84.2    1e-13 
 
 
 Figure 3.39: Sequences producing significant alignments in the EST database. 
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These three ESTs were from different sources. The BE042890.1 EST (Figure 3.40 
A) was generated from lung tissue and contains the Exon 1-Exon 2A boundary. The 
U80757.1 EST (Figure 3.40 B) had been detected in foetal brain cDNA during a 
study that involved using a RED assay to detect any repeat expansions in brain 
tissue [Margolis et al., 1997]. The third EST, BE779067 (Figure 3.40 C), was isolated 
from human retinoblastoma tissue and contained 2 base pairs of Exon1 and the 
entire Exon 2A. 
 
gb|BE042890.1| ho30c07.x1 NCI_CGAP_Lu24 Homo sapiens cDNA clone IMAGE:3038892  
mRNA sequence. 
Length=457 
CONTAINS EXON 1 /2A BOUNDARY Lung  
Score =  527 bits (285),  Expect = 5e-147 
Identities = 300/306 (98%), Gaps = 6/306 (1%) 
Strand=Plus/Plus 
 
Query  516  ACGCACGGATTCAAGGGGCGCTACGGGGTGCGGGAGTGCGCGGGCAACGGGGCCAAATAC  575 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2    ACGCACGGATTCAAGGGGCGCTACGGGGTGCGGGAGTGCGCGGGCAACGGGGCCAAATAC  61 
 
Query  576  GAAGGGACCTGGAGCAACGGGCTGCAGGACGGCTACGGGACCGAGACCTACTCGGACGGA  635 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  62   GAAGGGACCTGGAGCAACGGGCTGCAGGACGGCTACGGGACCGAGACCTACTCGGACGGA  121 
 
Query  636  GATGCCACCGCATTCGGGGCAGAGCCGGGGCCGGAAGccagggagctgcctgctgctgct  695 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  122  GATGCCACCGCATTCGGGGCAGAGCCGGGGCCGGAAGCCAGGGAGCTGCCTGCTGCTGCT  181 
 
Query  696  gctgctgctgctgctgctgctgctgctgctg-t-----aagatggtttctgtgcagggAA  749 
            ||||||||||||||||||||||||||||||| |     |||||||||||||||||||||| 
Sbjct  182  GCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGTAAGATGGTTTCTGTGCAGGGAA  241 
 
Query  750  CCTTGGCCGGCTCTGCAGCTGCCCGCCTGCCTGGACTCTCCGATATCCACTCCTCAGTGC  809 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  242  CCTTGGCCGGCTCTGCAGCTGCCCGCCTGCCTGGACTCTCCGATATCCACTCCTCAGTGC  301 
 
Query  810  ACCTGA  815 
            |||||| 
Sbjct  302  ACCTGA  307 
 
 
 
gb|U80757.1| U80757 Human fetal brain (R.L.Margolis) Homo sapiens cDNA, mRNA  
Length=2107 
2 BP OF EXON 1 AND ENTIRE EXON 2A  
      Score =  320 bits (173),  Expect = 1e-84 
Identities = 181/184 (98%), Gaps = 3/184 (1%) 
Strand=Plus/Minus 
 
Query  635   AGATGCCACCGCATTCGGGGCAGAGCCGGGGCCGGAAGccagggagctg-c--ctgctgc  691 
             ||||||||||||||||||||||||||||||||||||||||||||||||| |  ||||||| 
Sbjct  2009  AGATGCCACCGCATTCGGGGCAGAGCCGGGGCCGGAAGCCAGGGAGCTGCCTGCTGCTGC  1950 
 
Query  692   tgctgctgctgctgctgctgctgctgctgctgctgtaagatggtttctgtgcagggAACC  751 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1949  TGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGTAAGATGGTTTCTGTGCAGGGAACC  1890 
(A) 
(B) 
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Query  752   TTGGCCGGCTCTGCAGCTGCCCGCCTGCCTGGACTCTCCGATATCCACTCCTCAGTGCAC  811 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1889  TTGGCCGGCTCTGCAGCTGCCCGCCTGCCTGGACTCTCCGATATCCACTCCTCAGTGCAC  1830 
 
Query  812   CTGA  815 
             |||| 
Sbjct  1829  CTGA  1826 
 
 
gb|BE779067.1| 601464841F1 NIH_MGC_67 Homo sapiens cDNA clone IMAGE:3867947  
5', mRNA sequence. 
Length=902 
      Score =  241 bits (130),  Expect = 8e-61 
Identities = 179/199 (89%), Gaps = 18/199 (9%) 
Strand=Plus/Plus 
2BP OF EXON 1 AND EXON 2A retinoblastoma 
 
Query  635  AGATGCCACCGCATTCGGGGCAGAGCCGGGGCCGGAAGccagggagctgcctgctgctgc  694 
            ||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  188  AGATGCCACCGGATTCGGGGCAGAGCCGGGGCCGGAAGCCAGGGAGCTGCCTGCTGCTGC  247 
 
Query  695  tgctgctgctgctgctgctgct-gctgc-tgctg-t--aag-atggtttct-gtgcaggg  747 
            |||||||||||||||||||||| ||||| ||||| |  ||| ||||||||| |||||||| 
Sbjct  248  TGCTGCTGCTGCTGCTGCTGCTAGCTGCATGCTGCTGTAAGCATGGTTTCTAGTGCAGGG  307 
 
Query  748  -AACC-TTGGC-CGGCTCTGC-AGCTGCCC-GCCTGCC-TGG-ACTCTCCG-ATATCC-A  798 
             |||| ||||| ||||||||| |||||||| | ||||| ||| |||||||| |||||| | 
Sbjct  308  CAACCATTGGCACGGCTCTGCCAGCTGCCCAGACTGCCATGGCACTCTCCGCATATCCCA  367 
 
Query  799  CTCCTCAG-TGCACC-TGA  815 
            |||||||| |||||| ||| 
Sbjct  368  CTCCTCAGATGCACCGTGA  386 
 
 
   Figure 3.40: ESTs that contain Exon 1 and Exon 2A of JPH3 alternatively spliced mRNA.  
 
This investigation showed that a transcript wherein Exon 1 is spliced to a terminal 
exon containing the repeat does exist. Furthermore, this provides independent 
confirmation of the results of a study done by Holmes et al., [2001] which used RT-
PCR and gene prediction programmes to show that the repeat expansion which 
causes HDL2 occurs in an alternatively spliced version of the JPH3 gene.
(C) 
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Chapter Four: Discussion 
 
The primary objective of the present study was to ascertain the molecular cause of 
dementia and movement disorders in a South African family of Mixed Ancestry. After 
screening several novel loci and eliminating several potential disorders, it was 
determined that this family had Huntington’s disease-like 2 (HDL2) [Bardien et al., 2007]. 
The expanded repeats ranged from 42-59 repeats in three affected family members. 
HDL2 is a rare, autosomal dominant disease that occurs predominantly, if not 
exclusively, in individuals of Black African ancestry [Santos et al., 2008]. A possible 
reason for this may be that the distribution of the CTG repeats in the JPH3 gene within 
the Black African population is larger in comparison to other population groups which 
would potentially predispose this group to repeat expansions in the pathogenic range. 
This was investigated in a pilot study by determining the repeat distribution amongst 
three South African sub-populations. The results showed a statistically significant 
difference in the distribution of the repeats between the Black African and the Caucasian 
ethnic groups.   
 
Although it is known that HDL2 is caused by a triplet repeat expansion in the JPH3 gene, 
the mechanism of pathogenesis is as yet unclear. Therefore any research done on this 
topic may provide important insights in terms of managing the disease and developing 
suitable therapies. Given this, the present study also investigated factors that could 
possibly contribute to understanding the pathogenesis of this disease.  
 
The JPH3 expanded repeat is located in an alternatively spliced version of the gene. In 
the present study, it was determined whether the JPH3 mRNA transcripts could be 
detected in RNA derived from foetal brain. In addition, even though JPH3 is thought to 
be almost exclusively expressed in brain tissue, it was investigated whether the 
alternatively spliced transcript could be detected in the blood of HDL2 affected 
individuals due to the process of illegitimate transcription. Neither of the transcripts could 
be detected in transformed lymphocytes, however both transcripts were detected in 
foetal brain RNA.  
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4.1  Exclusion of loci  
 
Inherited dementias are caused by neurodegenerative diseases such as HD or 
Alzheimer’s disease. In studies of families with severe dementia of unknown genetic 
origin, several diseases need to be excluded before novel loci are screened. HD, SCAs, 
DRPLA, FENIB and PD are common candidate diseases to exclude in cases of familial 
dementia where a pathogenic mutation needs to be determined [Filla et al., 2002]. In the 
present study several of these candidate disorders were excluded. The loci for HD, 
FENIB, DRPLA, SCAs (types 1, 2, 3, 6 and 7) and the PARK2 gene were screened. In 
addition, loci implicated in MELAS, MERRF, Leighs’ disease and other novel 
mitochondrial loci were also screened. All of these loci were excluded as being the 
disease-causing mutation. 
 
For all the candidate loci, the proband was screened initially and any possible mutation 
was then assessed in other family members and ethnically matched controls. In the 
cases where a novel variant was identified, the variant was assessed for possible 
pathogenicity according to three criteria. Firstly, the sequence variant had to segregate 
in all affected family members and be absent in clinically unaffected family members and 
ethnically matched controls. Secondly, if the variant causes a non-synonymous change 
in the amino acid sequence of the protein, it had a greater potential of being pathogenic. 
Thirdly, if the variant occurs in a region of the gene which is evolutionarily conserved 
across species, it has an increased possibility of being pathogenic.  
 
In this study three novel sequence variants were identified in the MT-ND1 and MT-ND2 
genes in the mitochondrial genome. These three variants occurred in both affected and 
clinically unaffected members of Family R. These novel variants were deposited into the 
Mitomap database under the accession numbers 20061030001, 20061030002 and 
2006103003. Because mitochondrial DNA is essential in determining lineages of 
individuals, the reporting of novel variants may be useful in forensics and population 
genetics studies. Mitochondrial DNA is highly variable and prone to mutations. In fact, it 
is estimated that the mutation rate in mitochondrial DNA is 10-20 times higher than that 
of nuclear genes [Strachan and Read, 1996]. It is therefore difficult to prove the 
pathogenicity of any novel mitochondrial sequence variant.  
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Several sequence variants were identified in the PARK2 gene but were excluded as 
being the causative mutation because they are known polymorphisms and were 
previously shown to be present at similar frequencies in individuals with Parkinson’s 
disease and “healthy” controls [West et al., 2002, Lincoln et al., 2003 and Kay et al., 
2007]. Kay et al. [2007] argued that some of the so-called “mutations” in the PARK2 
gene are found in equal distribution among PD patients and healthy controls. The first 
stage of their study found that the frequency of the IVS8+48 C>T variant was reduced in 
PD patients compared to the unaffected control group. However, on analysis of a larger 
sample size this tentative bias fell away and the presence of this polymorphism did not 
differ significantly between the PD and control groups. In the same study the V380L 
polymorphism was also assessed and occurred at the same frequency in both PD 
patients and controls. Similarly, Lincoln et al. [2003] considered both the V380L and 
D394N to be normal variants as both of them occurred at equal frequencies in PD 
patients and controls. The -227A>G variant is found in the promoter region and was 
initially thought to influence the transcription of the gene. However, there was no protein 
binding sight in close proximity to this SNP and it was therefore concluded that this SNP 
had no effect on the functionality of the gene [West et al., 2002]. This group showed that 
the distribution of this variant did not differ significantly between 196 control individuals 
and 319 PD patients.  
 
While many common diseases are not caused by SNPs, the interaction of SNPs in 
multiple genes, coupled with non-genetic risk factors all contributes to the phenotype of 
the disease. Furthermore, SNPs may also affect drug therapy and influence the 
manifestation of the disease [Pirmohamed and Park, 2001]. It is therefore important to 
identify SNPs in candidate disease genes as it may explain clinical heterogeneity, drug 
resistance and why certain populations are more susceptible to a particular disease than 
others. 
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4.2  Clinical analysis of affected family members 
 
It was determined that Family R had HDL2, however, the clinical presentation of the 
disease in this family presented differently to other reported HDL2 cases. Firstly, the 
pedigree showed a strong trend towards a maternal pattern of inheritance as opposed to 
the HDL2 index family (Pedigree W) which displayed a strictly male-to-male transmission 
across three generations [Margolis et al., 2001]. Due to this potential bias for maternal 
inheritance, several candidate loci on the mitochondrial genome were screened. As the 
disorder was in fact autosomal dominantly inherited, it was concluded that this potential 
bias was most likely a chance occurrence just as Pedigree W’s potential paternal bias 
was later determined to be a chance event. However, this bias should not be completely 
disregarded as it is still unknown whether the sex of the transmitting parent plays a role 
in the aetiology of the disease. More families will need to be studied in order to 
determine this. Patients should therefore be screened for HDL2 regardless of family 
history and pattern of inheritance.  
 
Secondly, several groups emphatically state that HDL2 is indistinguishable from HD 
[Margolis et al., 2004 and Stevanin et al., 2003]. The clinical examination of two of the 
three affected Family R members showed that they presented with a phenotype atypical 
to HD. One of the family members had cortical myoclonus while the other had 
parkinsonism [Bardien et al., 2007]. Moreover, one case showed marked cerebral 
atrophy and normal caudate nuclei whereas in the advanced stages of HD, the caudate 
nuclei are usually severely atrophied and are affected to a greater degree than the 
cerebral cortex [Margolis et al., 2006].  
 
In addition, several features of the disease in Family R differ from those reported in the 
index pedigree. The autopsy examination of the first available case of Pedigree W 
showed that the caudate was severely atrophied and the white matter of the cerebral 
cortex was well myelinated after 15 years of disease duration. Since then four other 
brains have been examined and all these findings were similar to the first case. In 
contrast, the proband of Family R showed relative sparing of the caudate nucleus after 
15 years of the disease and extensive white matter changes. Furthermore, no 
acanthocytosis were observed in peripheral blood smears as had been reported in some 
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cases of HDL2 [Walker et al., 2003]. This finding lends support to the proposition that 
acanthocytosis might display reduced penetrance in HDL2 cases.  
 
A key point to note from the clinical analysis is that HDL2 appears to be a disease that 
has a highly variable clinical phenotype and differs considerably even amongst family 
members. For example, in Family R, (as stated previously) one affected family member 
had parkinsonism while the other had features of cortical myoclonus, which are two 
distinct movement disorders. This variability demonstrates that HDL2 is phenotypically 
heterogeneous. Whether the SNPs identified in the MT-ND1, MT-ND2 and PARK2 
genes are accountable for the clinical heterogeneity observed in this family could not be 
determined. A larger number of affected family members would be needed to determine 
whether a correlation between a particular SNP and the clinical features exists.  
 
The analysis of 26 HDL2 cases, in which the age of onset and repeat length was known, 
showed that a longer repeat length correlated with an earlier age of onset (anticipation) 
[Margolis et al., 2004]. This is a common feature of repeat expansion disorders and 
lends support to the fact that the repeat expansion is the causal mutation. It also 
suggests that a longer repeat length leads to more severe phenotype [Margolis et al., 
2004]. Although the recorded age at onset was estimated and based on verbal accounts 
from other family members, a similar correlation between age at onset (AAO) and repeat 
length was observed in affected Family R members. On examination of three affected 
family members it was found that the individual with 59 repeats had an AAO of 25 years 
while the individuals with 52 repeats and 49 repeats corresponded to an AAO of 39 and 
48 years, respectively. In addition each repeat is roughly equivalent to a 0.4 year earlier 
AAO. This differs greatly compared to the estimate of 1.24 year earlier AAO per repeat 
that was observed in the 26 cases described by Margolis et al. [2004]. 
 
4.3  Genetic ancestry testing 
  
To date, nearly all reported cases of HDL2 have been in individuals of definite or 
probable Black African ancestry. This tendency has further been supported by the 
absence of JPH3 repeat expansions in a large cohort of Caucasians from Germany and 
Austria as well as France and North America [Bauer et al., 2002 and Stevanin et al., 
2003]. Furthermore, individuals from Japan, with an HD-like phenotype, were also 
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negative for HDL2 expansions. Even two HDL2 cases, initially considered to be of non-
African origin, were later found to have possible African origins. One of these cases, an 
individual from Morocco, was shown to originate from an area in Morocco predominantly 
occupied by Africans. The other case, a Mexican family, came from an area in Mexico 
that was colonised by Africans [Margolis et al., 2004].   
 
The ancestry of Family R was determined by genetic testing of one of the family 
members. The resolved mitochondrial haplogroup, L1d1, represents the maternal 
lineage, which occurs almost exclusively in populations of sub-Saharan Africa. This 
haplogroup is usually associated with the Khoikhoi and San clans of early Africa 
[Barkhan and Soodyall, 2006]. The Y-chromosome haplogroup, representing the 
paternal lineage, FG-M213, occurs predominantly in populations of Asia and Europe 
[Semino et al., 2000]. Upon further analysis it was determined that the paternal 
haplogroup was found in 40 other males from a worldwide survey of 42 000 males. 
Moreover, this haplogroup exactly matched a male of South African Mixed Ancestry in 
the survey [Soodyall H, personal communication].  
 
The ancestry testing performed in this study only reveals the partial ancestry of the 
individual as it does not determine all the possible ancestries that contribute to the 
lineage of this individual, for example the paternal grandmother. However, these results 
strongly suggest that this family member is more likely of Mixed Ancestry as opposed to 
South African Black or Caucasian ancestry. Furthermore, an indigenous African 
maternal lineage and European paternal lineage is typically found in individuals of Mixed 
Ancestry in South Africa [Nurse et al., 1985]. 
 
This is the first published cases of HDL2 in a South African Mixed Ancestry family 
[Bardien et al., 2007] although a preliminary report had indicated 7/20 Black patients 
from South Africa had tested positive for HDL2 [Krause et al., 2002]. A recent report 
described a Brazilian Mixed Ancestry family with HDL2 that has no apparent African 
origins [Santos et al., 2008]. As more knowledge about this disease increases there will 
surely be more reports from different ethnicities. Given this, it is suggested that all 
patients of Mixed Ancestry, that present with an HD-like phenotype but are negative for 
the HD mutation, be screened for HDL2, not only Black individuals. Moreover, it will be 
useful to set up a genetic diagnostic test that will screen for both HD and HDL2 
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simultaneously in cases where an individual of Black African Ancestry presents with an 
HD-like phenotype. Thus far no studies have been done to ascertain whether a genetic 
founder effect in the African population predisposes Africans to developing HDL2.  
 
4.4  Distribution of the JPH3 CTG repeats in the unaffected South   
African population 
 
In the previous population studies that determined the distribution of the repeats in the 
JPH3 gene, the repeat sizes varied between 8 and 28 consecutive repeats in unaffected 
individuals [Bauer et al., 2002 and Stevanin et al., 2003]. It is reasonable to assume that 
larger alleles are prone to expand into the pathogenic range once it reaches a certain 
threshold as reported for HD and SCA [Gomes-Pereira et al., 2004]. To date, this 
threshold has not been established in HDL2, although repeats as short as 33 were 
shown to be unstable in vertical transmission when it expanded to 35 repeats during 
maternal transmission [Margolis et al., 2004]. This implies that a population with a larger 
than average number of repeats could be predisposed to developing HDL2. Since the 
disease only occurred in individuals of Black African ancestry it was hypothesised that 
individuals of Black African ancestry may have larger repeats than other population 
groups. Of relevance, a study done in Serbia assessed the repeat distribution in 198 
healthy individuals from Serbia and Montenegro to determine the risk of this population 
developing HDL2. The repeats ranged from 11 to 18 with 14 repeats being the most 
common. The authors suggested that HDL2 is rare in these populations because the 
repeat distribution was narrow compared to the range of repeats in the North African 
population (8-28 repeats) which consequently had a higher incidence of HDL2 
[Keckarevic et al., 2005]. Similarly, in the present study, the repeat distribution in three 
South African sub-populations was assessed to determine which sub-group had a higher 
risk for developing HDL2. 
 
The pilot study showed a greater diversity in the alleles of Black African individuals (11 
alleles ranging from 8 to 19 repeats) than in either the Mixed Ancestry or Caucasian 
cohorts. Moreover, the diversity in the Mixed Ancestry group (9 alleles ranging from 8 to 
21 repeats) exceeded that of the Caucasian group which had only 7 different alleles 
ranging from 13 to 27 repeats. This can be expected as the Black African population is 
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an older population than both Caucasian and Mixed Ancestry groups and would 
therefore have a greater genetic diversity than either.  
 
The repeats were in Hardy-Weinberg equilibrium for all three groups. However, a 
significant difference in the distribution of the repeats between the Black and Caucasian 
cohorts was observed. A difference was also observed between the Caucasian and 
Mixed Ancestry groups but it was not statistically significant.  
 
The mode for all three groups was 14 repeats as observed in all other population studies 
[Bauer et al., 2002; Keckarevic et al., 2005 and Stevanin et al., 2003]. However, the 
frequency of the 14 repeat allele differs significantly between the South African sub-
populations. The 14 repeat allele was present in 55% of the Caucasian cohort, 33% of 
the Mixed Ancestry cohort and 25% of the Black African group. Again, this infers 
decreased allele diversity in the Caucasian group compared to the Black African and 
Mixed Ancestry groups.  
 
In general, the results of this South African pilot study concurs with other population 
studies in that the mode is 14 repeats, with 16 repeats being the next most common 
allele. Although a significant difference in the distribution of the CTG repeat was 
observed between the Black and Caucasian cohorts, this study did not detect larger 
repeats in the Black African group. A follow-up study with a larger sample size is needed 
to determine whether the Black sub-population has the largest number of repeats and 
are subsequently at a higher risk for developing the disease.  
 
4.5   Independent confirmation of the alternatively spliced JPH3 mRNA 
transcript 
 
The expanded repeat in HDL2 patients occurs in an alternatively spliced version of the 
JPH3 mRNA transcript and due to variable splice acceptor sites the repeat can code for 
polyalanine, polyleucine or fall into the 3’UTR [Holmes et al., 2001]. This was confirmed 
by GENSCAN predictions, the presence of a polyadenylation signal upstream to the 
repeat, as well as the existence of ESTs which are composed of a similar transcript and 
finally, by RT-PCR with primers specific for the repeat [Holmes et al., 2001]. This 
transcript was only detected by one group, so in the present study the occurrence of this 
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transcript was tested for in commercially available foetal brain RNA as well as 
transformed lymphocytes of HDL2 affected family members in order to provide 
independent confirmation of the existence of this alternatively spliced transcript.  
 
Due to the process of illegitimate transcription every mRNA transcript that exists should 
be present in blood at extremely low levels [Chelly et al., 1989]. Chelly et al. [1989] 
showed that variably spliced transcripts of tissue specific genes could be detected in 
non-specific cells such as fibroblasts and lymphocytes. JPH3 is tissue specific and is 
only expressed in the brain [Takeshima et al., 2000]. In the absence of brain tissue from 
affected family members, an attempt was made to detect the transcript in lymphocytes 
because all transcripts should be expressed in blood due to illegitimate transcription. In 
addition, commercially available foetal brain RNA was used as a positive control 
because of JPH3’s brain-specific expression profile.  
 
Both the full length and alternatively spliced versions of JPH3 mRNA were detected in 
foetal brain cDNA but not in lymphocytes. This could be due to the extremely low levels 
at which JPH3 mRNA is expressed in tissues other than the brain. The possibility that 
the quality of the lymphocyte cDNA was at fault was excluded because primers designed 
to amplify a ”housekeeping” gene (HBB) produced the correct product (verified by 
sequencing) in a standard PCR reaction in both tissue types. A housekeeping gene is 
defined as a gene that is expressed in all tissues at relatively similar levels. The HBB 
gene was selected because it is expressed in relatively similar levels in all tissues 
[Shmueli et al., 2003]. Furthermore, HBB is highly conserved throughout different 
species and contains a relatively small intron which makes it easy to amplify in a PCR 
reaction. The primers were designed across exons so that differently sized products 
would be generated for genomic DNA and cDNA. This provided an important control for 
detecting genomic DNA contamination in the cDNA samples.  
 
The initial set of primers designed to amplify the full length JPH3 script was designed to 
amplify across the Exon 2–Exon 3 boundaries. However, the PCR reaction was 
unsuccessful for both lymphocyte and foetal brain cDNA. After extensive attempts at 
optimising the reaction, the PCR still failed. It was suspected that this may be because 
during the cDNA synthesis, the reaction was unable to extend all the way to the 5’ end of 
the mRNA. A second set of primers, closer to the 3’ end of the gene, was designed and 
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amplified the foetal brain cDNA on the first attempt. This implies that fragments closer to 
the 3’ end of the mRNA may be a better target region to amplify when using cDNA as a 
template. However, the amplification using lymphocyte cDNA was still unsuccessful.  
 
To replicate the results obtained by Holmes et al. [2001] the products generated from the 
PCR fragments with foetal brain cDNA were compared to sequences in the NCBI dbEST 
database. The database contains ESTs which are short randomly sequenced segments 
of cDNA. The database provides parts of gene sequences that are expressed in certain 
tissues, cells or disease states and is useful to confirm the existence of variably spliced 
mRNA isoforms.  
 
The alternatively spliced transcripts generated in the present study showed significant 
alignment with 17 ESTs. However, only three of these ESTs contained a sequence 
wherein Exon 1 was spliced to Exon 2A. These three transcripts were the same as those 
identified by Holmes et al. [2001]. The findings in the present study confirm the existence 
of an alternatively spliced transcript in foetal brain RNA that contains a CTG/CAG repeat 
as proposed by Holmes et al. [2001]. 
 
To further investigate whether JPH3 transcripts were detectable in lymphocytes, an 
exploratory study using real-time PCR was attempted. Real-time PCR is a more 
sensitive method than conventional PCR in that it measures the increase of fluorescence 
produced by the formation of PCR products in real time. In addition, real-time PCR 
enables the amplification of very low levels of template DNA. The melt curve analysis 
helps to determine whether contamination is present as the melt profiles are sequence-
specific. The HBB primers were used initially to determine the optimal concentration of 
the cDNA being used. The PCR using primers for the HBB gene was successful for 
genomic DNA, lymphocyte and foetal brain cDNA and this was confirmed with direct 
sequencing.  
 
Once the optimal cDNA concentrations were attained, PCR with the mRNA specific 
primers for the alternatively spliced and full length JPH3 transcripts were attempted. The 
crossing point (CP) values for most of the reactions were very high (30-35 cycles) and it 
was therefore concluded that these experiments were not optimised. Selected products 
were, however, analysed because JPH3’s expression, especially in the lymphocyte 
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cDNA, was expected to be at very low levels, and would therefore take a larger number 
of PCR cycles in order to produce a PCR product. 
 
No conclusions could be drawn about the detection of either the full length or 
alternatively spliced products in lymphocyte cDNA or whether it is present in blood due 
to illegitimate transcription. These reactions need to be optimised further as most of the 
melt curves still showed non-specific peaks. This section of the study was an exploratory 
endeavour to set up an experimental basis for future real-time assays of HDL2 brain 
tissue. 
 
4.6  Disease mechanisms of HDL2 
 
Several hypotheses describing the pathogenic mechanisms of unstable repeat 
expansion disorders exist although none have been conclusively proven. Expansions 
may occur in non-coding or coding regions and the proposed mechanism of 
pathogenesis depends on where these expansions occur [Gatchel and Zoghbi, 2005]. 
 
 Expansions in the non-coding, regulatory regions generally incur a loss of function 
mechanism in which the gene undergoes transcriptional silencing and the protein is not 
expressed. A well-known disease caused by a loss of function mechanism is Fragile X 
syndrome in which a triplet repeat expansion occurs in the 5’ UTR of the gene and 
inhibits transcription of the gene [Li et al., 2001]. JP3 knock-out mice showed motor 
abnormalities but no developmental impairment. Furthermore, the symptoms of HDL2 is 
much more severe than the phenotype in these mice [Nishi et al., 2002] suggesting that 
a loss of function is not the likely pathogenic mechanism. However, it is possible that 
reduced JPH3 expression may contribute to the pathogenic mechanism because 
untranslated full length JPH3 transcripts were present in the aggregations found in HDL2 
brains thereby insinuating that less transcript was available for translation [Rudnicki et 
al., 2007].  
  
Expansions in the coding region of a gene, often resulting in long polypeptide tracts, 
commonly polyglutamine tracts, have been associated with a gain of function 
mechanism of pathogenesis. A polyglutamine disease usually affects a specific cell type 
resulting in a disease phenotype that has selective neurodegeneration [Zoghbi and Orr, 
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2000]. Another feature of polyglutamine diseases is the presence of aggregations of 
mutant protein and other components of the ubiquitin-proteasome system in the nucleus 
[Ciechanover and Brundin, 2003]. Thus far there has been no evidence to suggest that 
HDL2 is a polyglutamine disease, although clinically, it has features of a polyglutamine 
disease such as the presence of nuclear aggregations and selective neuronal 
degeneration.   
 
A third proposed mechanism of pathogenesis describes expanded repeats in non-coding 
regions of the gene resulting in altered function due to mutant RNA and protein 
interactions. It has been suggested that in this mechanism the RNA containing the 
expanded repeat binds to RNA-binding proteins which are involved splicing, thereby 
disturbing normal mRNA splicing and forming aggregations [Gatchel and Zoghbi, 2005]. 
Increasing evidence suggest that HDL2 is due to a RNA-toxicity. CAG probes detected 
RNA foci in 30% of neurons in HDL2 brains. Probes specific for the alternatively spliced 
JPH3 mRNA co-localized with the CAG probes in specific regions of the brain [Rudnicki 
et al., 2007]. In addition, the cellular expression JPH3 mRNA containing expanded CUG 
repeats produced RNA foci which were toxic to the cell.   
 
Currently it is unknown how the repeat affects the mechanism of pathogenesis but 
further molecular studies may provide insight into this and may eventually lead to 
therapeutic intervention. The use of animal models to determine which pathogenic 
mechanism is involved in HDL2 is crucial.   
 
4.7.   Conclusions 
Limitations of this study 
 
More information about Family R would have been useful to assess the features of the 
disease in this family. Recruiting and examining more family members would have 
increased the significance of the differences in the clinical phenotype between family 
members. Screening more family members would have been valuable in determining 
whether the variants found in the MT-ND1, MT-ND2 and PARK2 genes were responsible 
for the clinical heterogeneity observed in this family. Unfortunately many of the affected 
family members were deceased and the individuals in the fourth generation were too 
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young and may have been pre-symptomatic. As the disease was a ‘sensitive topic’ to 
this family, it was difficult to recruit other family members.  
 
A study using a larger sample size may answer the question of whether Black Africans 
are predisposed to developing HDL2 due to the repeat size in this population group. 
 
With regards to the mRNA section of this study, precautions were taken to avoid RNA 
degradation but it may still have occurred because RNA is unstable and easily 
degraded. Due to time constraints, the real-time PCR reactions were not optimised and 
therefore these results are equivocal. They could be optimised by varying the PCR 
cycling parameters and template cDNA concentration or by the addition of PCR 
additives.  
 
Due to time constraints, the possible significance of the novel polymorphisms identified 
in the MT-ND1 and MT-ND2 genes could not be evaluated. It would have been 
advantageous to determine the frequency of the observed polymorphisms in a healthy 
control group, which could have ascertained whether the polymorphisms were significant 
in the manifestation of the disease. 
 
Future work 
  
It would be interesting to determine whether all HDL2 families worldwide share a 
common haplotype as the disease may have a genetic founder effect. The analysis of 
the Y-chromosomes and mitochondrial haplogroups for common SNPs or STRs to trace 
founder effects has previously been useful [Wise et al., 2005]. The information gathered 
would be useful in tracing other family members and offering genetic counselling, genetic 
testing and improved clinical management of the affected family members.  
 
The frequency of HDL2 cases in South Africa should be assessed in order to determine 
the burden of this disease in South Africa as it has been proposed that HDL2 might be 
as common as HD amongst Black South African individuals. This could be done by 
recruiting samples from all the major movement disorder clinics and diagnostic 
laboratories as was done in the study by Bauer et al., [2002].   
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Investigating common pathways affected by HD, HDL2 and other neurodegenerative 
diseases may provide target proteins to which therapeutic drugs could be designed.    
 
At the time of this study, brain tissue of the HDL2 affected Family R members was not 
available. Recently brain tissue from a deceased affected family member has been 
acquired and several studies on the tissues from the various brain regions could be 
proposed: 
 
Although a commercial antibody for the mouse orthologue of JPH3 is available, it is not 
known whether it would be effective for detection of the human protein and therefore it is 
proposed that antibodies against the human JPH3 full length and alternatively spliced 
forms be raised. If a successful human antibody can be created, immunohistochemical 
studies can be used to determine if the expression levels of both forms differ in different 
regions of the brain. In addition, one would be able to determine which version of the 
mRNA transcripts is predominantly expressed in those areas of the brain which are more 
severely affected in HDL2 patients.  
 
In all neurodegenerative diseases, the composition of the aggregates or inclusions have 
provided evidence of which gene may harbour the disease-causing mutation. The 
composition, morphology and histology of the intra-nuclear inclusions of the HDL2 brain 
should be investigated as it may provide vital information about the mechanism of   
pathogenesis of this disease. Recent studies proposed that the cellular toxicity observed 
in HDL2 is due to RNA transcripts as has been reported in myotonic dystrophy Type 1 
[Rudnicki et al., 2007]. The authors suggest that other transcripts of JPH3 may also be 
present and what those transcripts are remains to be determined.  
 
It would be interesting to determine the frequency of the inclusions in different regions of 
the HDL2 brain as one would expect the number of inclusions to increase in areas of the 
brain which are more severely affected. In diseases exhibiting anticipation, a larger 
repeat size may lead to a more severe phenotype. It would be expected that the number 
of these inclusions will differ between individuals with different repeat sizes and it will 
therefore be useful to document the number of inclusions as this can be used later in a 
comparative study once more cases become available. 
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A question that has thus far been unanswered is whether the repeat expansion disrupts 
the properties of the junctional complexes. The proposed function of JPH3 is to facilitate 
cross-talk across the junctional membranes. It can therefore be assumed that this 
function will be disrupted in the HDL2 cases. By using electron microscopy, it would be 
possible to compare the morphology and functionality of the junctional complexes 
between affected and unaffected regions of the brain. This could shed some light on why 
the JPH3-knockout mice do not exhibit such severe neuronal dysfunction as is seen in 
HDL2 [Nishi et al., 2002].  
 
Conclusive statements 
 
In summary, the disease-causing mutation underlying the disease phenotype in this 
Mixed Ancestry family was identified as a repeat expansion in the JPH3 gene. A genetic 
pre-symptomatic predictive test with informed counselling can now be made available to 
at-risk family members. In this regard, the wife of one of the affected family members 
has approached the genetic counsellor, Prof Greetje de Jong, and requested predictive 
testing for her 17-year old daughter. She was advised to wait until her daughter is over 
18 years.  
 
This molecular diagnosis is of great significance as it may provide insight to the course 
of the disease thus enabling the affected individuals and their families to make informed 
decisions on life or family planning. Identifying the genetic cause for a disease can assist 
the family of affected individuals to prepare themselves financially as medical costs can 
be exhaustive. Also, knowing the underlying genetic mutation enables clinicians to make 
informed choices about the treatment and clinical management of the individual instead 
of spending unnecessary resources on different therapies that are unsuitable. This is 
especially true for movement disorders and dementias, which are symptoms for a large 
number of different disorders.  
 
Identifying a family with HDL2 is significant because this is a very rare disorder. By 
studying this disease in different families, the clinical phenotype can be expanded on 
and finer description of this heterogenous disease can be formulated. Furthermore, 
studying HD-like disorders may provide insight into the pathogenic mechanisms of other 
common neurodegenerative disorders.   
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 Molecular investigations of this kind may provide insight into the disease which may 
identify disease modifiers or predisposing alleles. It may also lead to the development of 
disease models and novel therapies. The allele frequency of the HDL2 repeat was 
determined in order to provide an indication of the risk for developing HDL2 among 
South Africans. This study showed that the repeat sizes in the South African population 
was the same as the distribution of repeat sizes worldwide, inferring that individuals from 
South Africa are not at a higher risk for developing the disease than other nationalities. 
Furthermore, this study strongly suggests that South African patients presenting with an 
HD-like disorder, that are negative for the HD mutation, be tested for HDL2 regardless of 
their family history and ancestry.  
 
It is hoped that some aspects of this study may contribute to a better understanding of 
this rare and devastating disease and that it will provide data that may contribute 
towards the design of a possible cure. However, it is acknowledged that a lot more 
intensive research is needed to shed some light on the enigma of neurodegenerative 
diseases that appear to affect only certain brain cells. 
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 APPENDIX 1: Consent forms  
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APPENDIX 2: Solutions, media and buffers  
 
Sodium Borate (SB) buffer (20Xstock) 
38.137g of Na2B4O7 was dissolved in sterile distilled water to make up 1L. For 1XSB 
running buffer, a 100ml of the 20Xstock was made up to 2L with sterile distilled water 
(H2O).  
 
 TBE buffer (10Xstock) 
0.89M Tris-HCl, 0.89M boric acid and 20mM NaEDTA (at pH 8) was added to sterile 
distilled water to make up a 10XTBE stock solution. 
 
Bromophenol Blue Loading Dye  
0.2%(w/v) bromophenol blue; 50% glycerol and 10mM TRIS was added together and 
stirred gradually until all the ingredients were properly mixed.  
 
Luria-Bertani Medium  
5g of Bacto tryptone; 2.5g of Yeast extract and 5g of NaCl were added to a final volume 
of 500ml distilled H2O. The solution was autoclaved at 121ºC and left to cool before 
antibiotics were added where necessary. For Luria-Bertani Agar, 8g of agar was added 
to the solution. After autoclaving the solution was cooled to 55ºC before IPTG and X-
GAL were added. Approximately 15ml of this solution was poured into Petri dishes and 
allowed to solidify under sterile conditions.   
 
CAP Buffer  
10mM PIPES; 60mM CaCl2 and15% glycerol was made up to a final volume of 250ml 
with sterile Millipore H2O. The solution was pH to 7.0 with NaOH and stored at 4ºC. 
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APPENDIX 3: Phenol Chloroform method for DNA Extraction  
[Corfield et al., 1993] 
Reagents:  
• Cell lysis buffer (4ºC): 
 109.5g sucrose; 10ml 100% Triton X; 5ml 1M MgCl2 and 10ml 1M TRIS-HCl were 
mixed together and stored at 4ºC. 
• Phenol:  
pH to 8 with buffer. The buffer, phenol and equal volume Chloroform were mixed and 
stored at 4ºC overnight before use.   
• Na-EDTA: 
 18.75ml 4M NaCl was added to 250ml 100mM EDTA.  This was made up to 1L with 
sterile distilled H2O, pH to 8 and autoclaved. 
• Octonol-Chloroform: 
480ml Chloroform was added to 20ml octonol, mixed well and stored in a dark area.  
• 10%SDS:  
10g SDS was added to a 100ml of sterile distilled H2O and incubated at 37ºC to 
dissolve SDS. 
• 3M Sodium-acetate, pH to 6 with acetic acid.  
• 10mg/ml Proteinase K (Roche’) 
• 96% ice cold Ethanol  
• 1XTE solution 
• 70% Ethanol 
 
Method:  
 
1. 5ml EDTA blood samples were transferred to 45ml sterile tubes, cold Lysis buffer was 
added to the 45ml mark and vigorously shaken. The tubes were incubated on ice for 10 
minutes. The cells were then vortexed and pelleted at 3000rpm for 10 minutes after 
which the supernatant was poured off.  
 
2. The pellet was rinsed with cold lysis buffer a few times until the pellet was light pink. 
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3.  900µl Na-EDTA and 100µl 10% SDS was added to each pellet. At this point the 
pellets were either stored at -80ºC or used for DNA extraction as follows.  
 
4. 100µl 10mg/ml Proteinase K was added to each tube and the tubes were incubated at 
37ºC, overnight.  
 
5. 2ml Distilled H2O and 500µl 3M Sodium-acetate was added to each tube and the 
contents were mixed by inverting the tube.  
 
6. 2.5ml Phenol-chloroform was added to each tube. The tubes were placed on a shaker 
(at a 40º angle to the platform of the shaker) at the speed of 1400rpm for 10 minutes. 
   
7. The contents were then transferred to a 10ml Corex glass tubes and spun at 7000rpm 
for 12 minutes at 4-10ºC. 
 
8. A 3ml Pasteur pipette was used to transfer the supernatant to a clean Corex tube 
without disturbing the interphase. 
 
9. 2.5ml Octonol–chloroform was added to the tube containing the supernatant. The tube 
was sealed with a leak proof top and slowly mixed by inversion until the solution turned 
milky. 
 
10. The tops were removed from the tubes and the tubes were spun at 7000rpm for 10 
minutes at 4ºC. 
 
11. The supernatant was transferred to a 12ml falcon tube.  5-7ml ice cold 96% Ethanol 
was added to the tube and slowly mixed until the DNA precipitated.  
 
12. Once the DNA precipitate was visible a pipette was used to transfer the DNA to a 
1.5ml Eppendorf tube.  
 
13. The tube was filled with 70% Ethanol and spun for 3 minutes at 14 000rpm.  The 
Ethanol was slowly poured off so as not to loose the pellet. This step was repeated 
once.  
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14. The pellet was air dried at room temperature.  
 
15. 500µl 1XTE solution was added to each tube and the tubes were incubated at 37ºC 
overnight or for 10 minutes at 65ºC. 
 
16. The tubes were placed on a rotating wheel at 30rpm for 3 days after which the 
optical density and the purity of the DNA was checked with the NanoDrop®. 
 
APPENDIX 4: SSCP Gel preparation  
Reagents:  
Table A. Components for 8% and 10% SSCP gels 
 8% Gel 10% Gel 
Urea  24g 24g 
Sterile distilled H2O 91.8ml 84ml 
10XTBE 8ml 8ml 
Glycerol 8ml 8ml 
10% APS 1.6ml 1.6ml 
TEMED 160µl 160µl 
 
SSCP Loading Dye Reagents:  
SSCP Loading Dye contained 95% formamide; 20mM EDTA; 0.01% Bromophenol Blue 
and 0.05% of Xylene cyanol. 
 
Method:       
Glass plates and tanks were cleaned and prepared. A sheet of Gelbond® PAG film 
(Cambrex Bio science, Rockland, USA), was placed between the glass plates where it 
covalently bonded to the acrylamide gel during polymerization, thus providing support. 
Urea, sterile distilled H2O, 10XTBE and glycerol was added to a sterile beaker while 
stirring continuously.  10% APS and TEMED were added last (Table A). The solution 
was then immediately poured into the cast that had previously been prepared. The gels 
were kept in the cast until set. Meanwhile, 0.5XTBE running buffer was poured into the 
tank. The samples were prepared by combining equal volumes of SSCP loading dye to 
the samples and placing them on a heating block at 94.5ºC for 5 minutes. The samples 
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were incubated on ice for 5 minutes or until just before loading.  The gels were run at 23 
Watts at 4ºC overnight.  
 
APPENDIX 5: Silver staining of SSCP gels  
 
Reagents:  
• 1% AgNO3 (Solution B) :  
          1g AgNO3 was dissolved in distilled sterile H2O to make up 1L. 
• Developing Solution (Solution C): 
15g NaOH; 0.1g of NaBH4 and 4ml of Formaldehyde was dissolved in sterile 
distilled H2O to make up 1L. 
 
Method:  
500ml Solution B was added to a tray containing the SSCP gel .This tray was placed on 
a shaker at 3000rmp for 10 minutes. Solution B was then poured off and the gel was 
rinsed with sterile H2O. 500ml Solution C was then added to the tray containing the gel 
and this was placed on a shaker for a further 15 minutes or until the bands could be 
clearly seen. The solution was than poured off and the gel was once again rinsed with 
sterile H2O. The gels were then left to dry and sealed in plastic.  
 
APPENDIX 6: Preparation of E.coli DH5α competent cells for 
transformations 
 
Reagents and materials: 
• Sterile inoculation loop 
• LB media (Appendix 2)    
• 2L Elenmeyer flask 
• CAP Buffer 
 
Method:  
1. A loop of E.coli DH5α was scraped from a frozen stock and was inoculated into a 
sterile Falcon tube containing 10ml LB media (Appendix 2). 
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2. The media was incubated overnight at 37ºC with constant shaking at 200rpm. The 
following day 1ml of this culture was added to 200ml of LB in a 2L Erlenmeyer flask with 
a cotton wool plug.  
 
3. The flask was then further incubated at 37ºC with gentle shaking at 85rpm until the 
cells were grown to mid log phase  (Optical Density= 0.4-0.6nm).  
 
4. The media containing the cells were aliqouted into 4 X 50ml sterile Falcon tubes and 
centrifuged for 15 minutes at 4ºC. All the steps thereafter were carried out in a 4ºC cold 
room. 
 
5. The supernatant was removed and the cells were resuspended in one third the 
volume of ice cold CAP buffer (Appendix 2). 
 
6. The cells were once again centrifuged at 3000rpm for 15 minutes to pellet the cells 
and the supernatant was discarded.  
 
7. 5ml Cold CAP buffer was added to the pellet and the pellet was gently resuspended 
by pippeting. 200µl Aliqouts of the suspension was stored at -70ºC until further use.  
 
APPENDIX 7: Lymphocyte separation and transformation 
 
Materials:  
• RPMI medium:  RPMI 1640 with 15% foetal calf serum and 1% penicillin or 
streptomycin.  
• EBV medium : Epstein Barr Virus Medium  
• Histopaque: Histopaque 1077 
 
Method:  
1. RPMI and EBV medium were heated to 37ºC and Histopaque to 22ºC. 
2. 3ml Histopaque was syringed into a sterile tube and 4-5ml blood collected in 
Heparin tubes were slowly added so that it formed a separate layer. 
3. The tube was centrifuged at 1800rpm for 20 minutes to further separate the 
phases.  
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4. The white blood cell layer was removed using a sterile Pasteur pipette and 
placed into a clean, sterile tube to which 3ml RPMI was added. The tube was 
spun for a further 30 seconds at 1000rpm.  
5. The cell pellet was resuspended in 0.3ml RPMI medium and poured into a 25cm3 
flask containing 1.5ml EBV media.  
6. The flask was incubated in an upright position for a week at 37ºC, with 5% 
Carbon Dioxide and 90% humidity. 
7.  0.5ml RPMI media was added to the solution twice weekly until a final volume of 
5ml was reached. At various intervals the solution was viewed under a 
microscope to monitor cell growth.  
8. After a week the cell culture was spun at 1000rpm for 30 seconds. The 
supernatant was poured off and the cells were regrown to 5ml again in order to 
concentrate the cells. 
9. The cells were transferred to a 75 cm3  culture flask and 10ml RPMI medium was 
added twice weekly or until a final volume of 50ml was reached.  
10. The cells was frozen in liquid nitrogen by adding with 10% DMSO and RPMI 
medium in cryovials and stored at -70ºC.  
 
APPENDIX 8: RNA isolation using TRIzol  
. 
Reagents and materials:  
• 2ml Screw cap containing Hybaid ribolyser blue beads (Qiagen) 
• 2ml Tube containing Phase-Lock gel heavy (Eppendorf) pelleted at max 
speed for 20-30s 
• Chloroform:isoamyl alcohol (24:1)  
• Isopropanol  
• TRIzol® Reagent  (Invitrogen)  
• RNAse free water or 1ml DPEC was dissolved in IL water. This was 
incubated at 37ºC over night and autoclaved twice.  
 
Method: 
1. 200µl Transformed lymphocytes (Appendix 7) were pelleted at 3000rmp for 15 
minutes and the supernatant was poured off. 
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2. The cells were resuspended in 1ml of TRIzol and the suspension was transferred to a 
2ml screw cap tube containing ribolysing beads. This process was performed on ice. 
 
4. The cells were mechanically disrupted by vortexing for 20 seconds at a speed of 6 for 
3 cycles. The samples were cooled down after each cycle by placing it on ice for 2 
minutes between pulses.   
 
5. Thereafter the samples were centrifuged at 13000rpm for 45 seconds. 
 
6. The TRIzol solution above the beads was transferred into a 2ml tube containing 
phase-lock gel and 300µl Chloroform:isoamyl alcohol. 
  
7. The tubes were inverted gently but rapidly for 15 seconds and incubated at room 
temperature for 2 minutes.  
 
8. The tubes were centrifuged at 13000rpm for 5-10 minutes after which the top aqueous 
layer was transferred to a clean sterile tube.  
 
9. An equal volume of isopropanol was added to the tube containing the aqueous layer 
and mixed by inverting. This solution was stored at -20ºC overnight to precipitate the 
nucleic acid.  
 
10. The precipitate was collected by centrifugation at 12000rmp for 20 minutes in a 4ºC 
cold room and the supernatant was discarded.  
 
13. The pellet was washed once with 1ml 70% ethanol and centrifuged at 12000rpm for 
5 minutes at 4ºC. The ethanol was removed by aspiration and the pellet was air-dried. 
  
15. The RNA was dissolved in 20-40µl RNAse-free water. The sample was treated with 
Ambiance Turbo DNAse ™ Free as specified by the manufacturer.  
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